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Aims and Objectives 
This thesis stems from work conducted with Médecins Sans Frontières in Sierra Leone, during the 2014-
2015 Ebola virus disease (EVD) outbreaks. The thesis addresses 3 main public health knowledge gaps 
and aims to improve the response to future EVD outbreaks by: 
1) Understanding the factors that influenced EVD transmission and community compliance with con-
trol measures; 
2) Estimating the performance of the WHO EVD case definition, and what components could improve 
it; 
3) Estimating the design effect and mortality rates, and discussing how to improve future surveys for 
highly-clustered diseases. 
Methods 
The methods corresponding to each gap were: 
1) A mixed-methods study in one village experiencing sustained transmission in Sierra Leone; 
2) A review and meta-analysis exploring performance of WHO EVD case definitions against laboratory 
confirmed EVD; 
3) Two population-based clustered surveys, in Sierra Leone. 
Results 
Study 1 identified that non-compliance with public health guidelines was a consequence of the failure 
of the response to orientate itself according to the needs and values of the community.  
Study 2 estimated that the WHO EVD case definition performed sub-optimally to identify cases (sen-
sitivity 81·5% (74·1-87·2%); specificity 35·7% (28·5-43·6%)). Inclusion of intense fatigue as a key 
symptom and contact history could improve performance, but these changes would require collabora-
tion with, and trust of, affected communities.  
Study 3 identified a high degree of clustering in community-based surveys of EVD, this contributed to 
imprecise mortality estimates, which have limited utility when assessing the impact of disease. Esti-
mated the design effect along with methodological suggestions provided can inform future surveys for 
similar highly clustered diseases. 
Conclusion 
The thesis highlights that outbreak patterns are linked to social and cultural environments. Community 
influence key public health practices (i.e. case definitions). Recognition of transmission risks from 
responding organization requires a respectful and compassionate approach, understanding of social 
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The aim of the PhD is to address evidence gaps that pose major clinical and public health challenges 
for agencies involved in outbreak management of Ebola Virus Disease (EVD). The thesis shows the 
need to re-frame how MSF and other response organizations operate and relate to the community in the 
context of an outbreak. Through work with patients and communities, outbreaks can become an 
opportunity to reinforce a non-existent health system and to create opportunities for access to safe and 
equitable care. 
The work presented in this thesis reflects part of the work I have done as a medical doctor and Public 
Health advisor for Médecins Sans Frontières Operational Centre Amsterdam (MSF-OCA) during the 
2014-2016 EVD outbreak in Sierra Leone.  
As a staff member of MSF-OCA, I was deployed to Kailahun, Sierra Leone in June 2014, which was 
for several months the epicentre of the EVD outbreak. At the Ebola Management Centre (EMC), I 
supported patient triage, and set up the data management systems.  
Outside the EMCs, I was responsible for EVD case investigations and supported the Ministry of Health 
(MoH) on surveillance and the use of EMC data to identify areas of transmission and to plan 
interventions.  
In October 2014, I set up a community surveillance system in slum areas in Freetown. This supported 
the development of a novel MSF community strategy which ensured that the community were centrally 
involved in surveillance and were consulted to identify chains of transmission, and that households 
under quarantine were able to receive timely food, water, and mental health support1.  
In December 2014, I was appointed by MSF-OCA to coordinate and provide technical support to the 
field epidemiologists deployed by MSF-OCA in Sierra Leone. In 2015, I performed several field visits 
to support the design and implementation of population studies. In 2016, I supported to respond to the 
last EVD flare-up and supported Ministry of Health in Tonkolili District to reinforce health facility base 
surveillance2. 
In 2018 and 2019, I provided technical assistance and field work during two further EVD outbreaks in 
remote and conflict-affected areas in the Democratic Republic of Congo (DRC).  
My PhD and field work led to improvement of MSF and MoH outbreak control practices in DRC, and 
informed the development of MSF-OCA epi-anthropological approach on EVD outbreak response. This 
approach has recently shaped the development of MSF-OCA Community guidelines for the novel 
																																								 																				
1 Review of MSF-OCA surveillance and alert response in Freetown during the Ebola outbreak: lessons learned and challenges, MSF-OCA 
internal report. Available at https://www.researchgate.net 





coronavirus disease 2019 (COVID-19) response, and the design of a qualitative study exploring 
community perception toward COVID-19 in Sierra Leone. 
My role in this PhD was the conceptualisation of the project, the design of the studies, and leading the 
development of study protocols, field implementation, data management and dissemination. I also led 
the review and metanalysis of the literature to explore performance of WHO EVD case definitions. I 






Structure and methodological approach of the thesis  
 
This thesis is structured in a research paper style and comprises of three papers, with an introduction, 
discussion and linking material. The first chapter provides an overview of Ebola Virus Disease (EVD), 
EVD transmission, history of EVD outbreaks, public heath control measures, diagnostic methods, EVD 
clinical presentation, current treatments and vaccines, and a review of the salient events of the EVD 
outbreak in Sierra Leone.  
Chapter 2 provides the context to the work done by MSF-OCA in Sierra Leone and summarises the 
challenges faced while responding to the outbreak. The gaps and challenges experienced during field 
work informed the conceptualisation of the PhD and the development of the research objectives. 
Chapter 3 (Objective 1; Research paper 1) aims to understand transmission dynamics and factors 
associated with non-adherence to control strategies in the context of sustained EVD transmission in a 
village in Kailahun district. Supplementary material included a link to the study protocol and mix-
methods data collection tools designed for the study.   
Chapter 4 (Objective 2; Research paper 2) addresses the performance of WHO EVD case definitions 
and risk scores, which are crucial for accurate surveillance tools to detect suspected cases for referral 
and as screening tools for clinicians to support admission and laboratory testing decisions at Ebola 
health facilities. Supplementary material included PRISMA-DTA checklist, search strategies and 
additional analysis. 
In Chapter 5 (Objective 3; Research paper 3) I implemented and analysed data from two retrospective 
mortality studies implemented in 2015 to estimate overall and EVD-specific mortality rates in two areas 
where MSF suspended critical health interventions and refocussed on EVD care. This chapter highlights 
the challenges of using retrospective mortality studies for highly clustered disease outbreaks like EVD 
and suggests solutions to this problem. The supplementary material included a link to the study protocol 
and data collection tools designed for the study. 
In Chapter 6, I summarise the key findings from the thesis, and discuss the contribution of this work to 
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Chapter 1: Introduction 
	
1.1 Ebola virus Diseases (EVD) 
	
Ebola virus (EBOV) is an RNA virus belonging to genus Ebolavirus of the Filoviridae family 
(Mononegavirales order). This family includes other five genera: Cuevavirus, Dianlovirus, 
Marburgvirus, Striavirus, and Thamnovirus. (1, 2). The genus Ebolavirus consists of six biologically 
distinct species that differ in genomic structure, host variety and geographic distribution: Ebola virus 
(EBOV, previously Zaire ebolavirus), Sudan virus (SUDV), Bundibugyo virus (BDBV), Taï Forest 
virus (TAFV, formerly Côte d’Ivoire ebolavirus), Reston virus (RESTV) and Bombali virus (BOMV) 
(1). These were identified between 1976 and 2018. 
EBOV, SUDV and BDBV have caused large and recurrent outbreaks, known as Ebola virus disease 
(EVD) (3-5). In contrast, there has only been one documented case of TAFV which was not fatal and 
RESTV has caused only asymptomatic infection (3). BOMV was discovered in 2018, and its pathogenic 
potential is still unknown (6). RESTV is the only species that appears to circulate in South-eastern Asia 
(7). The rest of the Ebolaviruses circulate in Africa, where an estimated population of 22 million people 
in 22 countries live in areas considered at risk of EVD outbreaks (8). Currently, EBOV is the most 
studied member of the Filoviridae family, but all filoviruses are deemed to follow similar biological 
function (4). 
The World Health Organization (WHO) classify EVD as a zoonosis which can cause fatal illness in 
humans and non-human primates, and list Ebola and Marburg viruses (MARV) as Category 4 
Pathogens, requiring advanced biocontainment facility (Biosafety Level 4 (BSL-4)), and immediate 
notification (9-11).  
Table 1 summarizes the members of the genus Ebolavirus known to be pathogenic in humans (4). 
Table 1. Members of the genus Ebolavirus known to be pathogenic in humans, adaptation form Heinz et al. (4) 
Genus Species Virus Country Year of discovery 
Ebolavirus  Zaire  
ebolavirus 
Ebola virus  
(EBOV) 







DRC, South Sudan 1976 
Taï Forest 
ebolavirus  
Taï Forest virus 
(TAFV) 











1.2 Transmission  
	
Bats are the putative reservoir hosts and efforts to explore genetic diversity, habitat suitability, and 
clarify reservoir(s) for filoviruses are ongoing (4, 12-14). Fruit bats of the Pteropodidae family seems 
to play a major role in the transmission cycle of Ebolavirus, by infecting intermediate hosts (including 
monkeys, great apes, duikers and pigs) via saliva and/or faeces (4, 14). The intermediate host then plays 
an amplification role and can transmit infection to human (through consumption or handling of infected 
bush meat) with subsequent human-to-human transmission in the community and health facilities (13). 
The risk of “spillover events” (defined as transmission of the virus from wild animal populations to 
humans), depends on a range of interplay factors in host-viral dynamics, including human behaviour, 
animals’ susceptibility and anthropogenic land-use (15). A recent modelling paper predicts a 1.75 to 
3.2-fold increase of EVD spillover events in Africa by 2070 (15). 	
Human-to-human transmission occurs primarily via unprotected direct contact with body fluids of 
symptomatic persons or those who have died from EVD, or occasionally through contact with 
contaminated fomites (i.e., needles, clothes) (13, 16-19). Aerosol transmission has been documented in 
experimental studies, but its role in human transmission remains unknown (20). 	
The time interval from infection or exposure to infection to onset of symptoms (i.e., incubation period) 
is 2-21 days, and infectivity starts with onset of symptoms (9). However, the virus can be detected by 
real-time reverse transcription PCR assays (RT-PCR) (see section 1.5 Diagnosis and diagnostic 
methods) in biological fluids (faeces, tears, sweat, semen, breast milk and cerebrospinal fluid) and sites 
(conjunctiva, rectum, vagina, aqueous humour) months after infection, when symptoms are no longer 
present and RT-PCR blood tests for virus RNA are negative (19, 21, 22).	
EBOV has been isolated and detected from semen of Ebola survivors respectively 82 days and 18 
months after symptom onset (19, 23); and decline of EBOV in semen over time have been documented 
(23). Although sexual transmission has been described, the risk of transmission from EVD survivors 
via sexual intercourse is considered low (24, 25). A retrospective study conducted in West Africa after 
the most intense EBOV transmission period (February 2015), investigated a series of 13 possible viral 
persistence–derived transmission of EBOV events (VPDTe)3 (26). In four events, authors found strong 
evidence4 of sexual transmission from male survivors, and in one event transmission was documented 
65 weeks after recovery (26). A cohort study in Liberia which followed 171 EVD male survivors found 
detectable viral semen in 7.0% of survivors at 12 months, but no secondary cases despite participants 
																																								 																				
3 VPDTe was defined: as: person-to-person transmission of EBOV from an EVD survivor (source) to another person (recipient) that 
occurred >21 days after the source case recovered from acute infection.  
4 Strong evidence for sexual transmission of Ebola virus, was defined based on the following 3 criteria: Epidemiologic investigation 
identified sexual contact between recipient or index person and single proposed/probable source AND EBOV detected in single 
proposed/probable source’s semen or vaginal secretions (by a vaginal swab) by RT-PCR AND Sequencing indicates high likelihood of 





reporting unsafe sexual intercourse during this period (27). Current WHO interim guidelines advise all 
male EVD survivors to practice safer sex (i.e., abstinence or correct and consistent condom use) for at 
least 12 months after symptom onset or until their semen has twice tested negative (28).	
Among female EVD survivors, there is no evidence of EBOV transmission from contact with vaginal 
fluids (29), but mother-to-child transmission has been documented during pregnancy (30). One case 
report has documented virus persistence in immunologically-privileged sites (i.e. placenta, amniotic 
fluid, umbilical cord blood cord blood) and in foetus tissue after the disappearance of EBOV RNA from 
maternal blood (31). Another case report documented an EBOV-positive stillbirth from a woman with 
serological evidence of prior asymptomatic EVD, suggesting the possibility of ongoing infectivity 
during the convalescent period (32). A literature review found consistent evidence of EBOV RNA in 
pregnancy-related fluids and tissues both during acute EVD (positive blood RT-PCR for EBOV RNA) 
and after recovery, with a potential risk of secondary infection to healthcare workers and community 
members (33). A recent case report from Democratic Republic of the Congo (DRC) documented for 
the first time the birth of two healthy neonates with negative blood tests for EBOV RNA, born to 
positive mothers (positive blood RT-PCR for EBOV RNA) who received investigational monoclonal 
antibody before delivery (34). To mitigate possible secondary transmission during pregnancy and 
delivery, recent WHO guidelines recommend that childbirth and pregnancy complications should be 
managed at Ebola Treatment Centres (ETC) and that Ebola Infection Prevention and Control (IPC) 
measures should be used in pregnant women with acute EVD and in EVD convalescent pregnant (35).	
EBOV has also been detected in breastmilk, although the evidence of transmission via breastfeeding is 
conflicting (36-38). This may be due to the timing of testing the breastmilk, as it is likely that during 
the convalescent phase of the disease, the virus is detectable in breast milk but not in maternal blood 
(37, 39). However, given the high case fatality rates (CFR) associated with exposure in infants and 
neonates, WHO recommended that mothers with EVD confirmed should stop breastfeeding and be 
separated from their children until they have received two consecutive negative EBOV breastmilk tests 
by RT-PCR, separated by 24 hours (35).  
Transmission risk depends on viral load, which is associated with disease severity, culminating in death 
(5); CFR varies from 20% to 90% depending on the virus species (3, 40, 41). Funeral events may start 
a “super-spreading event”, in which contact with a case at their most infectious stage can amplify 
transmission within a community (13). As documented in 2014 in Guinea, 85 confirmed cases were 
traced back to a single funeral (42), and a specific protocol has been developed to guide safe and 
dignified burial in an EVD outbreak context (43).	
Transmission can also occur through nosocomial contacts, and this is a major cause of amplification of 
EVD outbreaks which hampers control efforts (44-46). Infections among Health care workers (HCWs) 





(now South Sudan), with catastrophic impact on the health system (47-49). In the 1976 South Sudan 
outbreak, the hospitalization of one positive case led to 41 HCW dying, and one-third of the 220 hospital 
staff acquiring infection (50). In the same year iatrogenic amplification due to use of infected needles 
was documented in a missionary hospital in Yambuku, DRC (47). In 1995, in Kikwit DRC, 80 HCW 
were infected in a regional hospital, and in 2000 in Uganda, 425 cases (including 17 HCW) were linked 
to nosocomial transmission (50). During the 2014-2016 EVD West African outbreak, 815 health staff 
were infected (for 635 the outcome was available), among those with known outcome 418 died (51). In 
Sierra Leone, 221 HCWs died from EVD and the ratio of skilled health staff to population size was 
dramatically reduced from 17.2/10,000 people before the outbreak to 3.4/10,000 at the end of the EVD 
outbreak (52). In the 2018-2020 outbreak in North Kivu/Ituri, DRC, 5% of all cases were among HCWs 
(171 cases) (53). Current WHO guidelines focus on the critical aspect of IPC, availability and correct 






1.3 EVD outbreaks  
	
Since its discovery in 1976 in two simultaneous and unrelated outbreaks in Zaire (now DRC), and 
southern Sudan (now South Sudan), EVD has been considered a severe rare infection causing localised 
outbreaks (47, 55). Historically, EVD outbreaks have been detected when a symptomatic case reaches 
a health facility, initiating nosocomial infection and amplification of transmission amongst patients and 
health staff (47). Between 1976 and 2012, twenty-three EVD outbreaks and isolated cases were 
documented, with the largest reported in Uganda (n=425 cases), and the most lethal in DRC 
(CFR=90%) (3, 50, 56, 57). Outbreaks repeatedly affected DRC (n=6), Uganda (n=5), Gabon (n=4), 
Republic of the Congo (n=3) and Sudan (n=3) (57, 58) (Figure 1).  
In 2014, two unrelated EBOV outbreaks occurred in DRC and West Africa. In DRC, the outbreak 
started in August 2014 and was controlled within 3 months. It resulted in 66 cases and 49 deaths (58). 
In contrast, the 2014-2016 West African outbreak caused 28, 639 cases and 11,316 deaths in 6 countries 
over 2 years (59). The outbreak began in December 2013 in Guinea (n=3,804)5. In March 2014 the first 
case was notified in Liberia (causing 10,675 cases), in May 2014 the first EVD case was notified in 
Sierra Leone (n=14,124), in July 2014 in Nigeria (n=20), in August 2014 in Senegal (n=1) and October 
2014 in Mali (n=8). Between 2014 and 2015, imported EVD cases from West Africa arrived in the USA 
(n=4), UK (n=1), Italy (n=1) and Spain (n=1) (59, 60) (Figure 1-2). 
 
In August 2014, WHO declared the West African EVD outbreak to be a Public Health Emergency of 
International Concern (PHEIC), which represent a public health ‘extraordinary event’ and a “public 
health risk to other States” (61). The outbreak was “extraordinary” in term of number of cases and 
deaths, geographical distribution (urban and rural areas) and the time required to control it. In September 
2014, the US Centers for Disease Control and Prevention (CDC) published forecasts indicating a 
catastrophic scenario of 1.4 million EVD cases unless 70% of cases were safely isolated (62). This 
announcement, coupled with advocacy efforts, triggered a number of international commitments to 
support the response effort, such as UN Mission for Ebola Emergency Response (UNMEER), although 
the majority of these were not delivered until after the peak of the epidemic had been passed (63). 
In 2015, after two incubation periods (42 days) since the last EVD patient had tested negative, WHO 
declared Liberia (9 May), Sierra Leone (7 November) and Guinea (29 December) free of EBOV 
transmission (64). Subsequently all three countries experienced small and isolated EVD outbreaks 
which were controlled with a combination of early detection and integrated interventions, resulting in 
a limited number of secondary cases (64). Finally, on 29th March 2016, WHO declared that the EVD 
																																								 																				
5 Guinea: WHO officially declared EVD outbreak on March 2014 when the first EVD case was confirmed, but the index patient, was 





outbreak no longer represented a PHEIC and the recommendations adopted in response to the outbreak 
were lifted (65).    
Virology studies suggest that the West African EVD outbreak strain was closely related to the Zaire 
strain circulating in a previous outbreak in DRC (97% homology, but classified as a different clade) 
and most likely had circulated in zoonotically in West Africa since 2004 (66, 67). The rapid and 
widespread West African EBOV transmission was due to a number of factors including weak 
surveillance, scant IPC in hospitals, non-specific initial clinical presentation, traditional burial 
procedures, porous borders, distrust of authority, late response and lack of knowledge about the disease 
and control strategies (64, 68). 
Between 2017 and 2020, DRC experienced four additional unrelated EBOV outbreaks including an 
area of protracted conflict (North Kivu and Ituri provinces) (69-72). The outbreak in North Kivu/Ituri 
is the second largest protracted EVD outbreak after the 2014-2016 West Africa outbreak, with 3481 
cases, among those 2299 died, it lasted from August 2018 to June 2020 (73). In July 2019, following a 
case in Goma (the capital of North Kivu province, a city of 2 million people on the border with Rwanda) 
and imported transmission from DRC in Uganda, the International Health Regulations Emergency 
Committee on Ebola Viral Disease (IHREC) declared the North Kivu/Ituri outbreak to be a PHEIC 
event (74). During this outbreak, important advances occurred on use of investigational drugs, and 
widespread EVD immunization campaign with promising preliminary results (4, 75) (see section 1.7 
Treatments and vaccines). However, this outbreak further challenged response organizations, and their 
modus operandi toward communities who have been largely neglected by humanitarian organizations 
(75-77). The outbreak unfolded in a war zone, with over one million internally displaced people (IDP), 
and was characterized by chronic tension between local civilian and the government (78, 79). The 
response was further exacerbated by the community withdrawing from the responding organization due 
to fear of being misdiagnosed with EVD and being forced to be isolate far from family and community 
in dedicated Ebola isolation centres, or due to the concern of being exposed to EVD in general health 
facilities (77) (see section 1.4, point 7 community engagement and barriers with EVD response). During 
the outbreak, several attacks to Ebola isolation centres and health facilities occurred, with causalities 
including HCWs and patients (80, 81). Use of military to support implementations of control strategies 
further contributed to distrust and reinforced the belief that the EVD response was part of a larger 
















Figure 2. Countries affected by 2014-2016 EVD West Africa outbreak, (‘‘darker shades of blue indicate higher 
numbers of confirmed EVD cases’’), original map from Bart SM (60)   



















1.4 Public health interventions to control EVD outbreaks  
	
Based on understanding of transmission routes, from previous outbreaks, seven public health pillars 
(plus access to laboratory facilities, see section 1.5 Diagnosis and diagnostic methods) have been critical 
to control EVD outbreaks occurring between 1976 to 2016 (82-85).  
Toward the end of the 2014-2016 West Africa EVD outbreak, the availability of vaccines supported 
outbreak response (see section 1.7 Treatments and vaccines).  
 
The public health pillars were surveillance, contact tracing, case isolation, safe and dignified burial, 
IPC, social mobilization and community engagement. The aims of each pillar are given below.  
 
1. Surveillance: To detect the index case, monitor population transmission, and identify areas for 
intervention;  
 
2. Contact tracing: To monitor contacts of cases for 21 days since their most recent EVD exposure 
and to timely isolate exposed contacts who become symptomatic; 
 
3. Case isolation in specific EVD centres: To prevent secondary transmission in communities and 
health facilities through the use of Ebola isolation centre (i.e., Ebola Management or Treatment 
Centres (EMC/ETC)), with specific IPC measures including PPE;  
 
4. Safe and dignified burial: To prevent secondary transmission during funeral ceremonies of 
those who have died or suspected to die from EVD; using trained burial teams and specific IPC 
procedures; 
 
5. IPC ring approach to non-Ebola health facilities: To prevent secondary infection in health work-
ers and health facilities using; enhanced IPC and triage approach in areas of intense EVD trans-
mission; 
6. Social mobilisation: To disseminate messages on infection, transmission, and control strategies, 
7. Community engagement and documented barriers for communities to engagement with EVD 
response. To actively consult communities by create a participatory infrastructure; gathering 
epidemiological and behavioural information to improve effectiveness and relevance of public 







The ethical aim of community engagement is to enhanced protection, benefits, legitimacy, and shared 
responsibility between public health actors and affected populations (86). However, those ethical 
principles have been challenged during EVD outbreaks, with consequent practical and moral dilemmas 
which have also impacted the performance of the other pillars (87). For instance, affected communities 
were often consulted only after months of uncontrolled EVD transmission, or retrospectively at the end 
of outbreak, or when critical security incidents have occurred (88, 89). 
 
In Sierra Leone, public health EVD responses have taken insufficient account the views and experience 
of affected population, with community left out of the decision-making process (89). This has fuelled 
misinformation and compromised the credibility of public health actions due to scepticism about the 
disease’s existence, and speculation about the use of the virus to suppress specific population groups. 
(89-91). Barriers faced by the community included the use of public health messages that emphasised 
that EVD was a deadly disease, and lack of incorporation of local beliefs and practices into patient care, 
as well as distance to isolation centres, as identified in previous EVD outbreaks in Uganda, Angola, 
DRC and West Africa (92-95). 
 
In the early months of the EVD outbreak in Sierra Leone, the community witnessed family members 
forcibly taken from their homes (88). Several families reported never hearing back from the relative 
taken to the Ebola centre (96). Other’s patients were buried in mass graves, against local practice and 
beliefs. These factors all contributed to fears about dying alone in an Ebola isolation centre (94).  
Poor community engagement has been in part ascribed to the architecture of the humanitarian system 
often rigid and driven by a biosafety perspective, where community engagement has not been prioritized 
as integral part the moral duties from responding actors (97). During the EVD West Africa outbreak, 
the fluid nature of social dynamics wasn’t acknowledged, with the response system unable to 
understand, negotiate, and adjust interventions over time and across contexts (98). Use of militarised 
escorts to implement EVD interventions in volatile contexts (i.e., North Kivu/Ituri, provinces in DRC) 
also contributed to community withdrawal, the deterioration of security, and consolidation of population 
distrust in the response effort (76). 
 
Public health stakeholders have often assumed that is responsibility of communities to meet the needs 
of responders, to hand over their relatives to an uncertain and often fatal outcome in Ebola facilities, to 
report their family, friends and neighbours to disease surveillance staff, and to then have limited 
freedom and livelihoods (99, 100). Use of vertical coercive EVD control measures have exacerbated 
pre-existing tension and contributed to compromise trust into public-health interventions (87). For 
instance, in Liberia, use of an incentive scheme to increase case reporting of suspected cases was refused 
by the community and perceived to further increase social disruption (101). Instead, consulted 





providing food for families in quarantine, increasing communication between Ebola facilities and 
families, increasing basic health services, providing psychosocial support for affected families, and 
including Ebola survivors in teams involved on active case-finders and contact-tracers) (101). 
 
Stigma associated with EVD infection has also been described as an additional factor that has 
contributed to generate rumours, community disengagement, with consequent delay on access to care, 
and outbreak control (102). 
 
Failure to recognise the social dimension and value of traditional burial rituals on management of EVD 
deaths during burial procedures have further discouraged community on reporting deaths and adhere to 
strict biomedical burial procedures (103, 104). In Liberia, cremation procedures used to manage EVD 
deaths have contributed to social breakdown, increasing inequalities among people who could afford 
private funerals and disadvantaged people who were obliged to accept cremation (105). Following the 
outbreak community have express the desire to have a form of formal commemoration to retrospectively 
honour EVD deaths (106). 
 
Inconsistent distribution of aid to affected communities have further contributed to social disruption 
and poor community compliance (105, 107). EVD outbreaks have occurred in settings with fragile 
health systems, and use of significant resources dedicated to EVD has led to neglect other relevant local 
health burden. Thus, resources for EVD control have been perceived largely inconsistent with the rest 
of health and humanitarian needs (107, 108). In Sierra Leone, significant changes in EVD-related 
behaviour (i.e., prompt referrals to treatment and safe burials) were documented when community 
meetings were held to identify priority area of interventions and when identified needs were consistently 
delivered (109). This was consistent with other successful public health models that engaged more 
meaningfully with communities, strengthening proximity and encouraging mutual dialogue (110, 
111).The discrepancies between different actors on how to set up participatory dialogue and practices 
with affected population has also contributed inconsistency on community engagement and on design 
and delivery of EVD interventions (89). 
 
Finally, in retrospect, interventions which failed to respect, sympathize and recognise community in 
their multiple social and believe dimensions have ultimately become barriers for community to engage 








1.5 Diagnosis and diagnostic methods 
	
Clinical presentation of patients with EVD is non-specific, and can be confused with other endemic 
tropical diseases, including malaria (see section 1.6 Case definition and clinical presentation) (4, 5, 11).  
Rapid and accurate diagnosis of EVD is therefore crucial for outbreak control to interrupt the chain of 
transmission, support patient management (i.e., isolation and discharge), follow EVD survivors during 
the convalescent phase, and retrospectively identify paucisymptomatic or asymptomatic cases (54, 112).	
Current EVD diagnostics include: i) molecular techniques to detect viral RNA nucleic acids, ii) rapid 
antigen test to detect viral proteins, and iii) serological assays to detect host antibodies produced against 
the virus (113). 
For EVD confirmation, WHO recommends the use of molecular technique such us RT-PCR which 
detect viral RNA in blood and non-blood specimens. RT-PCR results are expressed in cycle threshold 
(Ct), and are used as indicators of viral load (114). The lower the Ct value the higher the viral load, the 
minimum RT-PCR detection limit is 1000 virus RNA copies per mL of blood (5). However, RT-PCR 
can detect copies of viral RNA, but does not distinguish between viable, infectious, virus or residual 
RNA, therefore interpretation of Ct value needs to be always interpreted together with clinical and 
contact history of patients (25, 115, 116). For instance, RNA virus can be undetectable by RT-PCR in 
the first 1–3 days after symptom onset, and a second blood specimen is required for any negative test if 
taken within 72 hours of onset of symptoms. references (54). Viremia peak 3 to 7 days after disease 
onset, and decline under the detection threshold 2 to 3 weeks after the onset of symptoms (5).	
WHO defines EVD survivors as ‘a person: with a confirmed positive result on RT-PCR testing for 
Ebola virus on any body fluid who subsequently recovered; AND/OR who is IgM and/or IgG positive 
on serological testing for EVD and has not been vaccinated against Ebola virus’	(117).  
Current interim WHO guideline indicated that patients diagnosed with EVD are eligible for discharge 
from Ebola isolation facilities if they had ≥3 days without any symptoms and signs and negative blood 
RT-PCR; for patients with persisting symptoms discharge from isolation is considered after two RT-
PCR negative blood tests, conducted 48 h apart (54). However, in other centres in Europe and USA, 
which cared for EVD patients during the 2014-2016 West Africa outbreak, discharge criteria varied 
according centres; with some centres using as discharge criteria negative RT-PCR tests on blood and 
other non-blood fluids (i.e., urine) and EBOV cell culture under biosafety level 4 containment (118). 
Patients who survive EVD, can have a prolonged convalescence period, in those patients, RT-PCR is 
used to detect virus persistence in other non-blood body fluids (e.g. semen) and or immuno-privileged 





There are currently no available and validated diagnostics tests which could detect Ebola virus prior to 
the onset of symptoms, and diagnostic tests may vary on the panel of species which they are able to 
detect (i.e., EBOV, SUDV, BDBV) (113).  
During the 2014-2016 West Africa outbreak, WHO added the Xpert® Ebola Test (Cepheid AB - Solna, 
Sweden) to its list of RT-PCR Ebola diagnostics eligible procurement (120-122). (Table 2, section A) 
Use of rapid antigen test as screening tools in patients meeting clinical and epidemiological criteria 
compatible with EVD, is recommended by WHO in remote settings where access to RT-PCR is not 
immediately available or in settings where number of cases has overtaken isolation and laboratory 
capacity; any rapid antigen test specimens (either positive or negative) must be retested by RT- PCR 
for confirmation (123). The performance (i.e., sensitivity and specificity) of molecular diagnostic (RT-
PCR) and rapid antigen tests are currently benchmarked against the PCR Trombley assay, which is 
considered the gold standard (124). WHO define an acceptable performance for rapid antigen tests when 
sensitivity is > 95%, and specificity is > 99% (125). 	
Guidance on the use of rapid antigen test is based on a WHO Interim Guidance published in 2015. At 
that time Corgenix ReEBOV was the only rapid antigen test identified by WHO as appropriate for use, 
but it is no longer on the market (126). Currently the only rapid antigen test approved by WHO and the 
FDA (Food and Drug Administration) is the OraQuick Ebola Rapid Antigen, which can identify 
antigens/protein associated with EVD both in the blood from symptomatic patients and in oral fluid 
taken post-mortem (120, 127, 128) (Table 2, Section B). 	
An evaluation of the performance of other non-approved rapid antigen tests in a cohort of 205 samples 
from positive and negative EVD patients during the 2014-2016 West African outbreak found good 
performance (sensitivity 77.06%, specificity 91.67%) but still below the acceptable performance criteria 
set by WHO against the reference standard RT-PCR (129) (Table 2, Section C). 
Usually, molecular diagnostic (RT-PCR) and rapid antigen tests are used to identify EVD acute 
infection when patients are symptomatic and virus levels or virus protein are high in patients’ blood (3-
10 days after the onset of symptoms) (Figure 3). Both methods are also used post-mortem to test 
cadaveric fluid (oral swab) to retrospectively identity EVD deaths (113, 120, 128). As mentioned 
previously, RT-PCR is also used in the convalescent period to detect virus persistence in survivors in 
other non-blood body fluids (5).	
Serological tests are used to retrospectively identify paucisymptomatic or asymptomatic cases when 
RNA virus is not detectable in the blood and when Ebola-specific antibodies are present instead (130, 
131). In 1955, in the Kikwit outbreak in Democratic Republic of the Congo (DRC), a serological study 
among 29 EVD survivors found that IgM antibodies appeared 2-9 days after symptom onset (persisting 





to 749 days since the first test) (132). Recently, serological studies have been conducted in Republic of 
Congo, where recurrent EVD outbreaks had occurred, reporting seroprevalence of IgG Ebola-specific 
antibodies of 2.5%, reaching prevalence of 4% among rural populations (133). Another study, in DRC, 
found antibody seroprevalence of 18.7% among pygmies’ communities (134). In DRC, other authors 
have documented a sero-reactivity of 28.1% for IgG among 565 healthcare workers without history of 
EVD but living in an area where in 2014 an EVD outbreaks have been previously documented (135).  
More recently a cross-sectional seroprevalence study was implemented to rebuild chain of transmission 
in Guinea where the index case of the West Africa was first reported, the study involved 237 individual 
and identified additional eight previously undetected seropositive survivors, illustrating the use of se-
rology in understanding the chain of transmission (136). 	
There are few performance studies of serological tests, however a cross-sectional seroprevalence study 
among contacts of 151 EVD survivors found high sensitivity (95.9% (95% CI 89.8–98.9) and high 
specificity (100% (95% CI 98.9–100) in one serological essay not yet validated by WHO (131) (Table 
2, section D). Similar results were observed with another serological study among 94 EVD survivors 
using a different serological assay (137) (Table 2, section E). 
In summary, each diagnostic tool should be used and interpreted according to phase of infection, clinical 
presentation and contact history of patients. Each can inform outbreak response, through the 
identification of infectious cases (when RT-PCR is positive in blood or RT-PCR is positive in oral swab 
in EVD death), supporting follow up of survivors (by identifying RNA persistence in non-blood bodily 
fluids, such as semen in EVD survivors) or rebuilding chains of transmission to identify 
paucisymptomatic or asymptomatic case (i.e., serological test to detect IgM or IgG). 














Table 2. Main categories of diagnostic test for EVD and performance 
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Figure 3. Time sequence of the evolution of the Ebola virus infection and disease and diagnostic method; adaptation 


















1.6 Case definition and clinical presentation 
 
The initial clinical symptoms and signs of EVD are non-specific and overlap with other common 
tropical diseases (including malaria, Typhoid fever, Lassa fever, Meningococcal disease, shigellosis, 
plague, leptospirosis, anthrax, relapsing fever) (4, 11). This non-specificity contributes to delays in 
detection of cases, the confirmation of an outbreak, and timely implementation of control measures (9, 
11).	
EVD WHO case definition used during outbreak encompass four main categories: suspect, probable 
confirmed cases, and non-case, according to clinical presentation, history of contact, and laboratory  
results (138) (Table 3). 
The understandings of the clinical presentation and route of transmission of EVD have been established 
by retrospective review of exposure history, contact tracing and clinical observation (3, 5, 139, 140). 
These have indicated that people are not contagious until they develop symptoms (9). EVD incubation 
period (time interval from infection to onset of symptoms) range from 2-21 days depending on the 
species and route of transmission6 (5, 9, 140). Typically, the disease evolution is rapid (within 10 days 
of symptom onset), and following three main clinical phases (5):	
1. First phase: 1-3 days: flu-like symptoms (i.e., fatigue, myalgia); 
2. Second phase: 4-7 days: presentation of both “wet” symptoms (i.e., vomiting, diarrhoea (up to 
10 litres per day)), and “dry” symptoms (headache); 
3. Third phase: 7-10 recovery or death (bleeding that occur in less than half of affected patients); 
Additionally, chest pain, hiccups, miscarriage, cough, conjunctival injection, neurological and ocular 
symptoms have also been reported (5).	
The virus induces direct tissue damage, through a paradoxical cascade of inflammatory responses that  
can ultimately result in multiple organ failure and onset of a septic shock-like syndrome (141) (see 
Annex 1.1 Underlying EVD pathophysiology). A systematic review and metanalysis reported 
difference in clinical features between fatal cases and EVD survivors with bleeding, vomiting, and 
diarrhoea observed in more than 60% of patients who died compared to EVD survivors (142).	
During the convalescent period, longitudinal studies and systematic reviews have described several 
clinical and immunological alterations among EVD survivors, including arthralgia, encephalitis, post-
																																								 																				
6 Route of exposure and variation in mean incubation period (6·3 days, versus in infection known to be due to injection versus 9·5 days ex-
posures by contact). 140. Breman JG PP, Johnson KM, White MK, Mbuyi M, Sureau P, Heymann DL, Van Nieuwenhove S, 
Mccormick  JB,  Ruppol  JP, KIntokI V, Isaacson M, Van der Groen G, Webb PA, Ngvete K. The epidemiology of Ebola haemorrhagic 






traumatic stress disorder (PTSD), hearing loss, uveitis, inflammation of one or both testicles, changes 
in menstruation, impotence, persistence of immune activation and inflammatory pathways (143-152).  
These are described collectively as post Ebola syndrome or chronic Ebola virus disease (CEVD) (144, 
153). 
Among a cohort of 277 survivors, high viremia levels during the acute phase of EVD infection were 
associated with an increased risk of uveitis (adjusted odds ratio [aOR] 3.33, 95% CI 1.87–5.91) 
compared to those without uveitis (150).  
However, it is unclear whether the EVD-associated syndrome is caused by direct effect of virus or to 
immune complex deposition or dysregulated immune response (154).	
Annex 1 provides an overview of the likely underlying pathophysiology of EVD, the groups at most 
risk of negative outcomes, and malaria co-infection. 
Table 3. World Health Organization (WHO) EVD case definitions used during EVD outbreaks, to define 
suspect, probable, confirmed cases and non- case (138) 
 
Suspect  Probable  Laboratory confirmed 	 Non-Case 
a. Any person, alive or dead, 
suffering or having suf-
fered from a sudden onset 
of high fever and having 
had contact with: - a sus-
pected, probable or con-
firmed Ebola or Marburg 
case; - a dead or sick ani-
mal;  
OR 	
b. Any person with sudden 
onset of high fever and at least 
three of the following 
symptoms: - headaches - 
lethargy - anorexia / loss of 
appetite - aching muscles or 
joints - stomach pain - 
difficulty swallowing - 
vomiting - difficulty breathing 
- diarrhea - hiccups; 	
OR 	
c. Any person with 
inexplicable bleeding; 	
OR  
d. Any sudden, inexplicable 
death	
a. Any suspected case 
evaluated by a clinician; 	
OR 
b. Any deceased 
suspected case (where 
it has not been 





link with a confirmed 
case 
 
a. Any suspected or 
probably cases with a 
positive laboratory result. 
Laboratory confirmed cases 
must test positive for the 
virus antigen, either by 
detection of virus RNA by 
reverse transcriptase-
polymerase chain reaction 
(RT- PCR), 	
OR by detection of IgM 
antibodies directed against 
Marburg or Ebola.	
a. Any suspected or 
probable case with a 
negative laboratory 
result. “Noncase” 
showed no specific 
antibodies, RNA or 
specific detectable	
antigens.	
N.B.	During an outbreak, case definitions are likely to be adapted to new clinical presentation(s) or different modes of 







1.7 Treatments and vaccines 
 
1.7.1 Patient management and investigational treatments  
 
Before and during the 2014-2016 West Africa EVD outbreak, standard care of EVD cases was focused 
on addressing the main clinical symptoms and signs including: i) supportive care to balance volume 
deficits and hypoperfusion (using oral rehydration or intravenous crystalloid infusion); ii) treatment of 
presumptive co-infection (i.e., malaria treatment,	antibacterial therapies); ii) mitigation of symptoms 
like nausea, vomiting, pain (using of antiemetic agents, and opiates); iv) mental health support for 
patients and families, and (v) nutritional support (4, 5). Correction of electrolyte levels and 
hypoglycemia were introduced in patient care following the introduction of point-of-care biochemistry 
testing during the West Africa outbreak (155). Patient care is provided in dedicated Ebola isolation 
centre where trained HCWs and specific IPC protocols must be in place (54).	
In August and September 2014, WHO, with a committee of experts, listed investigational therapy which 
showed antiviral efficacy and safety in vitro or in animal models, and postulated that investigational 
therapeutics could be offered to EVD patients in clinical trials, or under emergency or compassionate 
use basis (although this last option would not allow sufficient evidence about safety and efficacy) (156, 
157). Since 2014, studies using a range of investigational therapies have been implemented (158),	in 
isolation centres, with a common aim of reducing EVD fatality by lowering viral replication, curbing 
the inflammatory response and facilitating the innate and adaptive immune responses to clear the virus 
(5).  
In 2014 in Guinea, a multicentre non-randomised comparative study assessed the survival benefit of 
Favipiravir (T-705) and standard of care (a synthetic drug with antiviral activity) versus historical 
controls who received only standard care (159). The study enrolled 126 patients and 540 historical 
controls (patients treated at the same EMC centre in the previous months). In the final analysis 99 
patients received Favipiravir and standard of care. Interim analysis showed that in the intervention 
group viremia was a strong predictor of mortality; mortality was 91% (95% CI 78.8%–91.1%) in the 
group of patients with high viral load (Ct value < 20) compared to a mortality of 20% (95% CI 11.6%–
32.4%) in patients with Ct value ≥ 20 (159), p< 0.001. Both 95% CIs for the mortality estimates included 
the predefined target values (baseline value in the centres before the trial) of 30% (for patents with Ct 
value ≥ 20) and 85% (for patients Ct value < 20). Thus, the study could not prove efficacy, in particular 
for patients with high viremia, but provided strong evidence for the rationale to stratify patients by Ct 
value when designing similar trials (159). Results from this study were judged by the Ministry of Health 
and Public Hygiene of Guinea sufficient to add Favipiravir, under a compassionate use, to standard of 





In 2014 in Liberia, a retrospective cohort study of EVD patients compared mortality between those who 
received two different antimalarial treatments in two different periods when the centre had a shortage 
of the first-line malaria drugs (artemether-lumefantrine) (161). The mortality risk was significantly 
lower among the 194 patients receiving artesunate-amodiaquine than among the 71 patients receiving 
artemether-lumefantrine (50% vs 64%; risk ratio=0.69, 95%CI 0.54-0.89 adjusted for confounding 
variables (age, sex, Ct value, time from symptom onset to admission, malaria test result, type of standard 
care and bed occupancy on the day of patient admission) (161). However, the study had several 
limitations including the observational design, that could not prove a definite survival effect, and 
authors recommended future study for stronger evidence.	
Between 2014 and 2015, in Sierra Leone, a non-randomised two-centre comparative study assessed the 
survival benefit of convalescent blood transfusions versus standard care (162). Among the 69 
participants (43 in the intervention group (one dropped out in a second stage), 25 in the control group), 
the odds ratio for survival was 2.3 (95% CI 0.8–6.5) in the blood convalescent group (162). However, 
the small sample size and the non-randomised design limited the conclusions about efficacy to reduce 
mortality.	
In 2015 in Guinea, a larger non-randomised comparative study with historical controls also assessed 
the survival benefit of convalescent plasma versus standard care (163). This study enrolled 84 patients 
given convalescent plasma and compared with and 418 historical controls (EVD patients isolated at the 
same centre in the previous months). The risk of mortality was 31% in the intervention group and 38% 
in the control group (risk ratio=0.88 (95% CI 0.51–1.51), adjusted for age and viral load) (163). Again, 
this study did not provide evidence of survival benefit of convalescent plasma. 	
In March 2015, the PREVAIL II (The Partnership for Research on Ebola Virus in Liberia) study started 
in Guinea, Sierra Leone, Liberia and United States (164). This was first and only multicentre 
randomised controlled trial (RCT) during the West Africa outbreak. Patients were randomly assigned 
in a 1:1 ratio to receive ZMapp (monoclonal antibody cocktail) plus standard of care versus vs standard 
of care alone. In Guinea, standard of care also included Favipiravir following the earlier study (159). In 
the study a probability ≥ 97.5% was required to establish efficacy. Overall, 72 patients were enrolled, 
stratified by baseline Ct value (≤22 vs. >22) and country of enrolment. Overall, the risk of mortality 
was 22% in the ZMapp group vs 37% in the control group. In the study the Bayesian estimate of the 
absolute difference in mortality, between the intervention group and the control group, was −14 
percentage points, and the relative difference was −38%, giving a 91.2% posterior probability that the 
intervention was superior to the non-intervention; this value was below the established probability 
threshold (≥ 97.5%) for declaring superiority of the investigational treatment. The frequentist results 
estimated a mortality difference of −15 percentage points (95% confidence interval [CI], −36 to 7) and 





required to establish superiority to standard care; the results were suggestive of effectiveness but not 
statistically conclusive. 
During the 2014-2015 West Africa outbreak, an additional four studies were conducted: i) two non-
randomised single-arm intervention studies with concurrent controls using TKM-130803 (interfering 
RNA product) and Interferon β-1a (immunomodulators) respectively in Sierra Leone and Guinea; ii) a 
non-randomised single-arm intervention study with historical controls using Favipiravir in Sierra 
Leone; and iii) a non-randomised single-arm intervention study without controls using Brincidofovir 
(antiviral drug) in Liberia, however none of them could prove survival benefit (165). 
Case reports on patients infected in West Africa but treated in USA and other European country were 
also published (166). Overall, 27 EVD patients received care outside West Africa. Among these, 23 
(85%) received investigational therapies (with 19 (70%) receiving more than one investigational 
therapy) (166). Overall, 7 patients (26%) received invasive mechanical ventilation, among those 5 
received also continuous renal replacement therapy. Five of the patients died, giving a CFR of 18.5% 
(95%CI 6.3%-38.1%) for the group treated outside West Africa compared to an estimated CFR of 
62.9% (95% CI 61.9–64.0%) among patients in West Africa (167). Ethical concerns were raised about 
access to investigational therapy, as fewer than 5% of patients in West Africa had access to 
investigational therapy versus 85% of those treated outside the region (168). Similar ethical concerns 
were raised in Guinea for EVD pregnant women, where access to investigational drugs outside clinical 
trials was extremely challenging (169). 
Lessons learned during the 2014-2016 West Africa outbreak on study design, implementation and 
outcome predictors (e.g. the importance of stratifying by Ct value in RCTs) were utilised during the 
2018-2020 second largest EVD outbreak in DRC (North Kivu and Ituri provinces). During this outbreak 
four investigational drugs were given to patients under a WHO protocol of Monitored Emergency use 
of Unregistered and Investigational interventions (MEURI) within an RCT (Pamoja Tulinde Maisha 
(PALM) trial) (170). The PALM trial was a multicentre RCT, in which patients were stratified by Ct 
value (≤ 22 or > 22) and ETC of enrolment. The primary end point was mortality by 28 days. All 
participants received standard care and were randomised with an allocation ratio 1:1:1:1 to receive 
either ZMapp™ (control arm), remdesivir (a broad-spectrum antiviral), mAb114 (single monoclonal 
antibody, obtained from memory B cells from a survivor of the 1995 Kikwit DRC outbreak) or REG-
EB3 (monoclonal antibody cocktail, obtained by mice that encode human antibody). ZMapp was chosen 
as the control condition, based on the PREVAIL II trial results (164). The REGN-EB3 group was added 
in a second version of the study protocol, therefore data from this group was compared with patients 
ZMapp group (called in the analysis the ZMapp subgroup), who were enrolled the time or after the 
REGN-EB3 group was added. From November 2018 to August 2019, the PALM trial enrolled 681 





for patients receiving MAb114 or REGN-EB3, compared with those receiving remdesivir or ZMapp, 
leading the independent study committee to recommend suspension of the remdesivir or ZMapp trial 
arms. The final results showed evidence that patients receiving Mab114 or RWGN-EB3 had better 
survival outcomes than patients receiving ZMapp. The mortality risk was 35.1% (61/174 patients) in 
the MAb114 group, compared with 49.7% (84/169 patients) in the ZMapp group (the difference was 
−14.6 percentage points (95% confidence interval [CI],−25.2 to −1.7; P=0.007); and 33.5% (52/155 
patients) in the REGN-EB3 group, compared with 51.3% (79/154 patients) in the ZMapp subgroup (the 
difference was a−17.8 percentage points (95% CI,−28.9 to −2.9; P=0.002).	 In addition the study 
observed that overall the proportion of patients who died was lower (27.1% (42 out 155)) among 
patients who reported history of vaccination (rVSV∆G-ZEBOV-GP vaccine, see section 1.7.2 
Vaccines) than among those who reported no previous vaccination (48.4% (225 out 465)). However, 
patients who reported vaccination were also more likely to have lower viremia (higher Ct values), better 
hepatic markers and early access to care since onset of symptoms (e.g. mean of 3.8 days among the 
vaccinated group versus a mean of 5.9 days in the non-vaccinated); further studies will better elucidate 
the relationship between previous vaccination and EVD outcome. The RCT included also pregnant 
women and children aged under five years respectively, thus providing the first preliminary data on 
safety and efficacy for these populations. The PALM trial results informed the recent WHO guidelines 
that now recommend “access to and use of investigational therapeutics under MEURI be carefully 
considered for each individual patient, including for vulnerable populations such as pregnant women 
and paediatric patients, as appropriate given the available data”, and that “In general, the expert panel 
recommends consideration of factors such as disease severity and risks/benefits of investigational 
therapy (including adverse effects in pregnant or paediatric populations)” (35). 
Between October and December 2020, the FDA approved the Inmazeb (also known as REGN-EB3) 
and the Ebanga (also known as mAb114), for both paediatric and adult populations (171, 172). 
However, despite the enormous progress, there remains a lack of evidence on efficacy of drugs that 
could penetrate immune privileged tissue (i.e. eyes, brain, testes) thus mitigating late patient sequelae 
and the virological reservoir in EVD survivors, along with combination of therapy to target multiple 
EVD strains (5). 	
The availability of specific EVD therapeutics has contributed to a shift in the language, design, and 
functions around Ebola isolation centres as places where patients were supported to places where 
patients can access treatment - thus we now refer to Ebola Treatment Centres (ETC) rather than Ebola 
Management Centres (EMC). These centres have a dual function – prevention (interrupting the 
transmission chain by isolating infectious cases), and treatment (providing specific individual treatment 





However, despite the availability of new effective therapeutics, the main challenge remains to improve 
health seeking behaviour, so people attend ETCs and to build community trust toward responding 
organisations. This is demonstrated by the low number of cases treated (n=681) versus the overall 
number of cases (n=3481) detected during the 2018-2020 North Kivu/Ituri outbreak. Findings from a 
community survey conducted in North Kivu DRC at the time of the outbreak, shortly before the PALM 
trials started, found that, among the 931 participants, 32% and 25% of survey respondents respectively 
had low trust in local authorities and believed that EVD was not real. In the study, both factors were 
associated with a reduced likelihood of seeking health care and with poor compliance with preventive 































In August 2014, WHO called for fast-track development of Ebola vaccines as part of the public heath 
road map for the Ebola response in West Africa (85). On November 2014, a special Strategic Advisory 
Group of Experts (SAGE), working Group on Ebola Vaccines and Vaccination was established (174). 
WHO set up an Emergency Use Assessment and Listing (EUAL) to accelerate the procedure and 
availability of Ebola candidates vaccines during public health emergency (175). 
 
Since the 2014-2016 West Africa outbreak, 15 Ebola vaccines candidate underwent clinical 
development (176); vaccines encompassed three main categories: i) non-replicating vector vaccines, ii) 
replicative vector vaccines, and iii) other types of vaccines (177). 
 
Between 2015 and 2017, two different vaccines have been domestically approved these included  
respectively the prime/boost candidate vaccine based on rVSV- and Ad5-vectored components 
(GamEvac-Combi) licensed by the Ministry of Health of the Russian Federation based; and the 
monovalent vaccine based on recombinant adenovirus type-5 vector (Ad5-EBOV) licenced by China 
Food and Drug Administration (CFDA) (177), Table 4. 
 
In 2019, the vesicular stomatitis virus–Zaire Ebola virus (rVSV-ΔG-ZEBOV-GP) was approved by the 
European Medicines Agency (EMA) and was licensed for marketing as Ervebo® in the European Union 
(178). This vaccine has also been granted approval for clinical use by United States and has been pre-
qualified by WHO (179). This vaccine is a live attenuated replication competent vaccine based on the 
vesicular stomatitis virus which was genetically modified to express a surface glycoprotein (GP) of 
EBOV Kikwit 1995 strain (180) (Table 4); originally developed by Public Health Agency of Canada 
(PHAC) it is currently licenced by Merck. The clinical approval for rVSV-ΔG-ZEBOV-GP, was 
supported by data on safety, immunogenicity and efficacy gathered from clinical trials conducted in 
Africa, Europe and North America (181-190). 
 
Clinical trials started in 2014, when a multicentre Phase 1 trial was designed to assess the safety, side-
effect profiles, and immunogenicity of single dose rVSV-ΔG-ZEBOV-GP (182). The study enrolled 
158 healthy participants and was implemented in 4 sites across Europe and Africa. In 3 sites the trial 
was design as an open-label, uncontrolled study assessing ascending vaccine doses (ranging from 
300,000 to 20 million PFU). In the fourth site the trial was a double-blind, randomized, placebo-
controlled, assessing doses of 10 million and 50 million PFU. The study was initially stopped since 
22% of participants had reactive arthritis, the study resumed using a lower dose of vaccine and showed 





Between February to March 2015, the Partnership for Research on Ebola Vaccines in Liberia I 
(PREVAIL I) implemented a randomised, double-blind, placebo-controlled trial evaluating safety and 
immunogenicity of the rVSV-ΔG-ZEBOV-GP vaccine and the chimpanzee adenovirus type 3-vectored 
Ebola virus vaccine (ChAd3-EBO-Z) enrolling overall 1500 adults (186); in this cohort antibody 
responses was present one months after vaccination (in 70.8% of people who received the ChAd3-EBO-
Z vaccine and in 83.7% of those who received the rVSV-ΔG-ZEBOV-GP), response persisted at 12 
months (in 63.5% of participants receiving ChAd3-EBO-Z and in 79.5% of those who received the 
rVSV-ΔG-ZEBOV-GP).  
 
Between March 2015 and July 2016, in Guinea, a phase 2 clinical trial targeting frontline health workers 
was implemented (189). The study was an open-label, non-randomized trial aiming to assess safety of 
a single dose of rVSV-ΔG-ZEBOV-GP which enrolled 2016 participants and 99 controls. Minor  
adverse events (headache, fatigue, arthralgia) were reported by 70% of participants 3 days after 
vaccination, and 2 of the 8 SAEs were identified during follow-up and occurred in pregnant women. 
Between April and August 2015, in Sierra Leone the STRIVE (Sierra Leone Trial to Introduce a 
Vaccine Against Ebola) clinical trials started; it was a randomized controlled phase II/III trial to assess 
efficacy, immunogenicity, and safety of vaccine of rVSV-ΔG-ZEBOV-GP among 8,673 frontline and 
workers health care workers; participants were randomized to receive either rVSV-ΔG-ZEBOV-GP at 
enrolment or 18–24 weeks after enrolment (190); the study could not prove vaccine efficacy since it 
was implemented when the number of case in Sierra Leone was low but confirmed, data on safety and 
immunogenicity.  
 
A follow up analysis of STRIVE data reported pregnancy outcome among 84 women health workers 
accidentally vaccinated during the STRIVE trial; women were either in early pregnancy or became 
pregnant less 60 days after vaccination (191). The study reported no congenital anomalies among the 
44 out of 51 live births who were examined; the frequency of pregnancy loss was 45% (14/31) among 
immediate vaccinated women compared to 33% (11/33) in the group assigned to deferred vaccination 
(unadjusted RR 1.35 (95% CI 0.73–2.52); p = 0.34). In this study the difference in pregnancy loss 
between the 2 groups was not statistically significant, solid conclusion could not be drawn due to the 
small size was and the retrospective study design (191). 
 
Between March 2015 to January 2016, in Guinea a Phase 3 open-label, cluster-randomised ring trial 
was undertaken in 2015-2016 in Guinea and Sierra Leone to assess the efficacy of a single dose of 
rVSV-ΔG-ZEBOV-GP (184). The study used a ring design in which a list of contacts and contacts of 
contacts was created for each EVD positive case. The list constituted a “ring” or cluster. Each cluster 





later). The primary outcome was laboratory-confirmed EVD with onset 10 days or more from 
randomisation. The trial included 4539 contacts and contacts of contacts, in 51 clusters randomly 
assigned to immediate vaccination, and 4557 contacts and contacts of contacts in 47 clusters randomly 
assigned to delayed vaccination. The trial showed an efficacy of 100% (95% CI 68.9–100.0) p=0.005), 
with mild adverse events. The study also showed the feasibility of implementing a ring-vaccination 
approach during an EVD outbreak.  
 
Use of ring vaccination was previously successfully implemented to eradicate smallpox in the 1970s 
(192). The aim of this approach is to create a ring of people immune around each confirmed case, 
thereby interrupting secondary transmission. Contacts are people who lived in the same household or 
had direct contact (unprotected care or prepared the body for a funeral ceremony) with a confirmed 
case. Contacts of contacts are neighbours or people living in the same geographical area. 
 
On June 2017, the SAGE recommend that in the occurrence of additional EVD outbreaks to use the 
ring approach with rVSV-ΔG-ZEBOV-GP vaccine under the Expanded Access framework (also called 
compassionate use, while safeguarding ethical and good clinical practice precautions), which allows to 
use of investigational vaccine outside of clinical trials (193, 194). SAGE also recommended 
consideration of other vaccines if a new outbreak was caused by species other than Zaire, and to include 
not just the social network of EVD cases (the “ring”) but to expand immunization to HCWs and front-
line workers in area of EVD transmission or area at risk of further expansion (193, 194).  
 
In April 2019, WHO reviewed data generated by Ebola vaccine manufacturers on two candidate 
vaccines: the adenovirus 26 vectored glycoprotein/MVA-BN (Ad26.ZEBOV/MVA-BN) vaccine 
developed by Johnson & Johnson (J&J), and the CanSino-Beijing Institute of Biotechnology (Ad5-
EBOV) vaccine (195). The Ad26.ZEBOV/MVA-BN is monovalent non-replicative adenovirus type 
vectored vaccine encoding Ebola virus glycoprotein (Ad26.ZEBOV), followed by a booster by a 
multivalent modified vaccinia Ankara-vectored vaccine encoding glycoproteins from Ebola, Sudan, and 
Marburg viruses as well as the nucleoprotein of Tai Forest virus (MVA-BN-Filo) (196). It is 
administrated as a two-dose vaccine, designed to induce long-lasting protection against to the EBOV, 
SUDV, TAFV and MARV (196, 197). Data on safety and immunogenicity came from a Phase 1 study 
of healthy volunteers (n=87) in the UK that showed minor adverse events and seroconversion at 1 year, 
with persistence of vaccine-induced T-cell response (198). These data were consistent with another 
Phase 1 clinical trials conducted in Uganda and Tanzania which showed that Ad26.EBOV prime/MVA-
BN-Filo boost elicited humoral responses at 12 months following immunization with minor adverse 
events (199). Another Phase 2 clinical trial assessed three different two-dose of Ad26.ZEBOV/MVA-





previous clinical trials indicated that the vaccine could be used as a pre-emptive tool in population at   
risk of transmission. 
 
Lessons learned from the implementation of ring vaccination in West Africa were capitalized in the  
2018 Équateur province EVD outbreaks in DRC and, further consolidated during the North Kivu/Ituri 
epidemic (2018-2020) (201). As per SAGE recommendations, during the 2018-2020 North Kivu/Ituri 
EVD outbreak ring vaccination activities using with rVSV-ΔG-ZEBOV-GP started under the Expanded 
Access framework principle covering 303 905 people (53). Apart from the ring approach a second 
approach was also used in North-Kivu/Ituri called the ‘targeted geographic vaccination’ were 
vaccination was offered to everyone in the neighbourhood or village where a confirmed EVD case was 
reported (202, 203) (Figure 4). Interim analysis on 679 rings (including 91,492 contact and contacts of 
contacts, and 28,888 HCWs) vaccinated using rVSV-ΔG-ZEBOV-GP during the 2018-2020 EVD 
outbreak in North Kivu/Ituri Ebola outbreak; estimated a vaccine efficacy of 97.5% (95%CI 95.8 – 
98.5%) for people vaccinated with an onset of illness more than 10 days after vaccination and 88.1% 
(95%CI 79.9-92.9%) for all those with EVD, regardless of the timing of illness onset (204). 
 
Over the course of the 2018-2020 North Kivu/Ituri outbreak, SAGE made specific outbreak 
recommendations on EVD immunization strategies and target population; SAGE consideration were 
based on epidemiological risks, review of evidence on new promising vaccines, and deterioration of 
security (205, 206). Over time SAGE recommendations were implemented by the MOHS in the 2018-
2020 North Kivu/Ituri these included (202, 205, 206): 
1. Implementation and evaluation of Ad26.ZEBOV/MVA-BN vaccine in area where there was no 
active transmission; 
2. Continuation to offer rVSV-ΔG-ZEBOV-GP to –‘’all people at high risk of Ebola infection 
including those who have been in contact with a person confirmed to have Ebola, all contacts 
of contacts, and others determined to be at high risk of contracting Ebola’’; 
3. Granted access to rVSV-ΔG-ZEBOV-GP vaccine to pregnant women beyond their first 
trimester of pregnancy and to lactating women, if identified as case contacts;   
4. When security or stigmatization make difficult to reach communities, complement 
immunization strategy with a temporary pop up strategy (i.e., vaccination sites set up at health 
posts, rather than near the homes of patients infected with Ebola); 
5.  Adjusting rVSV-ΔG-ZEBOV-GP vaccine dosage according to risk of exposure (i.e., highest 
risk (contacts and contacts of contacts) receiving a dose of 0.5ml of vaccine instead of 1ml 
(dosage equal to that used in ring vaccination trial in Guinea in West Africa); lower-risk / people 






More recently, a risk and benefit analysis of rVSV-ΔG-ZEBOV-GP has been published in a systematic 
review, which summarised data from clinical trials conducted since 2014 (151). This review included 
17,600 adults and 234 children who over time were vaccinated in different trials; and confirmed the 
safety profile with fewer than 2% of participants experiencing SAEs. The analysis concluded that the 
vaccine was able to elicit an immune response, with neutralizing antibodies persisting up to 365 days 
postvaccination, and was deemed to be effective to prevent EVD when vaccinated within 10 days. 
 
On January 2021, WHO and other partners announced the setup of a global Ebola vaccine stockpile of 
rVSV-ΔG-ZEBOV-GP to facilitate rapid access to vaccines during outbreaks (207). Currently the 
Ad26.ZEBOV/MVA-BN and the ChAd3-EBO-Z vaccines are progressing to be approved for clinical 
use (4, 186). 
 
Despite these remarkable achievements, questions remain about the optimal strategy to achieve rapid 
immunity versus long term immunity (i.e., the use of single-shot rVSV-ΔG-ZEBOV-GP vs use of 
prime–boost approach that could provide more durable protection). It also remains important to consider 
that current evidence of safety and efficacy of experimental vaccines are a tangible result of the trust 
that local populations and health staff have put into the research community and their contribution to 
generate evidence and practices to control EVD (208, 209). 
 
Annex 1.2 summarise key SAGE positions and recommendations on EVD immunization, 2014-2020 
(210, 211). The summary of statement and recommendations are direct quotes from SAGE guidance 
and the list is not exhaustive but focuses on the main considerations and recommended changes over 
time.  
 
Table 4. Overview of the main vaccine categories, adapted from Baptiste Martin et al.(212) 
Categories Vaccine Phase evaluated* 




Better tolerability profile 
 
General constrains 
High dosage of viral particles is 
needed to elicit a significant response   
Might require the injection of several 
doses  










Ad5-EBOV CanSino Biologics Inc. & Beijing Institute of 
Biotechnology, Chine (RPC) 
Approved by CFDA 
1-2 
 





Highly efficient with relatively low 
dosage 
rVSVΔG-ZEBOV-GP Merck, Germany  
Approved by EMA, FDA and Pre-qualified by WHO  
1-3 
Evac-Combi Gamaleya Research Institute of Epidemiology and 
Microbiology, Russia 
 
Approved by MOH of Russian Federation 






General constrain  
Some safety concerns associated with 
the replicative vector-based vaccines 
  
 
 Others             
Delta VP30 University of Tokyo & Waisman Biomanufacturing, 
Japon et USA 
1 
INO-4201, Inovio Pharmaceuticals, USA 1 
EpivacEbola Rospotrebnadzor, Russie 1 
Nanoparticle recombinant Ebola GP vaccine Novavax, USA 1 
*Phase-1: small trials in healthy individuals with the aim to evaluate the safety and immunogenicity 
Phase-2: recruits hundreds to thousands of subjects to identify safety, immunogenicity, and efficacy. 
Phase-3: recruits thousands of subjects, is essential for registration and approval to market of a vaccine, assess the effect of 
the final formulation and dose. (Ref. The clinical development process for a novel preventive vaccine: An overview) 




Figure 4. Ring immunization strategy used in North Kivu/Ituri, 2018-2020 EVD outbreak, from  WHO,- 
Ending an Ebola outbreak in a conflict zone (203) 
 
'first ring'= direct contact; 
‘second ring' = contact of contacts (those in 
direct contact with the first ring (i.e., 
neighbours and HCWs); 
'third ring'= contacts of the second ring (3 












1.8 EVD outbreak in Sierra Leone, 2014-2016 
 
Sierra Leone is located in West Africa, the country is bordered by Guinea in the north and east, and by 
Liberia in south and east. During the 2014-2016 EVD epidemic, Sierra Leone reported 14,124 cases 
and 3,956 deaths, in an estimated population 7.1 million in 2015 (40% residing in urban context ) (64, 
213, 214). Similar to Guinea and Liberia, this was the first time that Sierra Leone was affected by an 
EVD outbreak. 
The outbreak unfolded in a context of an extremely fragile health system, with the highest maternal 
and under-5 mortality indicators, with 45% of the population in a state of food insecurity, recovering 
from the effects of a protracted civil war (1998–2002) (213, 215, 216).  
The first cases in Sierra leone were reported in May 2014, among people returning from the funeral of 
a well-known traditional healer, who was reported to have treated infected patients in Guinea. Following 
this funeral, human-to-human transmission started in the District (217). The outbreak spread to the 
neighbouring Kenema District in June 2014. In Kenema Government Hospital (KGH), one of the largest 
nosocomial outbreaks started, 66 healthcare workers were infected (69% case fatality) representing the 
largest cluster of health workers in the West Africa outbreak (218). By mid-October 2014, all the 14 
Districts reported at least one case, by the end of December more than 9,000 cases were recorded (217). 
By the end of January, EVD incidence declined and the country moved to a phase of response where 
the focus was on the transition from low transmission to the end of the outbreak, by increasing capacity 
for case finding and contact tracing (219).  
In November 2015, WHO declared the end of the epidemic in Sierra Leone (64). However, in January 
2016 Sierra Leone had two new cases, but transmission was rapidly controlled. In March 2016, WHO 
declared Sierra Leone to be Ebola-free (65); since then no new cases have been reported. 
Table 5 summarises the key salient events in the EVD outbreak in Sierra Leone. 
To control the outbreak, the following public health measures were implemented in addition to the 
previous mentioned control pillars (se section 1.4 Public health interventions to control EVD 
outbreaks): 
1. Ebola Holding Units (EHUs; set up on May 2014): screening centres in existing health facility 
where suspect patients, received initial general care and waited for testing before been reefed 
to EMC if confirmed; aim to timely isolate case, prevent nosocomial transmission in non-Ebola 
facilities and refer to EMC only positive patients (220); 
2. Quarantine (set up in August 2014): Individuals and households exposed to EVD undergo ob-





possible exposure. Households were supposed to receive water and food supply for the duration 
of quarantine (221); 
3. Bylaw (set up in August 2014): Law making criminal offence to shelter patients suspect of 
EVD, imposing a prison sentence of up to two years (222);   
4. 1-1-7 hotline call system (set up in August 2014): To enhance Ebola surveillance the Govern-
ment of Sierra Leone repurposed an existing national, toll-free telephone line (1-1-7 system) 
requiring communities to report all deaths and suspected Ebola cases (223); 
5. Operation Western Area Surge (September and December 2014): A door-to-door Ebola aware-
ness campaign searching for suspect cases mainly implemented in Freetown (217); 
6. District Ebola Response Centres (DERCs), set up in October 2014, to provide at District level 
coordination and response (224);  
7. National Ebola Response Centre (NERC), set up in October 2014 set up in Freetown to provide 
national-level coordination and response (see Annex 3) (224);  
8.  National IPC training program (set up between October and December 2014); the aim was to 
prevent nosocomial transmission, it enrolled 1,200 peripheral health units (PHUs) across the 
Country (225); 
9. Community Care Centre (CCCs); set up in November 2014: Small facilities inside the commu-
nity were used to isolate suspected and probable cases of EVD while they waited for lab results, 
prior to transfer to an EMC. The aim was to reduce the delay to isolation, thus preventing on-
ward transmission, to increase acceptance of isolation from patients and the community, and to 
increase community engagement towards the response. This was mainly implemented in dis-
tricts without EMC facilities and in rural area (226, 227); 
10. Community-Led Ebola Action (CLEA); set up in November 2014: to support communities to 
conduct their own risk analysis, understand transmission routes and identify key actions to 
prevent EVD transmission; one of the main outcomes of this initiative was to connected 
communities with the DERCs (111);  
11. Mass Drug Administration (MDA) (December 2014–January 2015): A two-round, door-to-
door, campaign, with artesunate–amodiaquine (ASAQ) covering over 2.7 million people. The 
campaign was conducted in 8 Districts with high burden of malaria and affected also by EVD. 
The aim was to reduce malaria morbidity at community level to decrease health services burden 






12. National IPC guidelines (May 2015): to set standards during routine healthcare for safe and 
high-quality patient care (229);   
13. Ring vaccination (second flare up in January 2016): The rVSVΔG-ZEBOV-GP vaccine was 
used to vaccinate EVD contacts and contacts of contacts using a ring approach (overall 325 
contacts and 255 contacts of contacts were vaccinated (184) (see section 1.7.2 Vaccines). 
 
Annexe 1.3 provides a visualization of the response frame in Freetown or in similar DERCs, and Annex 
1.4 provides the bed capacity and number of cases in November 2014 in Sierra Leone. 
	
1.8.1 EVD outbreak impact and lessons learned: a few practical examples 
 
The 2014-2016 EVD outbreak was devastating for Sierra Leone. The World Bank estimated an impact 
of $1.9 billion on the local economy (230). The Ministry of Health and Sanitation (MoHS) reported that  
at least 295 health care workers had EVD, among those 221 died, with a consequent reduction of skilled 
health workers (from 17.2/10,000 people before the outbreak to 3.4/10,000 at the end) and a 23% 
reduction on health delivery services (52). Overall, 8,345 children were left orphans, and 3,034 people 
were EVD survivors with consequent social and health needs (52). 
Sierra Leone gained important experience and lessons learned from this catastrophic outbreak. For 
instance, prior to EVD outbreak Sierra Leone had no IPC programme or staff trained on IPC (229).  
MoHS also revitalised the Integrated Disease Surveillance and Response (IDSR) as an essential public 
health tool to timely recognise and respond to epidemic-prone diseases (231). 
Practical examples of application of lessons learned and improved public health practices were: i) timely 
response to the 2017 floods and landslides in Freetown, with the first implementation of a pre-emptively 
Oral Cholera Vaccination (OCV) campaign (232); ii) set up of ethical frame to Ebola data to support 
research, and to supporting families to locate the graves of family members died during the EVD 
outbreak (96); iii) recognition of crucial role of communities in outbreak preparedness and response 
and recovery (233); iv) standardization of data and decentralization of response during the current  novel 
coronavirus disease 2019 (COVID-19) (Personal communication with Médecins Sans Frontières 
Operational Centre Amsterdam (MSF-OCA)team in Sierra Leone).  
At the end of the EVD outbreak, MSF-OCA committed to Sierra Leone and set up medical intervention 
to improve maternal and child indicators in a Tonkolili District (234). I personally observed and 
contributed those important public health shift in Sierra Leone; during the support I provided to the 





in Freetown7,8, supporting the reconciliation project to support family to locate family grave, and the 
recent support to design and analysis of a community qualitative assessment conducted in May 2020 at 
the start at the start of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic 
in the Country (see Chapter 6).  
However, despite several improvements and lesson learned there are still extensive gaps to provide 
adequate services, with shortages of personnel, challenges in supply of drugs, and laboratory services. 
This has led recently to an increasing commitment of MSF-OCA in Sierra Leone also on TB care in 





















7 Integrated Disease Surveillance and Response (IDSR), Tonkolili District, Sierra Leone, MSF-OCA internal report 2016. 





Table 5. Key events in the Ebola outbreak in Sierra Leone, 2014-2016 (46, 217-219, 235, 236) 
Date Description  
2014 
May  • Outbreak began in Kailahun, on the border with Guinea.  
June  • A state of emergency was declared and Kailahun and Kenema Districts soon became the 
epicentres of the outbreak;  
• In late June, MSF opened an EMC, which continued to operate until January 2015, when 
the District was declared free; 
• In Kenema two wards of the government hospital, previously dedicated to Lassa fever, 
were converted for isolation of EVD cases. It became an important place of disease  
amplification, 66 healthcare workers were infected representing the largest cluster of 
health workers in the West Africa outbreak; 
• The first cases of EVD were reported in Freetown, the Sierra Leone capital, and Port 
Loko, eventually spreading to all the 14 Districts. 
July • Ebola Operations Centre (EOC) set up to support coordination of response; 
• School closed and reopened in April 2015.  
August  • The President declared a national state of emergency and quarantine was imposed to 
affected households; 
• The government also designed a law to inflict a severe penalty, up to two years of prison, 
on any people hiding suspect cases; 
• Between August and December the country entered the first phase of response during 
which efforts focused on increasing the number of beds, hiring and training teams in safe 
and dignified burial, and strengthening surveillance systems and social mobilization ca-
pacities. 
September  • A campaign known as the surge was implemented (repeated in December 2014) in which 
the country was locked down for 3 days, and active door to door case-finding was mainly 
implemented in the capital and Western Area District; 
• During this period hospitals lacked PPE, training and an adequate triage system.  
October  • The National Ebola Response Centre (NERC) was set up in Freetown to provide na-
tional-level coordination and response; (Annex1.3 example in Freetown). 
• At District-level, DERC’s were set up. In each affected district a central command was 
established. 
November  • The country reported 4,828 cumulative confirmed cases, with the highest burden in Free-
town where 150 cases per week were reported; 
• Only 7 EMCs were operating in the country, bed capacity was insufficient, resulting in 
patients being transported to distant EMCs and CCCs (Annex 4Bed capacity and number 
of cases); 
• CLEA model developed. 
December  • Gradually, bed capacity increased with an estimate 3.6 beds for every confirmed and 
probable case in December 2014. Distribution of EMC and CCCs were uneven leaving 
districts with active transmission still uncovered; 
• Doctors in Sierra Leone went on strike 
2015 January  • An extensive antimalarial campaign, covering 2.5 million of people in 8 districts was 
delivered; 
• By the end of January, EVD incidence declined. 
March  • National Lockdown (3 days) . 
April-
August  
• STRIVE stated (Vaccine trials for frontline health workers) 
June • Curfew imposed in Porto Loko and Kambia. 
November  • On 7 November WHO declared that the Sierra Leone EVD epidemic was over; 
• Sierra Leone then moved to a phase aimed at enhancing surveillance, managing residual 
risks and rapid identification and response to flare ups, including the use of vaccine;  
• Systematic oral swabbing of all deaths was implemented. 
2016 January  • A new case of EVD was detected in Tonkolili District; the patient died in the community 
and generated a secondary case. 





Annex 1.1 Underlying EVD pathophysiology, groups at risk of negative outcomes, and 
malaria-coinfection  
	
Underlying EVD pathophysiology 
EVD symptoms reflect the likely underlying pathophysiology (4). The virus seems at first to “sabotage” 
the immune system (innate and acquired) which enables uncontrolled virus replication, followed by the 
vascular system thereby inducing blood leaking and hypotension (4, 237). The cascade and 
dissemination start with infection of dendritic cells and macrophages, inactivating Interferon and 
releasing cytokines that amplify an inflammatory response with initial damage of blood vessels and 
initiate coagulation. Immune responses impair adaptive immune response by causing T-cell exhaustion 
and apoptosis (238). Susceptibility to secondary infections might be induced by lymphocyte depletion 
(139).  
The virus than infects reticuloendothelial and microvascular endothelial cells, further compromising 
vascular integrity and causing blood leakage. Infection of hepatocytes induces cell damage, 
disseminated intravascular coagulopathy (DIC), with risk of thrombosis and bleeding (139). Further 
dysregulation of blood pressure is due to damage of adrenal glands that are unable to produce steroids 
(crucial to regulate the immune response, and blood pressure) (139). Damage to renal tubular cells 
contribute to renal dysfunction. Damage to the gastro-intestinal tract with consequent diarrhoea 
additionally contributes to risk of hypotension, shock and death (139, 237). Weakness and muscle aches 
are caused by myositis and elevation of markers of muscle cell damage (4).  
Virus kinetics study of among EVD patients found that viral load tends to peak early in patients who 
survive compared with patients who do not (239). This could be explained by a previous study that 
observed that early and rapid increase in antibody level supported activation of cell mediated response, 
and virus clearance among survivors (240). Immune response seems to play a crucial role in possible 
relapses, due to resumption of viral replication in survivors (241). Severity of the disease was found to 
be associated associate with high viral load, cytokines, and chemokines and likely the outcome of direct 
cytopathic effects of viral replication and paradoxical host responses to infection (242, 243). 
Groups at risk of negative outcomes 
Previous studies have reported an association between age and EVD CFR; high fatality rates among 
children less than five and adults older than 40 have been consistently reported (244-249) as has an 
association between viral load at admission and CFR (247, 250-253). During the West Africa outbreak, 
a study including 6,191 EVD confirmed cases across West Africa estimated that CFR was higher in 
people aged over 45 years compared to patients aged 16- 44 years old (254) (manuscript supplementary 





CI 67.1-75.4) in Guinea, 76.5 % (95% CI 71.6-80.8) in Liberia, to 82.3% (95% CI 78.5-85.5) in Sierra 
Leone (254). In contrast among patients aged 16- 44 years old CFR varied from 56.3% (95% CI 53.5-
59.0) in Guinea, 66.5% (95% CI 63.7-69.1) in Liberia, to 70.3% (95% CI 67.9- 72.7) in Sierra Leone 
(254). 
Over the last EVD outbreaks the reported proportion of children infected, has varied from 9% in the 
Kikwit DRC outbreak in 1995, nearly 20% during the West African in 2014-2016, 29% during the 
2018-2020 North Kivu/Ituri, in DRC, and 41% in Gulu, Uganda (Sudan EVD) in 2000–2001 (53, 64, 
255, 256). Although children have accounted for a lower proportion of those infected, the risk of deaths 
in this group is significant.  
Children can be exposed to body fluids during baptism, close contact with mother, care giver or 
neighbours or acquire infection while attending health facilities (46, 257). In a cohort study conducted 
among 282 EVD positive children (less than 13 years old) admitted in 11 Ebola holding centres in Sierra 
Leone during 2014-2015 EVD outbreak, the overall CFR in this age group was 57% (95% CI 51%–
63%) but reaching a CFR of 70% in infants (258). In this cohort age was the strongest predictor of death 
(adjusted OR 0.92 [95% CI 0.86–0.98] per 1-year increment in age) (258). Another large retrospective 
study included 1,147 children under 16 years of age infected across the 3 affected countries in the West 
Africa outbreak (254). The study reported, for EVD confirmed cases, a CFR of 85.5% (95% CI 74.7-
92.2) for children under one years old versus 50.3% (95% CI 45.7-55.0) for children aged between 10-
15 years old (254). In this cohort the mean incubation period was shortest in children younger than 1 
year of age (6.9 days (95% confidence interval [CI], 5.1 to 9.5) compared to children 10 to 15 years of 
age (9.8 days (95% CI, 8.7 to 11.1) (254). Likely indicating a more rapid progress on infection among 
younger children, this is further exacerbated by the difficulties of recognising EVD symptoms in 
children thus hampering, early detection, and timely case management (253, 259).  
Historically EVD in pregnancy has been associated with high rates of maternal mortality, stillbirths and 
abortions (30, 260, 261). Before the 2014-2016 West Africa outbreak, the largest cohort of 82 pregnant 
women with suspected EVD came from the 1976 epidemic in DRC; in this cohort CFR was 89% (47);  
in this cohort the high CFR was attributed to iatrogenic and in-hospital EVD-transmission (47). In 1995, 
during the Kikwit DRC outbreak, only one out of 15 suspected EVD pregnant women survived, in all 
of them haemorrhagic signs were observed (261). However, a more recent retrospective cohort study 
including 175 EVD confirmed women of reproductive age (15– 49 years) in 5 Ebola treatment units 
(ETU) in Liberia and Sierra leone, reported no significant EVD specific mortality (46% vs 54%, P = 
.60) between EVD pregnant (n=13) and nonpregnant women (n=162) in the same age group (262). 
Although survivor pregnancy testing bias cannot be ruled out (pregnancy test only became standard 
from December 2014) difference in survival estimates between historical and more recent data might 





was mainly based on clinical data vs PCR-RT in more recent study) and exposure to infection (e.g., 
iatrogenic exposure in historical data versus non iatrogenic). Further studies are needed to investigate 
outcomes in pregnant women compared to non-pregnant in the same reproductive age group. Recently 
specific guidelines were developed for women acquiring EVD during pregnancy and or breastfeeding, 
indicating that pregnant women should have access to the same supportive and investigational 
treatments used for non-pregnant women (35).   
While for EVD pregnant women, recent evidence are more positive, foetal outcomes of children born 
to mothers infected with EVD remain poor (262); before the West Africa outbreak, fifteen neonates 
have been reported be born alive, but all died within few weeks after birth (263). During the West Africa 
outbreak only one neonate born from an EVD women (who did not received investigational therapy), 
is known to have survived to EVD, the neonate received investigational treatments (ZMapp, leukocyte 
transfusion, and remdesivir); and today is still alive and healthy (169, 264). A case series from the North 
Kivu/Ituri 2018-2020 EVD outbreak, reported a neonate born EVD negative to a EVD survivor mother 
(265). During the same outbreak another case report, documented the survival of two neonates enrolled 
in the PALM trials (34). Mothers and infants received investigational therapy, both neonates were born 
blood PCR-RT negative, and were discharged alive from the ETC. Unfortunately, despite receiving 
investigational therapy, both mothers died short after delivery (34). 
Malaria-coinfection  
Although malaria is a prevalent in countries where EVD outbreaks had previously occurred, before the 
2014-2016 EVD West Africa outbreak, there had been limited evaluation of the possible negative effect 
of malaria co-infection among EVD patients (266). A retrospective cohort study conducted in Liberia, 
found that risk of death was 36% lower (risk ratio, 0.64; 95% CI 0.49-0.85) among the 272 EVD positive 
patients who received artesunate–amodiaquine. However, this effect was lost among the 65 patients co-
infected with malaria (risk ratio, 1.00; 95% CI 0.54-1.85) (161). Another retrospective cohort study 
conducted in Guinea between 2014 to 2015, found that among the 97 patients EVD positive, mortality 
for EVD cases was 58%, rising to 86% if patients had both EVD and malaria co-infection (267).  
Another retrospective cohort study of patients admitted to 3 Ebola centres in Sierra Leone; found that 
among the 254 EVD positive patients, 21% had co-infection malaria; mortality for EVD cases alone  
was 52%%, rising to 66% if patients had both EVD and malaria infection (268), in this cohort mortality 
risk was increased both in patients positive to EVD and malaria (adjusted hazard ratio 9.36, 95% CI 
6.18–14.18, p<0·0001), and among patients EVD positive but malaria negative (5.97, 4.44–8.02, 
p<0·0001), compared to the group negative to both EVD and malaria (268). 
A modelling study found that administration of preventive antimalaria treatment to all EVD contacts, 
is cost saving, and would reduce the probability of EVD contacts to be misclassified and wrongly 





reduce the probability of admission by 29% in Liberia, by 33% in Sierra Leone, by 36% in Guinea for 
contacts aged <5 years old; and by 10% (in Sierra Leone and Guinea) and 11% in Libera for contacts 
aged 15 years or older (269).  
Current WHO recommendations include empirical treatment of malaria for patients isolated in Ebola 
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Annex 1.2 SAGE key positions and recommendations on EVD immunization 2014-2020  
 
Date   
Key positions/considerations  Keys recommendations  
2014 October  SAGE confirmed that it would provide expert advice on the deployment of Ebola 
vaccines on an emergency basis, as needed in response to requests from WHO.  
A consultation on potential Ebola vaccines and therapies followed to review plans 
for safety studies of 2 candidate vaccines – one utilizing a vesicular stomatitis virus 
(rVSVZEBOV) and another utilizing a chimpanzee adenovirus (ChAD3-ZEBOV), 
both expressing Ebola Zaire surface glycoproteins. Randomized controlled trials 
(RCTs) are the best study design, but when not feasible, alternatives may be 
considered, including cluster-randomized and step-wedge designs. The consultation 
noted that investigation of any candidate intervention must not detract attention 
from implementation of effective clinical care, rigorous infection prevention and 
control, careful contact tracing and follow-up, effective risk communication, and 
social mobilization 
SAGE confirmed that it would provide expert advice 
on the deployment of Ebola vaccines on an 
emergency basis, as needed in response to requests 
from WHO. Subsequently SAGE was asked to 
immediately establish a SAGE working group on 









April  SAGE was asked for feedback on framework to develop guidelines to support 
planning, implementing and monitoring vaccination once a vaccine becomes 
available. 
SAGE stressed the importance of transparent and prompt sharing of information on 
the trial protocols and data from the phase 3 clinical trials, and the need for a greater 
role for WHO in facilitating the sharing of information so that results between studies 
will generate the greatest benefit for policy decision-making. 
 
SAGE supported the proposed framework for making 
recommendations, but asked that it be made explicit 
that the identification and prioritization of target 
populations for vaccination will be based on a 
thorough assessment of risks (from disease as well as 
from vaccination) and benefits.  
Further development of the Emergency Use 
Assessment and Listing procedure being developed by 
WHO, which would allow use of a vaccine in the 
context of a Public Health Emergency of International 
Concern, be done in close consultation with relevant 
regulatory authorities, including those of the affected 
countries.  
Future use of unproven Ebola vaccines should be in the 







Lessons learnt from several EVD vaccines candidate and outbreak response was 
unprecedented; this experience has informed the development of a blueprint for 
research preparedness and rapid response for future epidemics.  
Vaccination during outbreaks should be part of an 
integrated strategy and complement other public 
health measures to interrupt transmission. It does not 
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Date   




Interim results from a Phase 3 trial suggest that rVSV-ΔG-ZEBOV is efficacious, 
safe, and likely to be effective at the population level when delivered during an EVD 
outbreak, using a ring vaccination strategy 
 
Data on safety in children, pregnant women, and those with underlying medical 
conditions are insufficient to draw conclusions. 
  
use, contact tracing and other infection control 
measures.  
Regular reviews of the epidemiological data should 
inform adjustments to the delivery strategies 
throughout the outbreak. Potential strategies include 
ring vaccination, geographic targeting of an area (mass 
vaccination) and vaccination of front-line workers. 
Pregnant women and infants have very high case 
fatality rates and may benefit from the indirect effects 
of their close contacts being vaccinated. 
Researchers should share data from pregnant women 
who were inadvertently vaccinated, and from HIV-
positive subjects if included in the ongoing trials. 
Future trials should consider collecting data from 
children, adolescents, pregnant and lactating women, 
and immunocompromised individual. 
Efforts to develop vaccines against filoviruses other 
than ZEBOV, such as Sudan, Bundibugyo and 
Marburg should be pursued. 
Community-based participatory approaches to engage 
participants in all stages of clinical trials, including 
design, monitoring and evaluation, should be 
implemented 
Pre-approved and pre-positioned protocols and local 
research capacity strengthening in countries at risk for 
outbreaks should be put in place to facilitate rapid 
implementation of relevant studies  
 
2016 April  
Promising data are emerging from the Ebola vaccine trials. Pending regulatory 
approval, WHO is developing a country-based “Expanded Access Brigade” to 
facilitate use until an Ebola vaccine is licensed. 
No additional recommendations made. 
2017  
April  
Should an Ebola disease outbreak occur before the candidate vaccine is licensed, 
SAGE recommended that the rVSVΔG-ZEBOV-GP vaccine be promptly deployed 
under the Expanded Access framework, with informed consent and in compliance 
with Good Clinical Practice.  
 
Ring vaccination, as used in the Phase 3 study in 
Guinea, is the recommended delivery strategy. 
This should be adapted to the social and geographic 
conditions of the outbreak areas and include people at 
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Date   
Key positions/considerations  Keys recommendations  
If the outbreak is caused by an Ebola virus species other than Zaire, consideration 
should be given to the use of other candidate vaccines that target the putative viral 
species. 
 
Available evidence on candidate Ebola vaccines, especially duration of protection, is 
insufficient to formulate conclusive recommendations regarding mass vaccination of 
the general population or vaccination of health-care workers in the absence of an 
outbreak. 
contacts of contacts; (ii) local and international health-
care and front-line workers in the affected areas and 
(iii) health-care and front-line workers in areas at risk 
of expansion of the outbreak. 
Further research is required to establish the 
acceptability of vaccines for use in health-care 
workers, duration of protection conferred by various 
candidate vaccines, cross protection between virus 
species and number of doses required, including need 
for boosting doses. 
2018 
October  
If an outbreak is caused by an Ebola virus strain other than Zaire, consideration 
should be given to using candidate vaccines that target the respective viral strain. 
Currently, 1 multivalent vaccine (Ad26.ZEBOV/MVA-BNFilo) is in phase 2 of 
clinical development. SAGE noted that opportunities should be sought to assess the 
efficacy of other candidate EVD vaccines, such as in health care and front-line 
workers in areas that are not at high risk for EVD and are thus not eligible to 
receive the rVSV-ZEBOV vaccine in current study protocols and SAGE 
recommendations. 
Particular consideration should be given to the inclusion of pregnant and lactating 
women into vaccine research. Data on use of the vaccine in paediatric populations 
in such trials should be recorded. SAGE reviewed the data on the risks and safety of 
vaccinating pregnant women with the replicating live virus vaccine rVSVZEBOV. 
The preliminary results of a risk–benefit analysis to compare the safety of rVSV-
ZEBOV vaccination in pregnancy with the risk of acquiring EVD in a setting of 
ring vaccination were examined. The risk for acquiring EVD of unvaccinated 
people, including pregnant women, in vaccination rings is very low (0.12%, 95% CI 
0.02; 0.28) at a vaccination coverage of eligible people of ≥50%, probably as a 
result of herd immunity. It was noted that the data were insufficient to establish the 
risk for EVD of vaccinated rings at lower coverage. Data on the safety of rVSV-




Should an EVD outbreak due to the Zaire strain occur 
before a candidate vaccine is licensed, rVSV-ZEBOV 
vaccine should be promptly deployed within the 
expanded access framework, with informed consent 
and in compliance with good clinical practice.  
Ring vaccination, as used in the phase-3 study in 
Guinea, is the recommended strategy for delivery, to 
be adapted to the social and geographical conditions 
of the outbreak areas and include people at risk:(i) 
contacts and contacts of contacts, (ii) local and 
international health care and front-line workers in 
affectedareas and (iii) health care and front-line 
workers in areasat risk due to extension of the 
outbreak.  
A geographically targeted vaccination strategy may 
be considered in when it is impossible to identify the 
individuals who make up ring vaccination cohorts 
because of serious security, social or epidemiological 
issues. In this case, the geographical area 
immediately around a case of EVD, such as a village 
or a neighbourhood, is most likely to include those 
individuals who were contacts or contacts of contacts 
of the index case 
SAGE recognized that a decision on whether to offer 
rVSV-ZEBOV, a systemically replicating vaccine 
virus, to pregnant women is complex, with ethical, 
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Inclusion of pregnant women in an EVD vaccine 
research protocol depends on local national 
regulatory authorities and local ethics review 
committees. SAGE encourages these bodies to assess 
the benefits and risk of offering rVSV-ZEBOV to 
pregnant and lactating women during an outbreak.  
As front-line and health workers are at increased risk 
of exposure in an outbreak, SAGE recommends that 
national authorities consider offering the EVD 
vaccine to those who are pregnant or lactating, with 








In exceptional circumstances, i.e. settings where because of serious security, social 
or epidemiological issues, ring vaccination (i.e. identification of contacts and 
contacts of contacts) cannot be adequately implemented, geographic targeted 
vaccination is recommended as an alternative strategy. 
Interim recommendations 
Consideration is given to the use of any of new 
vaccines to vaccinate HCWs and FLWs in the 
neighbouring areas where there is a possibility of 
spread. 
Use of rVSV-ZEBOV-GP vaccine in pregnant 
women currently remains limited to the EVD 
outbreak affected areas in DRC and should be 
continuously evaluated based on the emerging data 
on the safety and efficacy of the vaccine in this target 
population. 
April 
In modelling studies, geographically targeted mass vaccination and ring plus were 
less efficient in terms of cases averted, doses of vaccine required and cases 
prevented per 100 vaccine doses than ring vaccination. 
Ring vaccination is currently the most effective strategy in this outbreak of Ebola 
virus disease in the DRC. 
Targeting broader geographical areas should remain a fallback strategy if contact 
tracing is not feasible and vaccine supplies are sufficient. 
Known attack rates and case fatality rates (CFRs) 
among women and young infants outweigh these 
potential risks in favor of the use of the vaccine in 
these groups. 
SAGE considered that the high rates of 
attack and fatality in these groups and the 
accumulating data on vaccine safety and efficacy for 
other groups justify inclusion in the ongoing ring 
vaccination in North Kivu of infants aged 6–12 
months and lactating women. As data on the safety of 
the vaccine in infants aged 6–12 months accumulate, 
inclusion of infants from6 weeks of age should be 
considered. 
 
SAGE previously recommended that consideration be 
given to urgent evaluation of new candidate vaccines. 
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Date   
Key positions/considerations  Keys recommendations  
Manufacturers of candidate vaccines against Ebola 
virus disease prioritize strategies to generate data on 
safety, immunogenicity and possibly efficacy in 
pregnant women, lactating women and infants. 
May 
(Interim) 
the Democratic Republic of Congo (DRC) has deteriorated with a large increase in 
the number of cases . A major factor in this rise is an increase in critical security 
incidents that have dramatically affected the ability to identify, follow up and 
vaccinate contacts successfully.  
This context challenges the implementation of ring vaccination based on the 
identification of contacts and contacts of contacts, as recommended by SAGE in 
April 2017 and confirmed by SAGE during its April 2019 meeting.  
Further, a potential vaccine shortage may manifest in case the outbreak expands 
further and/or is prolonged. 
SAGE deliberated on the following recommendations 
on implementation of novel strategies and 
adjusted dose regimes: 
 
Implementation of innovative operational strate-
gies: 
Pop-up vaccination – In this approach, already 
successfully implemented to address security issues 
and tensions with the community vaccination is 
implemented at an agreed and temporary, protected 
vaccination site, at a distance from the residence of 
the contacts, often a health facility) and;  
Targeted geographic vaccination – In this 
approach, already successfully implemented to 
address security issues, all the contacts and contacts 
of contacts of all cases reported in a given village or 
neighbourhood are enumerated and invited for 
vaccination simultaneously.  
Revised vaccination strategy to adjust the target 
population for ring vaccination to include a second 
and third barrier of immunized individuals 
around each incident case. 
(I) Continue to offer as a priority rVSV-ZEBOV-GP 
vaccine and vaccinate those at higher risk of Ebola 
including contacts and contacts of contacts and health 
care workers (HCWs) and front line workers (FLWs) 
in affected Aires de Santé.  
(ii) Offer rVSV-ZEBOV-GP and vaccinate to those 
who can potentially be involved in the tertiary 
generation of cases (e.g. 3rd level of contacts) to 
create a barrier around the contacts of contacts in 
affected Aires the Santé.  
(iii) Offer a vaccine other than rVSV-ZEBOV-GP to 






Annex 1.2 SAGE key positions and recommendations on EVD immunization 2014-2020  
 
Date   
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cases, although at a lower risk than those described in 
(i) and (ii) above. 
SAGE recommends that these lower risk populations 
would be vaccinated with the J&J vaccine with 
informed consent. The latter ideally implemented as 
per the SAGE recommendation from April 2019 
which outlines that studies using other candidate 
vaccines should be done in this context:  
3)Alternative dosing for the rVSV-ZEBOV-GP 
vaccine. 
To ensure vaccine continues to be available and 
offered to individuals at greatest risk of Ebola during 
this outbreak and in order to secure the availability of 
the rVSV ZEBOV-GP in the mid-term, SAGE 
revised the following proposal, based on an analysis 
undertaken by the U.S. Food and Drug 
Administration to exceptionally adjust the vaccine 
dose for the currently available lots of rVSV-
ZEBOV-GP being used in DRC:  
For those at higher risk of Ebola including contacts 
and contacts of contacts including HCWs and FLWs 
in the affected areas: offer a vaccine dose with a simi-
lar potency to that used in the Guinea Ebola ça suffit 
trial (i.e. 2 x 107 pfu).  
 
(ii) For those who can potentially be involved in the 
tertiary generation of case (e.g. 3rd level of contacts), 
a 5-fold dose adjustment compared with the current 
dosing of the vaccine is recommended (in relation to 
the potency of the vaccine lots being used in DRC). 
The 5-fold dose reduction in the broader population 
was motivated on immunological considerations re-
lated to dose-response analysis using a 4.8-fold dose 
reduction in various subpopulations and seroconver-
sion rates in those groups at 28 days after vaccination 
and later, noting this dosing regimen provides a rea-
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SAGE supports the adjusted dosing administration as 
proposed above. SAGE acknowledges, that since the 
vaccine is available in 10-dose vials at 1 ml/dose, that 
a 2-fold and a 5-fold reduction in dose could be read-
ily implemented by injection of 0.5 mL and 0.2 mL, 
respectively. 
October 
Strategies and a mechanism will be built for creation of a stockpile and allocation for 
outbreak response and for preventive use of 
EVD vaccine outside of outbreaks, which will be 
reviewed by SAGE for endorsement 
SAGE will develop a priori defined criteria for 
implementation of the dose reduction if future 
vaccine supply is significantly constrained and the 




At a future SAGE meeting, it is expected that possible recommendations for off-label 
use for specific populations such as young infants, children and pregnant and 
lactating women will be discussed to allow best use of the recently licensed rVSV-
ZEBOV vaccine in future outbreaks. 
 
SAGE recommended that a comprehensive review be 
conducted of the recent experience of Ebola virus 
vaccine implementation and policy development 
during an outbreak response in order to inform future 
processes for the development of recommendations, 
the use, and the monitoring of un-licensed vaccines in 
emergency and outbreak response situations. 








• District Surveillance Officer (DSO) were responsible for working with local chiefs, community monitors 
and local health facilities for the timely detection of new cases (both deaths and living). The local population 
could report alerts by calling the 177 or reporting to DSO, local chief. The DSOs were in charge of verifying 
the alerts and calling the central command to request an ambulance or a burial team depending on the out-
come of investigation. 	
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Chapter 2: MSF-OCA in Sierra Leone 2014-2016 EVD outbreak  
	
2.1 MSF-OCA response activities, challenges, and definition of research objectives 
 
This chapter provides the context for this thesis, by summarizing the main work undertaken by MSF-
OCA during the EVD outbreak (both within the EMC and in the community) and the subsequent 
definition of the PhD research objectives.    
Since the Kikwit DRC EVD outbreak in 1995, MSF has gained important experience supporting the 
response to several Filovirus outbreaks (e.g. EBOV, BDBV SUDV, Marburg) in multiple countries 
(e.g. DRC, Gabon, Uganda, South Sudan, Angola, ROC) (1-5). Early MSF interventions mainly focused 
on water, sanitation and hygiene, creation of isolation wards, health workers protection. Subsequently, 
there was increasing emphasis on patient care and surveillance. Documentation of adaptation of 
protocols on burials, home disinfection and psychosocial support to affected families during Marburg 
outbreaks have been previously reported by MSF as key interventions to respectfully and successfully 
engage with community (5).  
However, despite MSF updating its guidelines regularly, lessons learned from the response to Filovirus 
outbreaks were mainly gained by two sections of MSF with limited systematic transfer of knowledge 
and practices to other MSF operational centres.  
Thus, MSF-OCA gained his first experience EVD response only during the 2014-16 EVD outbreak in 
Sierra Leone. Over the 2 years of the outbreak response, the MSF-OCA strategy shifted from patient 
management to interventions to prevent infection and mortality at community level. At the end of the 
outbreak mobile clinics for EVD survivors and referral for eyes complications surgery were set up. 
Overall, 1,948 patients were referred to three EMCs run by MSF-OCA in Kailahun, Bo and Tonkolili 
Districts in Sierra Leone (Table 6). In October 2014, at the height of the outbreak in Freetown, MSF-
OCA set up a community surveillance project in a slum area where general transmission was reported9. 
This was the first time that surveillance was the primary component of an MSF-OCA intervention for 
Ebola and also, given there was no MSF-OCA EMC in Freetown, the first time that their role was not 
directly linked to an EMC.  
Multidisciplinary teams were set up to strengthen community surveillance while addressing 
humanitarian gaps for quarantined households in slum areas. In January 2015, in Tonkolili and Bombali 
																																								 																				
9 Review of MSF-OCA surveillance and alert response in Freetown during the Ebola outbreak: lessons learned and challenges, MSF-OCA 





Districts, to identify area of transmission a new rapid mapping method was implemented in 
collaboration with local community and MoHS (6). 
The work in Kailahun informed the conceptualization of Objective 1 (Chapter 3). Much of what is 
known about the EVD epidemic in Kailahun District, including the large number of cases, inpatient 
case fatality rate and routes of transmission, came from the MSF EMCs (7-11). Ebola was previously 
unknown to the local population. As such, there was no knowledge either amongst health-care workers 
or in the community about routes of transmission and strategies to control it such as safe burial, isolation 
of patients, quarantine, and contract tracing (12). The reactions of the population were characterised by 
fear and distress (13). 
Understanding the factors which determined population willingness and the ability to comply with 
protective measures is essential but was largely undocumented. To address this evidence gap, I designed 
a mixed-method study to explore the factors which influenced EVD transmission dynamics and 
community compliance with control measures in a rural village that experienced sustained EVD 
transmission and high mortality burden, despite frequent community engagement visits in the village 
by MSF teams. The study also offered insights into the humanitarian and operational aspects that MSF 
should enhance to adapt EVD health interventions to local realities to reflect community perspectives 
and priorities. 
Objective 2 (Chapter 4) was conceptualised in response to the work done at triage while admitting 
patients in the three EMCs, and during surveillance to identify suspect cases at community level in 
Freetown. Identifying suspected cases at EMCs and at community level was challenging due to the 
limited effectiveness of the WHO EVD case definitions. There had been no systematic and rigorous 
evaluation of the performance of WHO EVD case definitions. Such an evaluation was needed to guide 
communities and public health practitioners to improve the effectiveness and efficiency of identification 
and management of suspected cases during an EVD outbreak. 
The third research question (Objective 3, Chapter 5) was conceptualised in the aftermath of the EVD 
outbreak in Bo District, where MSF-OCB was running a 200-bed secondary level referral hospital.  In 
October 2014, MSF suspended health services due to the high risk of EVD nosocomial transmission 
and concerns about staff safety (14). The hospital had been operating since 2003, providing 8,000 
paediatric, and 2,500 emergency obstetrical and gynaecological admissions per year. The closure of the 
MSF hospital in Bo District was perceived to contribute to an increase in mortality in the local area, 
however in the absence of a functional national civil registration and strong surveillance system in place 
there was limited capacity to measure the extent of the crisis. Thus, I designed two retrospective 
mortality surveys were to benchmark the crude and EVD specific mortality. The studies offered 





effect for EVD, and prompted reflection on the utility of using of retrospective mortality studies for 
highly-clustered diseases.	
The research was led by the candidate and conducted as part of a collaborative approach with other 
MSF-OCs, Ministry of Health (MOH) as well as other relevant academic institutions. 
 
Table 6. Characteristics of patients admitted to MSF EMCs, 2014-2015 
(Excluding dead on arrival (n=61, positive 44), transferred and defaulters (n=52), Total patients referred to EMCs 1,948) 






Age, in years  
 
Median (IQR) 27.85 (16-39) 30.08 (20-40) 28.49 (17-40) 
< 5 (%) 77 (5.75) 46 (8.61) 123 (6.57) 
5-14 (%) 224 (16.74) 46 (8.61) 270 (14.42) 
15-54(%) 941 (70.33) 381 (71.35) 1,322 (70.62 ) 
≥ 55(%) 96 (7.17) 61 (11.42) 157 (8.39) 
 
Sex (%)  
               Male 661 (49.40) 328 (61.42) 989 (52.83) 
Female 677 (50.60) 206 (38.58) 883 (47.17 ) 
Outcome. N (%)  
Died 581 (43.4) 37 (6.92) 618 (33.66) 
















2.2 Rationale for the PhD 
	
The 2014-2016 EVD outbreaks in West Africa posed serious clinical and epidemiological challenges, 
in part due to limited investment in EVD research in previous EVD outbreaks. It was also the first time 
that MSF-OCA had been part of an EVD outbreak response, and intensive efforts were made to collect 
extensive data to improve patient care, and to conduct community studies to inform more humane and 
effective future interventions. 
The research objectives were developed targeting specific questions that continue to pose major 
obstacles for agencies involved in outbreak response and local MoHS. The PhD was part of a 
consolidation process on lessons learned for MSF-OCA, and documentation of use of operational 
research conducted under outbreak conditions.  
2.3 Aim of the PhD 
	
The aim is to address evidence gaps on three main areas around community EVD experience and 
transmission, the accurate identification of EVD cases, methodological constraints on estimating EVD 
burden for clustered diseases at population level. These issues continue to pose major clinical and public 
health challenges for agencies involved in EVD outbreak management. 
Research objectives 
The objectives of this thesis are to: 
 
1. Understand of population-level transmission dynamics and factors associated with 
compliance to EVD control in a rural village that experienced sustained EVD 
transmission in Kailahun District, Sierra Leone;	
2. Assess the performance of the WHO EVD case definition and other EVD screening 
scores, to support surveillance and admission testing decisions at EMCs;  
3. Estimate and discuss the utility of empirical mortality rates and design effects for 
highly-clustered disease outbreaks like EVD.  
Table 7 summarises evidence gaps, objectives, and clinical or policy implication identified by this the-
sis. 
The study protocols for Objectives 1 and 3, were approved by the Independent Ethics Review Board of 







Table 7. Synopsis of the evidence gaps addressed by the thesis, its objectives, clinical or policy implication, 
corresponding chapter and research paper 
 
Evidence gap PhD Objective Clinical or policy 
implication 
Chapter and research paper  
Lack of knowledge of the 
factors that influence EVD 
transmission dynamics and 
community compliance 
with control measures over 
time. 
Investigate drivers of EVD transmission and 
community perspective toward EVD control in 
Kailahun District, Sierra Leone.  
To inform responses to 





Investigation of concerns 
about the performance of 
WHO EVD case 
definitions and lack of 
evaluation of its 
performance.  
Assess performance of the WHO EVD case 
definitions and other screening scores, to support 
surveillance and admission testing decisions at 
EMCs. 
To guide communities 
and public health 
practitioners to improve 
the effectiveness and 
efficiency of 
identification and 
management of suspected 




Lack of a benchmark of 
EVD mortality, and 
guidance on survey 
methods for highly 
clustered diseases.  
Measure overall and EVD mortality rates and the 
design effects in two areas where MSF 
suspended paediatric interventions, Bo District, 
Sierra Leone. 
Prompt reflection on the 
utility of using 
retrospective mortality 
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Chapter 3: (Research paper 1) The factors affecting household transmission dynamics 
and community compliance with Ebola control measures: a mixed-methods study in a 
rural village in Sierra Leone 
	 
3.1 Preamble  
 
This chapter addresses the lack of in-depth understanding of transmission dynamics and factors 
associated with non-adherence to control strategies in the context of sustained EVD transmission in an 
EVD-affected village in Kailahun district, Sierra Leone conducted in April 2015. 
This research paper was published in the BMC Public Health in 2018, and it is reproduced as follows 
with no revisions or adaptation from the published manuscript. The original publication is included at 




Caleo G, Duncombe J, Jephcott F, Lokuge K, Mills C, Looijen E, Theoharaki F, Kremer R, Kleijer K, 
Squire J, Lamin M, Stringer B, Weiss HA, Culli D, Di Tanna GL, Greig J. The factors affecting 
household transmission dynamics and community compliance with Ebola control measures: a mixed-
methods study in a rural village in Sierra Leone. BMC Public Health. 2018 Feb 13;18(1):248.  
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3.4 Abstract  
Background 
Little is understood of Ebola virus disease (EVD) transmission dynamics and community compliance 
with control measures over time. Understanding these interactions is essential if interventions are to be 
effective in future outbreaks. We conducted a mixed-methods study to explore these factors in a rural 
village that experienced sustained EVD transmission in Kailahun District, Sierra Leone. 
Methods 
We reconstructed transmission dynamics using a cross-sectional survey conducted in April 2015, and 
cross-referenced our results with surveillance, burial, and Ebola Management Centre (EMC) data. 
Factors associated with EVD transmission were assessed with Cox proportional hazards regression. 
Following the survey, qualitative semi-structured interviews explored views of community informants 
and households.  
Results 
All households (n=240; 1161 individuals) participated in the survey. 29 of 31 EVD probable/confirmed 
cases died (93·5% case fatality rate); six deaths (20·6%) had been missed by other surveillance systems. 
Transmission over five generations lasted 16 weeks. Although most households had ≤5 members there 
was a significant increase in risk of Ebola in households with >5 members. Risk of EVD was also, 
associated with older age. Cases were spatially clustered; all occurred in 15 households.  
EVD transmission was better understood when the community experience started to concord with 
public health messages being given. Perceptions of contact tracing changed from invading privacy and 
selling people to ensuring community safety. Burials in plastic bags, without female attendants or 
prayer, were perceived as dishonourable. Further reasons for low compliance were low EMC survival 
rates, family perceptions of a moral duty to provide care to relatives, poor communication with EMC, 
and loss of livelihoods due to quarantine. Compliance with response measures increased only after the 
second generation, coinciding with the implementation of restrictive by-laws, return of the first 
survivor, reduced contact with dead bodies, and admission of patients to the EMC.  
Conclusions 
Transmission occurred primarily in a few large households, with prolonged transmission and a high 
death toll. Return of a survivor to the village and more effective implementation of control strategies 
coincided with increased compliance to control measures, with few subsequent cases. We propose key 
recommendations for management of EVD outbreaks based on this experience.  





3.5 Manuscript  
3.5.1 Background 
 
The first case of Ebola virus disease (EVD) in Sierra Leone is believed to have occurred in mid-May 
2014, in a remote village of Kailahun District (estimated population 465,048) (1, 2). On 12th June 2014, 
the President of Sierra Leone declared a state of emergency in the district (3). The last case was recorded 
in Kailahun in mid-December 2014 and the Ministry of Health and Sanitation (MoHS) declared 
Kailahun District free from human-to-human transmission on 22nd January 2015, following 42 
continuous days without a confirmed case (1). Médecins sans Frontières (MSF) opened an Ebola 
Management Centre (EMC) in Kailahun on 26th June 2014 to support the district MoHS (4). The MSF 
EMC was the only functioning Ebola management centre in the district, responsible for isolating 63·0% 
of confirmed cases. In total, the district MoHS reported 565 confirmed EVD cases in the population of 
Kailahun (attack rate 0·12%), including 287 deaths (case fatality rate [CFR] 51·0%) (5).  
Evidence-based interventions for EVD control include early detection of cases through effective 
surveillance and contact tracing, admission of symptomatic cases to EMCs where staff adhere to high 
standards of infection control procedures, and safe burials by trained teams (6, 7). Quarantine measures 
were also widely implemented (8), and by-laws imposed that included travel restrictions and penalties 
for hiding suspected cases (9).  
The transmission dynamics of the West Africa EVD epidemic have, so far, been reconstructed from 
EMC and surveillance data, and mathematical modelling (4, 10-12). However, poor surveillance 
systems and limited EMC capacities are likely to have resulted in underestimation of the true extent of 
the outbreak, limiting the ability to understand the dynamics and experience of the epidemic at 
community level, in particular in Sierra Leone, the country most affected by the West Africa EVD 
outbreak (13, 14).  
Little is known of the factors that influence EVD transmission dynamics and community compliance 
with control measures over time. Such understanding is essential if interventions are to be effective, 
particularly in areas like Sierra Leone with no previous local EVD experience. In order to address this 
knowledge gap and inform future responses, we conducted an in-depth mixed-methods study in a rural 




To enable assessment of behaviour adaptation over time, we used data from MSF EMC patient registers 
to select a village in the District that had experienced a very protracted EVD outbreak. We then 
conducted a mixed-methods study combining data gathered via a cross-sectional survey and semi-





the dynamics of transmission. Semi-structured interviews were used to document community 
perception, resistance, and adaptation to response strategies. Survey and interview data were 
triangulated with data from the safe burial and MoHS surveillance databases to verify the reconstruction 
of the EVD transmission, and explain changes in transmission and behaviour over time. 
Cross-sectional survey 
All consenting households in the village were included in the cross-sectional household survey. A 
trained MSF team, using a validated instrument for household mortality studies and EVD case 
investigation forms, collected demographic data from household heads on household members, births, 
arrivals, departures, deaths, illnesses (including signs and symptoms compatible with the EVD case 
definition), and history of contact with individuals symptomatic for EVD (15, 16). Verbal consent for 
participation was obtained from the head of each household after a briefing about the aim of the survey, 
the questions and duration of the questionnaire, and the option to end the interview at any time if wished.  
The household survey was conducted in April 2015, with a recall period for responses between May 
2014 (date of the first reported EVD case in the district) and the date of the survey. A local events 
calendar was developed to aid recall. MSF-EMC patient registers were used to verify the date of 
admission, symptoms, laboratory confirmation of EVD, and outcomes of patients admitted to the EMC. 
Each household in the village was enumerated and listed; from this list we randomly selected the 
households for the semi-structured interview. 
Geographic positioning system (GPS) data were used to map the village layout and location of all 
households. Data were de-identified and entered into a password-protected electronic database.  
Semi-structured interviews 
At the end of the cross-sectional survey, semi-structured interviews were conducted with key 
community informants and selected households. Households were divided into two groups based on 
whether they had experienced at least one EVD case or no EVD cases. Ten households were randomly 
selected for interview from each group (total of 20 interviews).  
A purposive approach was used to select key community informants: traditional healers; biomedical 
health-care providers; and community leaders including tribal authorities, heads of community groups, 
and religious leaders. The heads of the selected households and key community informants were 
interviewed after verbal consent to participate was obtained. Participants were briefed about study 
objectives, questions and duration of interview, and the option to leave the study at any time. All 






Interviews were conducted in the local language using an interpreter to translate and back translate to 
English. The local events calendar developed for the household survey was also used in the semi-
structured interviews. Topic guides directed interviewers to explore changes over time in perceptions 
of EVD and perspectives related to EVD response activities including contact tracing activities, the 
MSF EMC, the safe burial team, and quarantine. Interviews explored how these EVD control strategies 
were implemented and how these accorded with cultural beliefs. The topic guide was the same for 
household and key informant groups except for an additional section in the key informant guide, 
regarding how the outbreak started in the village. After initial data analysis had been completed, a 
summary narrative was compiled and shared with the village in the format of a story. Participant 
validation was achieved in this way in order to refine findings (17). 
Case definitions  
World Health Organization (WHO) EVD case definitions were used to define suspect, probable, and 
confirmed cases (16). A suspect case was defined as: any person, alive or dead, suffering or having 
suffered from sudden onset of high fever and having had contact with a suspect, probable, or confirmed 
EVD case or with a dead or sick animal; any person with sudden onset of high fever and at least three 
relevant symptoms (headaches, vomiting, anorexia/loss of appetite, diarrhoea, lethargy, stomach pain, 
aching muscles or joints, difficulty swallowing, breathing difficulties, hiccup); any person with 
inexplicable bleeding; or any sudden, inexplicable death. A confirmed case was defined as anyone with 
a positive quantitative reverse transcription polymerase chain reaction (PCR) result. PCR cycle 
threshold (Ct) results were used as indicators of viral load. The lower the Ct value the higher the viral 
load (18). A probable EVD case was defined as anyone who met the clinical case definition and had a 
history of contact with a person with confirmed EVD, but who did not have a confirmed laboratory test 
result (16). 
Data analysis 
Cox proportional hazards regression models were fitted to estimate hazard ratios (HRs) and 95% 
confidence intervals (95% CI) for the association between EVD (probable and confirmed cases) and 
covariates previously documented to be associated with EVD, including household size, sex, and age 
(19, 20). Events were dated by epidemiological week and used as the time parameter in the Cox model. 
Cox shared frailty models were used to allow for within-household correlation. 
The crude mortality rate (CMR) and EVD-specific mortality rate were estimated as deaths during study 
period/(mid-period population at risk x duration of period), where mid-period population at risk 
accounted for births, deaths, arrivals, and departures during the recall period (21). Mortality rates were 
expressed as deaths per 10,000 per day. The attributable risk percent (AR%) and population attributable 
risk percent (PAR%) were used to estimate excess mortality risk due to EVD in the exposed households 





The proportion of EVD cases isolated by admission to the EMC and the proportion of people who died 
from EVD and received safe burial were assessed by comparing cases reported in MoHS surveillance, 
EMC, and burial team data with cases (confirmed and probable) identified through the household 
survey. 
Transmission dynamics were constructed using contact history, and described using transmission 
chains. Relationships between individuals were categorised as nuclear (immediate family), extra 
nuclear (extended family), and social (neighbours and friends).  
Statistical analyses were carried out using Stata 14.0 (Stata Corporation, Texas-USA); maps were 
generated using QGIS™ software (version 2.14, http://qgis.org). Participant responses from all semi-
structured interviews were translated and transcribed at the time of the interview. Key community 
informants and household interview data were analysed separately using an inductive framework 
approach via an iterative process of coding and categorization (using ©NVivo 10) leading to the 
identification of emerging themes. The former contributed to the description of initial phase of the 
outbreak along with documenting the village experience over time, and the latter to exploring affected 





The village consisted of 240 households (1161 individuals); all heads of households gave consent to 
participate. The median age of villagers was 18 years (interquartile range [IQR] 7-34 years), with 44·4% 
(n=515) younger than 15 years old. Approximately half the villagers were female (52·7%). Household 
size ranged from 1-17 people, with a median size of 5 (IQR 3-6).  
Transmission dynamics 
Overall, 31 EVD cases (15 confirmed, 16 probable) were identified, giving an overall attack rate in the 
village of 2·7%. The index case was an adult male who was resident in a city that was a known EVD 
hotspot in June-July 2014. In late July 2014, while symptomatic, he travelled back to his village of 
origin and died 1 week after his return. Table 8 details the possible routes of EVD transmission that 
were reported by his household and key informants. There was no record of the index case being tested 
for EVD, although he was reportedly taken to a holding centre for testing.  
Following death, the index case was buried in an unsafe manner by community members, many of 
whom had unprotected contact with the body. It is believed that this may have started the chain of 





over five transmission generations: 11 cases in the 1st generation, seven in the 2nd, five in the 3rd, four 
in the 4th, and two in the 5th. For the one remaining case, a traditional birth attendant, a clear source of 
infection and transmission generation was not established (Figure 5). The time from exposure to 
symptom onset was ≤2 weeks for all cases with known exposure. The first survivor came back to the 
village in week 35 (late August), after 7 weeks of transmission, when most of the cases in the village 
had already occurred. 
Amongst the secondary cases with known exposure: 38·0% (11/29) had, as sole exposure, contact with 
a symptomatic person who was a probable/confirmed case; 10·3% (3/29) had a history of attending a 
funeral; and almost half (14/29; 48·2%) had history of both contact with a symptomatic person and a 
funeral exposure. The proportion of cases exposed via a funeral decreased over time from 90·9% 
(10/11) in the 1st generation to 71·4% (5/7) in the 2nd, 40·0% (2/5) in the 3rd, 25·0% (1/4) in the 4th, 
and none in the last. Contact with a symptomatic person increased from 72·7% (8/11) in the first to 
100·0% in the following generations. Among the 30 secondary cases, 28 died (93·3%) and two survived 
(6·7%). 
There was strong evidence of clustering of EVD (p <0·0001), with all cases occurring in 15 of the 240 
households (Figure 6). Thirty-two percent of cases occurred in two households, in which cases occurred 
over three- and four-generation chains.  
Most secondary cases were exposed via the nuclear (57·6%; 17/30) or extended family (30·0%; 9/30). 
Affected households had a median of seven members (IQR 6-8), and non-affected households a median 
of three (IQR 2-4) (p <0·0001). 
 
Factors associated with EVD  
EVD was associated with older age and household size in unadjusted analysis; these associations 
became stronger after adjustment for both variables and sex (Table 9). The rate of EVD was similar by 
sex (aHR 1·03; 95% CI 0·49-2·17 for females vs males), but was greater among those aged 15-54 years 
(aHR 23·04; 95% CI 3·06-173·12) and ≥55 years (aHR 57·28; 95% CI 7·03-466·33) compared with 
those aged 5-14 years, and among those living in larger (>5 members) (aHR 56·53; 95% CI 19·64-
162·73) compared with smaller households (Table 9). 
Mortality 
Of the 31 cases (index case plus 30 secondary cases), 29 died (CFR 93·5%; 95% CI 78·6-99·2%). 
Thirteen of 15 confirmed cases and all 16 probable cases died. About half (55·2%) of EVD deaths were 





The community reported five non-EVD deaths during the recall period. The CMR for all causes of death 
(EVD and other) was 0·97 per 10,000 per day. EVD-specific CMR was 0·83 per 10,000 per day and 
the non-EVD CMR was 0·14 per 10,000 per day.  
The AR% for death associated with EVD was 99·5% (95% CI 98·6-99·8) among the exposed 
households, while the PAR% for death associated with EVD in the whole village was 84·5%. 
Admission to the MSF EMC 
In mid-August 2014, cases started to be admitted to the EMC. Of the 31 cases, 15 were admitted to the 
EMC and had Ebola infection confirmed by PCR testing. Twelve cases had an exact date of symptom 
onset recorded, with a median time from first onset of symptoms to admission of 4·0 days (IQR 3-5). 
The median time to admission was 5·0 days in the first generation (IQR 4-7), falling to 1·0 day in the 
last generation (IQR 0-1). The mean Ct value at admission was 21·8 (SD 4·5). Among the confirmed 
cases at EMC, 12 (80·0%) presented at admission with at least one wet symptom (diarrhoea, vomiting, 
or bleeding).  
Burial, quarantine, and contact tracing  
Of the 29 EVD deaths, 13 (44·8%) occurred within the EMC; five deaths in the community then had a 
safe burial by the burial team. Six deaths (20·6%) were captured during the survey but were not listed 
in the EMC, MoHS surveillance system and/or safe burial database. A further five people who died 
were reported by families to have been transported to an MSF or local Government hospital, however, 
there was no record of those patients in the EMC database. Contact tracing was reported to have 
occurred starting in late July; one in five village households reported they had been under contact tracing 
and quarantine measures. However, in August 2014, when 18 secondary cases had already occurred, 
the entire village was put under restriction of movements.  
Community perception, resistance, and adaptation to response activities 
Semi-structured interviews were conducted with 38 participants: 10 households reporting EVD cases 
(affected households (AH)), 10 households with no cases (UH), and 18 key community informants (CI). 
Introduction of EVD in the village 
When discussing how EVD had been introduced to the village, all participants referred to a single 
member or index case in the family or community, ranging from a family visitor to a health worker.  
“The man [index case] brought Ebola here. He used to treat people in [city] that was a hotspot 
at the time. When he got sick, he came here to see traditional healers and a herbalist came 





“An ambulance came to collect him and take him to [XX] holding centre. It was anecdotally 
reported that he tested negative, so some relatives went to pick him up. People were very happy, 
so they came to greet him/celebrate.” - (CI04_m)  
Misgivings toward Ebola 
Initially, it was difficult for villagers to believe that infection could spread through everyday person-to-
person contact. This perception was compounded by a climate of mistrust of authorities, fear of death, 
and lack of understanding of complex health messages such as the importance of isolation of those 
infected.  
“We had never seen a sickness like this before, where you touch someone and you die.” - 
(CI12_m) 
“It seemed like someone had poisoned our village; many, many, many people died. It was 
similar to other diseases [e.g. malaria].” – (CI16_m)  
"We thought it was a curse; some people thought that it was some kind of traditional medicine 
that was being thrown on them." - (CI13_f)  
"People thought it was a conspiracy between the President and the westerners, who needed 
blood. They thought that if you go to the EMC, you will die.” - (CI03_m)  
"People didn’t believe it: like war, we didn’t believe it could come here. There was lots of 
arguing - some people thought Ebola wasn’t real. They thought it was something sent by God.” 
- (CI04_m) 
"People were hiding symptoms and deaths because they were scared of the camp [EMC]; by 
the time they were found and the ambulance called, they were already dead.” - (CI11_m) 
“Early on, people were hiding if they were sick. By the time we knew they were sick, they 
weren’t alive long enough to send them to the EMC (1-2 days).” - (UH05_m)  
“We beat the contact tracers - we thought they were responsible for our relatives’ deaths 
because they went for training at the same time [end of July] XX [index case] got sick.” - 
(CI16_m)  
“At the start, people hated the contact tracers - they beat them. One man in particular was 
beaten almost to death.” - (CI17_f)   
“The man [index case] came with a letter that said he should be isolated for 21 days. But we 





Change in perception  
The perception of EVD held by the villagers changed when information received from contact tracers 
and the MSF health promotion team was consistent with what villagers observed in their lives at the 
community level. Implementation of the by-laws on travel and penalties for non-reporting cases 
supported the understanding of the severity of the outbreak by villagers, and helped them accept that 
control measures were intended to protect and help the community.  
"When we saw that people touched sick people and got sick, we could see the communication 
of it and realised that it is real." - (CI13_f) 
“Sensitisation from different sources [MSF/MoHS/radio] started to make sense; symptoms in 
our loved ones were exactly the same as they were telling us.” - (CI11_m)  
“We realised that no contact was good, after a while, we saw the benefit.” - (CI15_m)  
“But we had to follow the law we had to pay 500,000 Leones if there was a sick person found 
in the house.” - (CI12_m)  
“It was for our own safety - to avoid touching bodies. To help them to stop the spread of Ebola. 
The word ‘safe’ equals ‘help’.” - (CI16_m)  
Behaviour adaptation  
Understanding of the route of transmission, and observing survival of cases admitted to the EMC 
supported changes in behaviour and adaptation by the community. This mainly occurred in late August 
coinciding with the return of a survivor, reduced contact with dead bodies, restriction of movements 
and isolation of patients. 
"When we heard about people surviving people's attitude changed.” - (CI03_m)  
“We would go far away from the person and inform contact tracers who will call an 
ambulance to remove them to the camp [EMC].” - (UH04_f) 
“Initially, it [burial team] was not good but when we saw that the deaths increased, we knew 
it was for our own safety.” - (AH02_m)   
The village implemented a number of local measures to prevent spread between households. 
“During the outbreak, some people even devised their own preventive measures, like stopping 
children from playing football so they don’t have contact with each other, and stop visit other 





“Traditional birth attendants stop doing deliveries.” - (CI17_f)  
Understanding control strategies and constraints 
All strategies such us MSF/EMC, MSF health promotion, contact tracing, burial practices, 
quarantine/restriction of movements were understood by the community as helping to control EVD. 
However, resistance to specific practices that were perceived as offensive to socio-cultural norms was 
reported; this resistance continued until the value of such practices was understood.  
MSF/EMC 
The EMC was understood to help people survive: 
“Without the camp [EMC] - we would have no survivors.” - (CI04_m)  
However, communication regarding the status of admitted patients was perceived as poor: 
“We received no information while they were still alive. When they died, a nurse who worked 
at the camp [EMC] told us.” - (CI14_f)  
“When the ambulance went with XX to the camp [EMC], some family members went to visit 
and they learned that he had died.” - (CI07_m)   
The MSF health promotion team were perceived as empowering the community: 
"It gave the Community Health Workers a zeal to call ambulances; they empowered us. They 
sensitised us about preventive methods and no touch.” - (CI06_m)  
“Helped to decrease cases.” - (CI12_m)  
“We learned not to touch other people, and use water and soap.” - (CI15_m)  
Contact tracing  
Contact tracing was perceived as a mechanism to remove people from the community who were thought 
to be a risk, which initially created mistrust. This gave contact tracers a reputation for invading privacy 
and disrupting family and community life and sending people to their deaths.  
“There was no sensitisation about why contact tracers were here. They would just call the 
ambulance and collect people to the EMC.” - (CI01_m)  





“Invasion of privacy - it was not their business to investigate our household.” - (CI04_m) 
“We didn’t like the fact that they were involving themselves in our affairs, we thought contact 
tracers were selling us to other people and that they were too inquisitive.” - (CI17_f)  
However, contact tracers were valued once people understood that they were trying to protect people 
and prevent the spread of Ebola: 
“It is our culture to touch people when they are sick, so if you don’t take people out of the 
village, people will touch them.” - (CI11_m)  
“Without contact tracers we would have continued touching people. Instead, sick people were 
collected to the camp [EMC].” - (CI16_m)  
“Otherwise we would have far more deaths.” - (CI14_f)  
“Contact tracers should be empowered with training to stop the spread.” - (CI13_f)  
Burial practices 
The value of safe burials was understood: 
“Without the burial team, the disease would have spread because touching dead bodies is 
bad.” - (CI02_f)  
However, burials were initially seen as lacking honour in terms of how they were performed, 
specifically the use of plastic bags, and the lack of burial clothes and prayers. Respondents also 
commented on the lack of women in the burial team and on the arrival of the teams in the village already 
dressed in personal protective equipment (PPE).  
“Plastic bags are not traditional - there is no honour when you bury people this way.” - 
(CI03_m)  
“Praying was not allowed.” - (CI09_m)  
“Sometimes, in dreams, my husband appears and says ‘I have no clothes’.” - (AH06_f)   





“We weren't happy about it. Before the outbreak, if a chief dies or a special person dies, they 
are buried by other special people. Now, we can't do that. There is no clothes, no dressing - 
and men are burying women, which is a problem for us.” - (CI11_m)  
“People were afraid of the burial team when they came dressed in full protective clothes. They 
thought they were ghosts.” - (CI03_m)  
In October, the burial procedures were improved to incorporate greater respect for local tradition: 
“We couldn’t pray before, either, but now we can.” - (CI03_m)  
“Now they [burial team] dress in protective clothes in the village.” - (CI11_m) 
Quarantine/restriction of movements  
The community understood the value of quarantine: 
“Because of quarantine, we couldn't spread Ebola to other households." - (AH07_m) 
However, people were also angry about quarantine: 
“It destroyed many things, especially farming, our crops were destroyed and there is no food 
available now.” – (CI15_m) 
In September, quarantine measures were improved by incorporation of food supply to quarantined 
households: 
“We had no food at the start. They should have given us food like they did in other households 
at the end.” - (AH06_f) 
Affected versus unaffected households 
Both affected and unaffected households were sensitive to law enforcement and were in favour of 
stricter methods to control Ebola in the future. The consequences of quarantine, in terms of financial 
and emotional impact and stigma, were harsher in affected households compared with non-affected 
households, since non-affected households were only directly impacted when the entire village was 
quarantined.  
“Seven members of my family were taken to EMC. They all died there. Everyone would yell 





Affected households provide some insight into factors that led to continued transmission in some homes 
but not in others, and why within-household transmission continued even when between-household 
transmission was reducing: 
“We could not abandon sick people – we must care for [them].” - (AH05_f)  
“People didn’t come around - it was like the devil was here.” - (AH04_m) 
3.5.4 Discussion  
 
Our study provides a comprehensive description of EVD in one village in Kailahun District, Sierra 
Leone that experienced sustained EVD transmission during 2014. We attempt to capture the 
complexities of the social context influencing outbreak control in this specific epidemic. We 
documented that immediate family members of large households were at greater risk of being infected, 
and because of the larger number of inhabitants, these households were more likely to maintain 
transmission. This finding corroborates insights from other studies. This may imply that future 
responses to an EVD outbreak could justify prioritization of affected large households and their 
immediate family members, in particular when human resources are insufficient to address the scale of 
the outbreak (19, 22).  
Within affected households, transmission was maintained by the need to provide care for sick relatives, 
with cases continuing to occur over several generations. Compliance with response measures increased 
only after the second generation, coinciding with the return of a survivor, and strict implementation of 
other components of the EVD response, such as restriction of movements, reduced contact with dead 
bodies, and isolation of cases. However, this changing context only occurred after 7 weeks of 
transmission, when most of the cases in this outbreak had already died. 
In particular, return of survivors to the village after treatment prompted a shift toward belief in Ebola 
and increasing acceptance of control measures. Late return of survivors prevented teams from building 
trust within the community. At the time that survivors returned, the village was experiencing a peak in 
case numbers, the MSF EMC was reaching the limit of its capacity (100 beds), and communication with 
households was primarily to inform of deceased loved ones, thus contributing to community fear and 
despair. People reported avoiding the MSF EMC because of poor survival rates, which reinforced the 
community perception of the EMC as a place where people die. One approach to improving community 
understanding and uptake of EMC services in future could include developing the role of an EMC-
village liaison, whose role would be to support timely communication with communities about the status 
of relatives throughout admission. Use of EMC-village liaisons could acknowledge the gap in 
understanding of health system workers as to why patients may undermine control measures when faced 





therefore have the potential to be seen as providing something positive to the community rather than 
just reporting and tracing cases. 
Reduced misgivings and doubt about Ebola were crucial to influencing attitudes toward control 
measures. This change likely occurred once the health messages given to the community mirrored their 
reality. Once Ebola transmission was understood, the perceptions of contract tracing changed from 
invading privacy, selling people to working collectively toward community safety. The community then 
participated in control measures by setting up a number of local strategies such as stopping babies being 
delivered in the community, preventing children from playing contact games together, and not visiting 
other households. These strategies contributed to outbreak control, as observed by other authors (23). 
Our findings emphasised the importance of the community having a role in tailoring outbreak responses. 
Following a localised governance approach may permit incorporation of accepted local social norms 
from the outset of intervention efforts, making them more acceptable and therefore effective. 
Clear communication of complex health messages was challenging, but played a role in the acceptance 
of EVD control measures. It was essential that the community understood there was a 21-day incubation 
period, the importance of EMC isolation (both self-imposed and institutional), and that a single negative 
test result could not rule out disease during the incubation period. Other authors described similar issues 
for messaging in Sierra Leone and in previous outbreaks (24, 25).  
Similarly to the rest of the country, the age structure of the village was young, with those under age 15 
accounting 44% of the population. The limited life experience of youth, and particularly collective 
experience with death from exposure to body fluids (e.g. ”touch someone and you die”) or with infection 
prevention and control concepts (e.g. “we didn't understand what 'isolation' meant”) may have 
contributed to delays in understanding and adoption of the necessary responses, rather than villagers 
being deliberately uncooperative. However, we documented that regardless of age, the population in 
general suffered an overwhelming level of inexperience toward this disease and its impact. Response 
agencies must acknowledge community demographic structure and perspectives on the presence of 
EVD in parallel with launching control measures cognisant of their baseline understanding.  
Our study findings show nuanced perceptions toward quarantine as both a way to control the spread of 
Ebola, and a cause of social and livelihood disruption, which challenged compliance, as reported by 
other researchers (26). This argues for such social disruption to be taken into account when planning 
how best to protect affected people and control transmission. 
Safe burial using plastic bags, lack of burial clothes, and the absence of women in the burial team were 
described as showing a lack of honour for the deceased. Burials were described as being more compliant 
to control measures when practices such as community prayer were permitted. In addition, the burial 
team started to dress in PPE after arrival in the village as now recommended by WHO Guidelines (27). 





female members in the burial team, and safe alternatives to plastic burial bags, would further enhance 
community acceptance compliance, and should be included in EVD control guidelines. 
The comprehensive design of this study enabled every household in the village to be surveyed, and 
therefore a number of deaths were captured by our survey, that were not identified by MOHS 
surveillance, EMC, or burial data. All cases and deaths detected were spatially clustered; this is a key 
finding since traditional methods to estimate mortality rely on cluster sampling approaches, which in 
this case could have generated either an under- or over-estimation of EVD, depending on whether the 
limited number of affected households was randomly selected. This is an important element to take into 
account while trying to benchmark the burden of highly clustered diseases like EVD. Even in a highly 
affected community, clustering of disease means that household sampling is likely to miss many 
households unless an appropriate estimate of intra-cluster correlation is available. It is noted that it 
would not have been feasible to carry out exhaustive studies on the wider population in the middle of 
the EVD outbreak. In future, we recommend developing alternative methods of sampling to estimate 
disease and mortality that account for the highly clustered nature of diseases such as EVD. 
Strengths and limitations 
A major strength of this study is its mixed methods design, which provides a deeper understanding and 
explanation of the social reactions to dealing with EVD at community level. Half of the EVD cases in 
this study were not confirmed by PCR. However, they met the suspected case definition, died, had clear 
epidemiological links with a confirmed case, and some generated secondary cases, some of which were 
confirmed EVD. The number of deaths may have been under-reported, as villagers may have feared a 
penalty for not adhering to the mandatory notification by-law. However, it should also be noted that the 
study was well perceived by villagers, as demonstrated by the participation of the entire village, their 
help in documenting the transmission chains, and their willingness to tell the story of the village 
outbreak. We cannot exclude underestimation of the burden of EVD infection in the village by missing 
mild or asymptomatic cases. We also collected data on morbidity at the time of the outbreak, and three 
living people reported history of symptoms compatible with EVD, and a history of exposure, but they 
were never tested or isolated and thus not included in the analysis. If they were true cases, our EVD 
mortality may be overestimated, however, when we did include these cases in the analysis it did not 
change our findings significantly. The true EVD infection rate could be known only via a serological 
study (28). 
Incorrect recall of the timing of deaths may have occurred, but the impact of Ebola makes this less 
likely, and the use of a local community calendar of events aided recollection of timing. In addition, we 
validated dates and symptoms for cases admitted to the Kailahun EMC, MOHS surveillance, and buried 
by the burial team. We were able to rebuild accurate dates for the events of each case we identified, 





For the qualitative part of the study, we acknowledge it was more difficult to definitively link 
community behaviour change with specific measures or events. Furthermore, we recognise that those 
are reported perceptions recollected at the time of the outbreak, however, these were consistent among 
the different people interviewed and suggested a shift in the way the community expressed their ideas 
of EVD. We acknowledge that perception of changes in the village may have been influenced by the 
differing roles played by community informants, and in relation to the differing experiences of affected 
vs. unaffected households.  
It is also important to note that our observations were based on a single, high-burden village. Our 
findings are therefore likely to be generalizable to similar rural settings with high levels of transmission. 
However, it is possible that the outbreak and response would be different in villages with lower levels 
of transmission, as experience of the disease was an important driver of behavioural change. 
Finally, the main limitation of our qualitative work was that questions regarding burial practices seemed 
to provoke a limited depth of response in particular among affected households. This may have been 
because respondents were still affected by their loss. 
3.5.5 Conclusion 
 
In this high-burden village, transmission was maintained by a small number of large households; the 
outbreak was controlled in this community only after prolonged transmission and a high death toll. A 
key recommendation emerging from these findings is to ensure that large households and immediate 
family members are prioritized in control and prevention activities. There is also a need to develop 
novel sampling methods appropriate for estimating mortality for highly clustered diseases like EVD. 
Our findings provide practical information on how future interventions could be implemented more 
humanely and effectively. We emphasise the following factors: recognising the role of communities for 
their contribution in controlling outbreaks; identifying community liaison roles which can keep families 
informed of their relatives’ progress in the EMC; ensuring survivors are engaged to increase community 
trust to delegate care to EMCs; conveying complex health messages around incubation periods and 
infectivity clearly to the community; using appropriate alternatives to burial in plastic bags; including 
women in burial teams; and compensating quarantined households and communities to ensure they can 
maintain and re-establish livelihoods.  
Factors underlying delays in implementing control measures included community belief or otherwise 
in the presence of EVD, lack of trust, and the toll imposed by interventions such as safe burial 
procedures and the social disruption of quarantine. Early understanding of social norms and experiences 





Including these findings in future recommendations for outbreak control policy could help to improve 
the accuracy of mortality estimates and avoid unnecessary deaths and protracted suffering in future 
outbreaks. 
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Table 8. Possible sources of infection for the index case 
 
Contact with EVD patient(s) in the course of his work as a pharmacist 
Contact with EVD patient(s) when he had a tooth extracted at a local Government Hospital, which was, at 
that time, a major hotspot of EVD 
Contact with a traditional healer, who reportedly came from Guinea to treat the index case, who may have 
been infected 
Contact with EVD patient(s) at a holding centre he was taken to for testing because he was symptomatic fol-
lowing the tooth extraction 















95% CI p Adjusted 
hazard ratio 
95% CI p Adjusted hazard ra-
tio from shared 
frailty Cox 
95% CI p 
Sex            
Male 549 13 (2·4%) ref   ref   ref   
Female 612 18 (2·9%) 1·24 0·61–2·54 0·55 1·03 0·49–2·17 0·92 1·19 0·52–2·73 0·68 
 
Age group (years) 
< 5 174 4 (2·3%) 7·87 0·88–70·48 0·0001 6·02 0·66–54·39 < 0·0001 6·10 0·63–58·63 0·12 
5–14 341 1 (0·3%) ref   ref   ref   
15–54 552 18 (3·3%) 11·27 1·50–84·45  23·04 3·06–173·12  20·26 2·48–165·09 0·005 
≥ 55 94 8 (8·5%) 31·57 3·94–252·48  57·28 7·03–466·33  53·06 5·89–477·66 < 0·0001 
 
Household size 
≤ 5 members 973 4 (0·4%) ref   ref    ref   
>5  
members 188 27 (14·4%) 37·15 12·99–106·19 < 0·0001 
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Chapter 4:(Research paper 2) Clinical and epidemiological performance of WHO Ebola 
case definitions: a systematic review and meta-analysis 
 
4.1 Preamble  
 
In this chapter I present the work undertaken to address the lack of systematic and rigorous evaluation 
of the performance of WHO EVD case definitions and other clinical and epidemiological characteristics 
such as symptoms and signs at admission and contact history, against the reference standard (laboratory 
confirmation of Ebola virus infection).  
This was investigated through a systematic review and meta-analysis of studies published in English 
between June 13, 1978, and Jan 14, 2020. 
The paper was published in the Lancet Infectious Diseases in November 2020, and it is reproduced as 
follows with no revisions or adaptation from the published manuscript. The original publication is 
included at the end of this thesis. 
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4.4 Summary  
Background  
Ebola virus disease case definition is a crucial surveillance tool to detect suspected cases for referral 
and as a screening tool for clinicians to support admission and laboratory testing decisions at Ebola 
health facilities. We aimed to assess the performance of the WHO Ebola virus disease case definitions 
and other screening scores. 
Methods 
In this systematic review and meta-analysis, we searched PubMed, Scopus, Embase, and Web of 
Science for studies published in English between June 13, 1978, and Jan 14, 2020. We included studies 
that estimated the sensitivity and specificity of WHO Ebola virus disease case definitions, clinical and 
epidemiological characteristics (symptoms at admission and contact history), and predictive risk scores 
against the reference standard (laboratory-confirmed Ebola virus disease). Summary estimates of 
sensitivity and specificity were calculated using bivariate and hierarchical summary receiver operating 
characteristic (when four or more studies provided data) or random-effects meta-analysis (fewer than 
four studies provided data). 
Findings  
We identified 2493 publications, of which 14 studies from four countries (Sierra Leone, Guinea, 
Liberia, and Angola) were included in the analysis. 12021 people with suspected disease were included, 
of whom 4874 were confirmed as positive for Ebola virus infection. Six studies explored the 
performance of WHO case definitions in non-paediatric populations, and in all of these studies, 
suspected and probable cases were combined and could not be disaggregated for analysis. The pooled 
sensitivity of the WHO Ebola virus disease case definitions from these studies was 81·5% (95% CI 
74·1–87·2) and pooled specificity was 35·7% (28·5–43·6). History of contact or epidemiological link 
was a key predictor for the WHO case definitions (seven studies) and for risk scores (six studies). The 
most sensitive symptom was intense fatigue (79·0% [95% CI 74·4–83·0]), assessed in seven studies, 
and the least sensitive symptom was pain behind the eyes (1·0% [0·0–7·0]), assessed in three studies. 
The performance of fever as a symptom varied depending on the cut-off used to define fever. 
Interpretation 
WHO Ebola virus disease case definitions perform sub-optimally to identify cases at both community 
level and during triage at Ebola health facilities. Inclusion of intense fatigue as a key symptom and 
contact history could improve the performance of case definitions, but implementation of these changes 






Médecins Sans Frontières (MSF). 
4.5 Manuscript  
4.5.1 Introduction 
 
Ebola virus disease case definition is a crucial surveillance tool to detect suspected cases for referral 
and as a screening tool for clinicians to support admission and laboratory testing decisions at Ebola 
health facilities. However, there have been long-standing concerns about the poor performance of the 
WHO Ebola virus disease case definitions, including the inability to distinguish Ebola virus disease 
from common diseases such as malaria and typhoid fever (1-3). 
The scale of the 2014–16 west African Ebola epidemic further challenged the operational use and 
validity of the WHO case definitions in detecting suspected cases at the community level and allocating 
patients appropriately to high-risk or low-risk wards for testing at specialised isolation centres (4 
).Consequently, during and since this epidemic, organisations involved in the Ebola virus disease 
response have estimated the sensitivity and specificity of the WHO case definitions and its constituent 
symptoms and signs, and developed alternative definitions and risk scores to identify clinical and 
epidemiological factors that could predict infection under outbreak conditions(5, 6). Discordance on the 
use of WHO Ebola virus disease case definitions with consequent delay on outbreak control and 
community disengagement have been reported in west Africa and, in the current outbreak, in the 
Democratic Republic of the Congo along with its bordering countries (7-9). 
However, the operational use and performance of those definitions and risk scores has not been 
rigorously evaluated. Such an evaluation is needed to guide communities and public health practitioners 
to improve the effectiveness and efficiency of identification and management of suspected cases during 
Ebola virus disease responses. 
We aimed to assess the performance of the WHO Ebola virus disease case definitions and other clinical 
and epidemiological characteristics, such as symptoms and signs at admission and contact history, as 




Search strategy and selection criteria  
For this systematic review and meta-analysis, we searched PubMed, Scopus, Embase, and Web of 
Science, without regional restrictions, for studies in English published between June 13, 1978 (when 




to capture data on the current outbreak of Ebola virus disease in the Democratic Republic of the Congo 
by contacting relevant people involved in the response. 
The search terms included “Ebola”, “EVD infection”, “case definition”, “admission symptoms”, 
“sensitivity”, “specificity”, “likelihood”, “score”, “classification”, “validity” and “performance” 
(Appendix, pp 5-6). 
We included observational retrospective studies that estimated the sensitivity and specificity of WHO 
Ebola virus disease case definitions and other clinical and epidemiological characteristics (symptoms 
and signs at admission and contact history) against the reference standard (laboratory confirmation of 
Ebola virus infection), and studies that developed, or externally validated, predictive risk scores (based 
on a combination of symptoms and signs, and epidemiological information) to predict the risk of being 
positive for Ebola virus. 
We also included studies looking at sensitivity and specificity of WHO case definitions for Ebola or 
Marburg virus infections because they belong to the same family of viruses (Filoviridae) and share the 
same case definitions, and the reference standard is laboratory confirmation of infection (12). 
We excluded studies on the sensitivity and specificity of diagnostic tests, animal and vaccine studies, 
studies of survivors of Ebola virus disease, and studies on predictors of outcomes or severity of Ebola 
virus disease, community surveillance, and outbreak and clinical management. Studies specifically on 
frequency of symptoms at admission were also excluded as a previous review exists (13). 
Two reviewers (GC and FT) independently screened all titles and abstracts to identify those meeting 
the selection criteria, and a third author (LI) arbitrated for studies without consensus. A full-text review 
was then done for these articles, and their bibliographies were assessed for other eligible studies. We 
extracted data on author, year of publication, country, virus, period of data collection, study design, 
study objective, outcomes measured, setting in which data were collected (eg, Ebola treatment centres), 
age of population included in the study, study size including number of patients who were negative and 
positive for Ebola virus, diagnostic method, limitation of individual studies, and performance of the 
WHO Ebola virus disease case definitions, and individual symptoms and signs, and epidemiological 
links or contact history with known patients with Ebola virus disease. 
Performance data extracted included sensitivity, specificity, predictive values and risk score, and area 
under the receiver operating characteristic (ROC) curve (AUC). We developed a spreadsheet to compile 
extracted data based on the Cochrane data tool (14). The primary data extracted from each article were 
checked by a second researcher (FT). No protocol was developed for this study. 
WHO Ebola virus disease case definitions were used to define suspected, probable, and confirmed 
cases, which varied by context and period of outbreak. In 2014 in Sierra Leone, WHO included 




definitions (12,15) For paediatric populations, the modified WHO case definition used in Sierra Leone 
was evaluated (figure 7) (15). 
Data analysis  
We derived the numbers of true positive, false negative, true negative, and false positive cases in each 
study using data provided in each article for each symptom and sign, and WHO Ebola virus disease 
case definition. Sensitivity and specificity are correlated, and univariate measures of heterogeneity, such 
as I², are not suitable to report heterogeneity in diagnostic test accuracy reviews (16). We used bivariate 
and hierarchical summary ROC (HSROC) models for meta-analysis (17,18). 
The bivariate model provides estimation of a summary of sensitivity and specificity, whereas the 
HSROC model provides the estimation of a summary curve from studies that have used different 
thresholds, the 95% confidence region for the summary point, and the 95% prediction region. The 
prediction region graphically illustrates between-study heterogeneity as well as the bivariate 
relationship between sensitivity and specificity (19). Only studies that used comparable thresholds, 
symptoms and signs, or definitions were combined using these methods. 
Given that HSROC models cannot be fitted when there are data from fewer than four studies, for some 
symptoms and signs we did a random-effects meta-analysis to calculate pooled estimates for sensitivity 
and specificity (20 ).Compared with bivariate and hierarchical models, pooled estimation from random-
effects meta-analysis could slightly overestimate point estimation, so estimates from the random-effects 
model are provided for completeness. 
We summarised, without any further re-analysis, studies that developed or externally validated risk 
scores for predicting Ebola virus infection. Scores were used to identify individuals with a higher or 
lower risk of Ebola virus infection during screening at Ebola health facilities. To obtain the risk scores, 
these studies used the regression coefficients of independent risks obtained by multivariable logistic 
regression against Ebola virus infection and then converted regression coefficients into an integer-based 
point-scoring system. Reviewed studies assigned positive and negative risk scores with calculated AUC 
to epidemiological, demographic, and clinical characteristics. Positive values indicated higher risk of 
Ebola virus infection and negative values indicated higher risk of another infection such as malaria or 
typhoid. 
Values assigned to the risk score varied by study; therefore, a meta-analysis of risk scores was not done, 
but instead evidence was systematically reviewed. For comparability, we reclassified the risk scores 
reported in the included studies into categories, from very low risk to very high risk (appendix p 7). 
STATA 15 was used for statistical analysis.  
PRISMA guidelines for Diagnostic Test Accuracy Studies (PRISMA-DTA) were followed (appendix 




Role of the funding source  
GC, KL, AS, and JG were employed by the funder, and participated in planning the study, carrying out 
the research, and writing the report. The funder of the study had no further role in study design, data 
collection, data analysis, data interpretation, or writing of the report. The corresponding author had full 
access to all the data in the study and had final responsibility for the decision to submit for publication. 
4.5.3 Results 
 
Of the 2493 studies initially screened using the article title, 143 were deemed to be potentially eligible 
on the basis of the abstract, and their full-text articles were assessed. Of these studies, 18 met the 
inclusion criteria, but three were excluded because data on sensitivity and specificity could not be 
extrapolated (appendix p 8). One was excluded because it is yet unpublished (FG). Of the 14 included 
studies, 11 were full manuscripts (5,6,22,24,25,27,29–33), one a letter (28), one an oral plenary abstract 
(26), and one a conference poster (23) (the author of this poster was also contacted and they provided 
an abstract with additional data [Kuehne A, Epicentre, Paris, France, personal communication]; table 
10). 13 studies were published between 2015 and 2019 and assessed Ebola virus disease in the west 
Africa outbreak (seven in Sierra Leone (5,6,25,26,30,32,33), four in Guinea (24,27,28,31), and two in 
Liberia (23,29)). The remaining article was published in May, 2010, assessing Marburg virus in 
Angola.(22). 
Overall, 12 021 people with suspected disease were included, of whom 4874 were confirmed as positive 
for Ebola virus infection. Study populations varied from 75 to about 2847 (table 10). All studies, apart 
from the national surveillance study, included patients who presented alive to health facilities for 
assessment. The national surveillance study included all cases (suspected, probable, and confirmed), 
including patients both alive and deceased, identified in both the community and health facilities. Eight 
studies’ data were from single Ebola treatment centres (23,27–33), with the remaining using a national 
surveillance list (24), three from Ebola holding units (5,25,26), and two from hospitals screening 
patients for Ebola virus disease while still functioning as general health facilities (6,22). All studies 
covered distinct patient groups from different periods and geographical areas, except for two studies 
from Guinea (24,27). Although these two studies covered overlapping patient groups, they reported on 
different clinical and epidemiological characteristics (WHO case definition performance vs symptom 
performance) (24,27). 
All selected manuscripts analysed all ages combined, except one author who assessed, in two different 
studies, the sensitivity and specificity of 2014 WHO Ebola case definitions and also developed a risk 
score specifically for the paediatric population (younger than 13 years) (25,26). 
Six studies explored the performance of a WHO case definition in non-paediatric populations 




disaggregated for analysis. The following results therefore apply to this combined group of suspected 
and probable cases. The pooled sensitivity was 81·5% (95% CI 74·1–87·2) and pooled specificity was 
35·7% (28·5–43·6; figure 8). One study assessed WHO 2014 case definitions for a paediatric population 
(younger than 13 years old); the sensitivity was 98·0% (95% CI 95·0–99·0) and specificity was 5·0% 
(3·0–7·0) (25). 
When WHO subdefinitions were assessed, history of contact and symptoms had high specificity 
compared with clinical symptoms alone, ranging from 62·3% (95% CI 49·8–73·5) to 94·4% (95% CI 
not provided in original paper; table 11). The highest sensitivity (100·0%) was documented for the 
WHO subdefinitions in which fever was not mandatory. Among studies using clinical symptoms and 
signs alone, the definition including three or more symptoms (intense fatigue, confusion, conjunctivitis, 
hiccups, diarrhoea, and vomiting) had the highest specificity (79·1% [95% CI not provided in original 
paper]). Unexplained death had high specificity (92·8% [95% CI not provided in original paper]) but the 
lowest sensitivity (14·2% [95% CI not provided in original paper]; table 11). 
For children, the highest specificity (97·0% [95% CI not provided in original paper]) was with a case 
definition of contact, fever, and conjunctivitis, or contact, fever, anorexia, and two of abdominal pain, 
diarrhoea, or male sex (older than 2 years; table 11) (26). 
Seven articles developed a risk score (22,23,25,29,31–33) and among those five (25,29,31–33) did an 
internal validation (using bootstrap or test and training methods) and one assessed a risk score according 
to outbreak prevalence in a paediatric population (25). An eighth study (28) externally validated the score 
developed by Oza and colleagues (33) without developing an alternative score. Of the 44 potential 
predictors of Ebola virus infection included across the seven studies that developed risk scores, 20 were 
found to be positive or negative predictors (figure 9). The score system ranged from very low to very high 
risk, with intermediate categories varying across studies (appendix p 7). 
One study created a malaria sensitive score aiming to discriminate between Ebola virus infection and 
malaria infection, which indicated a predictor power of 89·6% (95% CI 86–93) to discriminate Ebola 
virus positive versus negative, reaching a discrimination power of 98·5% (95% CI not provided in original 
paper) during the malaria season (32). The same study obtained similar results (AUC 76·8% [95% CI not 
provided in original paper] vs 75·0% [70·0–80·0]), when externally validating the scores developed by 
Levine and colleagues (29,32). 
The study validating Oza and colleagues’ algorithm found poorer performance in their cohort (AUC 58% 
[95% CI 56–61] vs 83·0% [79–86]) (28,33). 
The highest performing score was developed by Hartley and colleagues (32), a key difference being 
referral time (figure 9). For the adult population (six studies 22,23,29,31–33), a positive risk score for 




epidemiological link (eg, history of contact), diarrhoea, conjunctivitis, unexplained bleeding, difficulty 
swallowing (also called dysphagia; figure 9).  
Fever was assessed at different thresholds (>38·0°C or ≥38·5°C), and inclusion of fever in the final 
predictive score was only reported by two studies (31,32) (figure 9). Discordant values were assigned 
across studies (either positive or negative) for anorexia or loss of appetite, muscle pain (also called 
myalgia), and abdominal pain. 
For the paediatric population (one study 25), positive predictors were age (2 years or older), sex (male), 
epid-emiological link, diarrhoea, conjunctivitis, fever (>38·0°C), anorexia or loss of appetite, and 
abdominal pain. Negative predictors were difficulty swallowing, rash, headache, and difficulty breathing 
(also called dyspnoea; figure 9). The same study compared two different time periods over the Ebola virus 
disease 2014–16 outbreak in Sierra Leone (high prevalence in October, 2014 [77% of suspected cases 
testing positive], and low prevalence in March, 2015 [4% of suspect cases testing positive]): a low cutoff 
for the risk score (with high sensitivity) performed better at periods of high prevalence transmission, and 
a high cutoff with high specificity performed better during low prevalence (25). Similarly, the positive 
predictive value decreased from 93% to 31%, and the negative predictive value increased from 23% to 
90% when comparing high (early) to low (late) transmission periods in the Ebola virus disease outbreak 
in another study in Liberia in an all ages population (23).     
Eight studies measured sensitivity and specificity of individual symptoms at admission, assessing a total 
of 35 symptoms (5,22–24,27,29–31). The pooled sensitivity per symptom ranged from 79·0% (95% CI 
74·4–83·0) for intense fatigue (seven studies) to 1·0% (0·0–7·0) for pain behind the eyes (three studies). 
By contrast, the pooled specificity ranged from 98·0% (95% CI 91·0–100·0) for pain behind the eyes to 
32·3% (95% CI 25·8–39·4) for intense fatigue (appendix p 9). 
Haemorrhagic symptoms and signs were the most specific indicator of infection. Other symptoms and 
signs with high specificity included confusion, coma, hiccups, rash, and sore throat with specificity 
ranging from 92·0% (95% CI 91·0–94·0) for hiccups to 97·8% (95% CI 95·2–99·0) for rash (appendix p 
9). Performance of fever was assessed by seven studies, but each one used a different definition of fever 
(5,22,23,27,29–31). The optimal performance (definition that achieved best balance between maximising 
sensitivity vs maximising specificity) for fever was a threshold at ≥38·5°C (sensitivity 80·2% [95% CI 
69·2–88·2]; specificity 82·6% [71·2–90·3]; table 12).31 In the random- effects analysis, a threshold at 
greater than 38·0°C (three studies 22,27,29) gave a pooled sensitivity of 80·0% (95% CI 69·0–90·0) and 
specificity of 25·0% (17·0–33·0; table 12). 
Seven studies assessed sensitivity and specificity of an epidemiological link (5,22–24,29–31). Across 
these studies, the sensitivity of an epidemiological link ranged from 21·6% (95% 17·9–25·6) to 100·0% 
and specificity ranged from 29·0% (95% CI 19·0–41·3) to 86·0% (95% CI 74·0–94·0). The most sensitive 




The most specific definition was direct contact with an individual potentially infected with Marburg virus 
or his or her body fluids, or direct contact during funeral practices (22). 
4.5.4 Discussion 
 
Our results indicate that, for all ages combined, the WHO case definitions have a sensitivity of 81·5% 
and a specificity of 35·7%. The sensitivity is not high enough to achieve acceptable false negative rates, 
particularly in low-prevalence settings, the primary requirement for community-based screening. The 
low specificity results in high numbers of false positives and thus potentially unnecessary admissions 
to Ebola treatment centres, with associated risk of nosocomial transmission and costs of managing 
suspected cases (1). As a consequence, a large number of people who do not have Ebola virus disease 
will experience unnecessary invasive procedures, risk of being infected with Ebola virus, isolation from 
family, fear of being stigmatised, and delay to appropriate care, and community mistrust in response 
activities will increase. 
 
In our meta-analysis, fever had low specificity (25·0%), except for when defined as a threshold at 
38·5°C or more (82·6%), and the WHO case subdefinition had 100% sensitivity only when fever was 
not a mandatory criterion. In the risk score systematic review, the association of fever with Ebola virus 
infection was not consistent across studies, with only two studies including it in the final predictive 
score. Presence of fever is likely to be related to the stage of infection at admission, with previous 
studies reporting absence of fever in a large proportion of suspected cases at admission (34). This 
finding is consistent with a recent Ebola seminar reporting that fever was absent in at least 10% of the 
cases in the west Africa outbreak (35). 
 
Therefore, exclusion of fever from the case definition at the community level is likely to increase the 
sensitivity of the case definition. Intense fatigue was the most sensitive symptom (79·0%) that could be 
used at the community level to facilitate early referral of suspected cases and prevent community 
transmission. 
 
The meta-analysis did not identify any individual symptom or sign having an optimal trade-off between 
sensitivity and specificity. Conjunctivitis, unexplained bleeding, difficulty swallowing, and diarrhoea 
were individual symptoms and signs with the best discriminatory accuracy in the studies that explored 
risk score for the all-age population and with the exception of diarrhoea all had high specificity (>80%) 
in the studies that explored their performance. However, these symptoms and signs could also be a 
proxy for late-stage disease when the virus infects endothelial cells, compromising vascular integrity, 
with massive tissue injury resulting in disseminated intravascular coagulopathy with risk of thrombosis, 




signs could enable health practitioners to prioritise patients for admission to an Ebola treatment centre 
when resources are scarce but are less useful at the community level because they appear at a late stage 
of the disease when transmission risk is the highest. 
 
None of the studies assessed miscarriage, despite it being included in the December, 2014, WHO case 
definition (15). History of miscarriage and other associated pregnancy complications (eg, stillbirth) 
could help to identify cases that can be a major source of nosocomial transmission in general health 
facilities.(39). 
Although only one study focused on a paediatric population, this study used data from 11 Ebola holding 
units and included a large population of children (1006), providing useful guidance for this age group 
(26).  
 
The WHO paediatric definition had very high sensitivity (98·0%) but very poor specificity (5·0%). 
When the same authors assessed a WHO subdefinition (including contact, fever, and conjunctivitis, or 
contact, fever, anorexia, and two of abdominal pain, diarrhoea, or male sex [older than 2 years]), the 
sensitivity dropped markedly to 23·0% but the specificity improved to 97·0%. The optimal fever 
temperature cutoff for the paediatric population was not explored. However, in another study of a 
paediatric population of patients with confirmed Ebola virus disease admitted to one Ebola treatment 
centre in Sierra Leone, 25% of children aged 5 years and younger were afebrile (40). This difference 
might be due to several factors: how fever was assessed (either reported in their history or measured at 
admission), age groups included (younger than 13 years vs younger than 5 years), period of data 
collection (August–March, 2015, vs June–Dec, 2014) when seasonality of other febrile illnesses could 
have influenced fever prevalence, background Ebola virus transmission rates, and viraemia at admission 
and time since onset of symptoms. 
 
The paediatric analysis did not explore sensitivity and specificity of individual symptoms and signs at 
admission for children. Alongside the fact that they might have different clinical presentations 
compared with adults, children are more likely to experience adverse outcomes from Ebola virus disease 
and are less able to report symptoms and history of contact. 
 
Similarly, pregnant women with non-Ebola virus disease-related  complications usually present with 
symptoms (such as bleeding and abdominal pain) that mimic Ebola virus infection (39). As suggested 
elsewhere, the paediatric and pregnant women populations might require adaptation of case definitions 
that take into account their specific characteristics. (41–43). None of the selected manuscripts explored 
the performance of WHO Ebola case definitions among pregnant women. Therefore, further evidence 
specifically applicable to children and pregnant women is required to develop appropriate tools for 




Reported history of contact was a strong predictor for paediatric and adult populations, often performing 
better than many of the clinical symptoms included in accepted case definitions, as also reported by 
other studies (44). However, it is likely that this is an underestimate of the potential performance of 
actual contact history in screening for Ebola virus disease. 
Levels of disclosure of self-reported clinical information and contact history depend on community 
engagement with intervention strategies, including trust in the health-care provider. Therefore, to 
improve WHO case definition performance, effective and trusted collaboration with communities is 
essential to ensure reliable understanding and reporting of such crucial epidemiological information. 
Equally, it is the responsibility of response agencies to understand the underlying pattern of Ebola virus 
transmission, local traditions, coping mechanisms, and family dynamics in order to identify people at 
risk of infection. Genetic sequencing has also been put forward as a tool for identifying chains of 
transmission when contact history is unknown(45).  
 
One of the limitations in interpreting the results of this meta-analysis is that all the evidence reviewed, 
apart from the national surveillance study, came from patients triaged at health facilities or Ebola 
isolation centres. Thus, this meta-analysis might represent only cases with severe symptoms, limiting 
generalisability to the performance of these screening criteria at the community level and in early stages 
of disease. Second, there was significant heterogeneity between selected studies, and considerable 
variation in the quality of data on clinical symptoms and recollection of patients’ history, with different 
variables and thresholds used in each study, and limited data on co-infection. For example, fever is a 
key symptom in the WHO case definitions, but different temperatures were used to define fever, which 
could explain the between-study heterogeneity. Inconsistency on thresholds for fever and the decision 
to include fever or not have been reported in the Democratic Republic of the Congo and in four 
neighbouring countries (9). 
 
For the two studies with overlapping patient populations, performance of WHO case definitions was 
assessed only using national surveillance data, with Ebola treatment centre data for these patients being 
assessed for only individual symptoms or WHO subdefinitions. These two studies were therefore not 
included together in pooled estimations, so the cohort overlap would not have affected results. 
Individual studies mentioned small sample size and poor quality of data as part of their limitations. 
A range of contextual factors related to study setting will affect the performance of Ebola virus disease 
case definitions, including seasonally occurring diseases such as malaria and Lassa fever, which have a 
similar clinical presentation to Ebola virus disease. Such factors will affect the generalisability of our 
findings to other settings. In addition, only two of the recommended risk scores were externally 
validated (28,32), limiting the generalisability of those scores because performance appears to vary 





Finally, there is potential for publication language bias because we considered only studies in English. 
However, for Guinea, a French-speaking country, we included data from national surveillance and two 
major Ebola treatment centres; therefore, we consider that bias due to language restrictions was 
minimised in our results. We included peer-reviewed abstract and poster data to capture data on 
paediatric populations and additional evidence for all age cohorts, and we sought unpublished evidence 
from French- speaking countries. 
This systematic review is relevant to inform public health practitioners in the current Ebola virus disease 
outbreak in the Democratic Republic of the Congo, in which only 8% of suspected cases isolated are 
confirmed, possibly because of inconsistent use of WHO case definition at community and health 
facility levels (46). 
 
In conclusion, this first systematic review and meta-analysis of the strengths and limitations of the WHO 
Ebola virus disease case definitions highlights the need for further studies to assess consistent thresholds 
for fever, to explore viraemia and symptoms and signs at admission, and to externally validate risk 
scores for Ebola virus infection. The sensitivity and specificity of WHO Ebola case definitions could 
be improved by excluding fever and instead including both intense fatigue and history of contact. 
However, reliable disclosure of reported symptoms and history of contact requires effective 
collaboration with, and the trust of, affected communities. To achieve this trust and collaboration, 
responding organisations must recognise the paramount role of communities in controlling transmission 
and ending outbreaks. We also identified important gaps related to the paediatric and pregnant 
population, which must be addressed through future research. 
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4.5.5 Research in context 
 
Evidence before this study 
There have been long-standing concerns about the poor performance of WHO case definitions for Ebola 
virus disease, including their inability to distinguish Ebola virus infection from common tropical 
diseases. We did a systematic search of the scientific literature using PubMed, Scopus, Embase, and 
Web of Science, without regional restrictions, for research articles published in English between June 
13, 1978, and Jan 14, 2020. We used the search terms “Ebola”, “EVD infection”, “case definition”, 
“admission symptoms”, “sensitivity”, “specificity”, “likelihood”, “score”, “classification”, “validity” 
and “performance”. We also contacted relevant experts. We found that different organisations have 
attempted to assess the performance of WHO Ebola case definitions and developed alternative 
definitions and risk scores. However, there has been no systematic and rigorous evaluation of those 
studies. Such an evaluation is needed to guide communities and public health practitioners to improve 
the effectiveness and efficiency of identification and management of suspected cases during an Ebola 
virus disease outbreak. 
Added value of this study 
To our knowledge, this study is the first systematic review and meta-analysis that assesses the 
performance of the WHO Ebola virus disease case definitions, and other clinical and epidemiological 
characteristics such as symptoms and signs at admission and contact history, against the reference 
standard (laboratory confirmation of Ebola virus infection). Our analysis provides the most 
comprehensive evidence on the limitations of WHO case definitions and its constituent symptoms and 
signs, and predictive risk scores. We show that the WHO case definitions perform sub optimally to 
identify cases at both the community level and during triage at general and specialist health facilities. 
The performance of fever as a symptom varied depending on the cut off used to define fever. The most 
sensitive symptom was intense fatigue. History of contact was a key predictor for the WHO case 
definitions and for risk scores. This study identifies important gaps related to the paediatric and pregnant 
population and highlights the need to use consistent thresholds (e.g., for fever) to explore viraemia and 
symptoms at admission, and to externally validate risk scores for Ebola virus infection. 
Implications of all the available evidence 
Inclusion of intense fatigue as a key symptom could improve the sensitivity, the primary requirement 
for community-based screening, of WHO and alternative case definitions. Inclusion of contact history 
will improve specificity, resulting in a lower number of false positives and thus a lower number of 
unnecessary admissions to Ebola health facilities. These improvements will contribute to reduced 






Figure 7. WHO Ebola virus disease case definitions for all ages and the paediatric population 
 
 
WHO case definitions (August, 
2014) all ages12 
WHO case definition (December, 
2014) all ages in Sierra Leone15 
Late 2014 WHO case 
definition for paediat-
ric population in Si-
erra Leone15 
Suspected Any person, alive or dead, suffering 
or having suffered from sudden onset 
of high fever and having had contact: 
• a suspect, probable, or confirmed 
Ebola virus disease case 
• with a dead or sick animal (for Ebola) 
• a mine (for Marburg);  
OR 
any person with sudden onset of high 




• anorexia or loss of appetite 
• aching muscles or joints 
• stomach pain 
• difficulty swallowing 
• vomiting 
• difficulty breathing 
• diarrhoea 
• hiccups;  
OR 
any person with inexpli-
cable bleeding;  
OR 
any sudden, inexplicable death 
Any person having had contact with a clini-
cal case and presenting with acute fever 
(>38°C); 
OR 
having had contact with a clinical case 
(suspected, probable, or confirmed) and pre-
senting with three or more of the symptoms 
below; 
OR 
presenting with acute fever and presenting 
with three or more of the symptoms below: 
• headache 
• nausea or vomiting 
• loss of appetite 
• diarrhoea 
• intense fatigue 
• abdominal pain 
• generalised or articular pain 
• difficulty in swallowing 
• difficulty in breathing 
• hiccups 
• miscarriage;  
OR 
any person with unexplained bleeding or 
miscarriage; 
OR 
any unexplained death 
Any child with fe-
ver and either one 
symptom (in chil-
dren younger than 
5 years), two 
symptoms (in chil-
dren aged 5–12 
years), or more 
than three symp-
toms (in children 
older than 12 
years); for children 
younger than 1 
years old, maternal 
history is very im-
portant 
Confirmed Any suspected or probable cases with 
a positive laboratory result; laboratory-
confirmed cases must test positive for 
the virus antigen, either by detection of 
virus RNA by 
RT-PCR, or by detection of IgM anti-
bodies directed against  Marburg or 
Ebola 
Any person with a positive PCR test for 
Ebola or Marburg virus 
Any person with a posi-
tive PCR test for Ebola 
or Marburg virus 
Probable Any suspected case evaluated 
by a clinician;  
OR 
any deceased suspected case (where it 
has not been possible to collect speci-
mens for laboratory confirmation) 
having an epidemiological link with a 
confirmed case 
A suspect case that is known to have had 
contact with a known case (suspected, 
probable, or confirmed); 
OR 
any person who is, on clinical or epidemi-
ological grounds, very likely to have Ebola 
or Marburg 










 Table 10. Overview of articles included in the systematic review and meta-analysis  
  Country Virus Period of Design Objective Outcomes Setting of Age of Patients positive Method (reference Limitations  
   data    data collection study for Ebola virus/ standard) and   
   collection     population total patients timing of Ebola   
          virus confirmatory   
          testing   
Roddy et al Angola Marburg March–July, Observational Evaluate the diagnostic Sensitivity and Screening at All ages 41/102 Quantitative PCR Small sample; only saw pa-
tients 
 
(2010)22   2005 retrospective validity of individual pa-
tient 
specificity of WHO one hospital   on admission at admission; data only cap-
tured 
 
    study of data clinical and epidemiologi-
cal 
case definition,     Marburg haemorrhagic fever;  
    at admission characteristics and WHO case     hospital-based data collec-
tion; 
 
     WHO-recommended case subdefinitions,     detailed data not available for 
all 
 
     definitions for Marburg symptoms at     Marburg haemorrhagic fever  
     haemorrhagic fever, and admission, and     cases; only presenting symp-
toms 
 
     develop a data-derived epidemiological     were recorded; highlights the  
     diagnostic algorithm for link; and risk score     necessity of collecting high-  
     Marburg haemorrhagic 
fever      
quality clinical and  
     that improves the      epidemiological data during  
     WHO-recommended      outbreaks; over-representation 
of 
 
     definitions      individuals with more serious  
           symptoms that required hos-
pital 
 
           admission; no reported vali-
dation 
 
           (external or internal)  
Kuehne Liberia Ebola August, Observational Study the discriminative Sensitivity and One Ebola All ages 1235/1832 Quantitative PCR Reporting bias; poor data qual-
ity; 
 
et al   2014– retrospective accuracy (sensitivity, specificity of WHO treatment   on admission conference poster and abstract  
(2015)23   March, 2015 study of data attributable frequency, case subdefinitions, centre    data (Kuehne A, Epicentre, 
Paris, 
 
    at admission diagnostic test odds ratio, symptoms at     France, personal communica-
tion); 
 
    and clinical area under the receiver admission, and     no reported validation (exter-
nal or 
 
    results operating characteristic epidemiological     internal)  
     curve) of clinical signs, link; and risk score       
     contact history, and        
     combinations thereof        
Levine et al Liberia Ebola September, Observational Develop a clinical prediction Sensitivity and One Ebola All ages 160/382 Quantitative PCR Data collected only at admis-
sion, 
 
(2015)29   2014– retrospective model that can help to guide specificity of WHO treatment   on admission different stages of disease  
   January, study of data care for patients with case definition, centre    process; data might not be  




     provide specific parameters admission, and     with Ebola virus disease; 
poor 
 
     for isolation and admission 
to 
epidemiological     data quality; small sample;  
     treatment centres, and link; and risk score     patients pre-screened by 
Ebola 
 
     maximise resource use      treatment units (ambulance  
           travel); only assessed  
           14 variables; no reported  
           external validation, only in-
ternal 
 
          
 
 validation  
 Country Virus Period of data col-
lection  
Design Objective Outcomes Setting of data 
collection  






standard) and timing 
of Ebola virus con-
firmatory testing  
Limitations  
Lado et al Sierra Ebola May, 2014– Observational Identify clinical characteris-
tics 
Sensitivity and One Ebola All ages 464/724 Quantitative PCR Small sample; poor accuracy 
on 
 
(2015)5 Leone  December, retrospective that were predictive of Ebola   specificity of WHO holding unit   on admission reporting of symptoms and  
   2014 study of data virus disease diagnosis and case definition,     history; no access to patients 
who 
 
    at admission assess the accuracy of WHO case     chose not to present to hospital 
or 
 
     suspected Ebola virus disease subdefinition,     did not have access; no re-
ported 
 
     case definitions symptoms at     validation (external or inter-
nal) 
 
      admission, and       
      epidemiological link       
 Arranz et al (2016)30 Sierra Leone Ebola December, 2014– 
March, 2015 
Observational retrospec-
tive study of data at ad-
mission 
Compare the clinical charac-
teristics of  confirmed cases 
(patients with Ebola virus 
disease) and non-confirmed 
cases (patients without 
Ebola virus disease), assess 
the diagnostic validity of in-
itial symptoms used in 
WHO case definition to di-
agnose Ebola virus disease 
in a low-incidence situation 
Sensitivity and specificity of 
WHO case definition, WHO 
case subdefinition, symptoms 




 All ages 31/75 Quantitative PCR on 
admission 
Only data at admission; 
poor data quality; retrospec-
tive design; small sample; 
no reported validation (ex-
ternal or internal) 
 
 Loubet et al (2016)31 Guinea  Ebola  December, 2014– 
February, 2015 
Observational retro-




ical variables associated 
with Ebola virus disease di-
agnosis and to create, based 
on these variables, a predic-
tive score for identification 
of confirmed Ebola virus 
disease 
Sensitivity and specificity of 
WHO case definition, WHO 
case subdefinition, symp-
toms at admission, and epi-




All ages 76/145 Quantitative PCR on 
admission 
Data collected only at ad-
mission; poor data quality; 
retrospective design; pa-
tients included might have 
been reluctant to come to 
the Ebola treatment centre, 
and thus were more likely to 
present severe clinical 
presentation with late symp-
toms; temperature taking 
might be affected by several 
factors; small sample size; 
anorexia and temperature 





were associated with an in-
creased likelihood of Ebola 
virus disease) are not easy to 
measure and interpret; no 
reported external validation, 
only internal validation 
  Country Virus Period of data col-
lection  
Design Objective Outcomes Setting of data 
collection  






standard) and timing 
of Ebola virus con-
firmatory testing  
Limitations  
 Hartley et al (2017)32 Sierra  
Leone 
Ebola  December, 2014– 
November, 2015 
Observational retro-
spective study of data at 
admission 
Construct an easy-to-use 
and highly accurate triage 
scoring system that discrim-
inates Ebola virus infection 
risk in a malaria-sensitive 
manner and improve the 
predictive accuracy for 
Ebola virus disease and ma-
laria 
 Risk score            One Ebola virus 
treatment centre 
All ages 158/566  Quantitative PCR on 
admission; rapid di-
agnostic malaria test 
(histidine-rich pro-
tein-II antigen rapid 
diagnostic kits were 
used) 
Only the most prevalent 
symptoms at admission 
were included in the 
score; poor data quality; 
did not fully cover all the 
malaria season because 
the Ebola treatment centre 
was opened from Decem-
ber to June; recall bias 
 




Ebola  August, 2014– 
March, 2015  
Observational retro-
spective study of data at 
admission 
Refine the case definition 
and describe outcomes of 
admitted children  
Sensitivity and specificity of 
WHO case 
 subdefinitions 
11 Ebola holding 
units 
Paediatric popula-
tion (younger than 
13 years) 
309/1006 Quantitative PCR on 
admission 
Only included children 
younger than 13 years; 
oral plenary abstract; no 
reported external valida-
tion, only internal valida-
tion 
 
 Ingelbeen et al 
(2017)27 
Guinea Ebola  March, 2014– Sep-
tember, 2015 
Observational retro-
spective study of data at 
admission 
Describe the burden of non- 
cases in relation to the 
phase of the outbreak; deter-
mine the duration of their 
stay at the Ebola treatment 
centre and (potential) subse-
quent nosocomial infec-
tions; compare characteris-
tics, outcome, and risk fac-
tors for death in confirmed 
cases and non-cases to im-
prove the selection, diagno-
sis, and care of people with 
suspected Ebola virus dis-
ease 
Sensitivity and specificity of 
WHO case subdefinitions 
and symptoms on admission 
One Ebola treat-
ment centre 




Sunnyvale, CA USA) 
on admission 
The Ebola treatment cen-
tre for part of the outbreak 
was located within one 
hospital but then moved to 
another area in July; could 
not assess possible drivers 
for the large proportion of 
non- cases; no reported 
validation (internal or ex-
ternal) 
 
 Oza et al (2017)33 Sierra  
Leone 
Ebola November, 2014– 
March, 2015 
Observational retro-
spective study of data at 
admission 
Develop two Ebola risk 
scores to supplement the 
broad WHO case definition 
by further separating triaged 
patients based on their like-
lihood of being positive for 
Ebola virus  
Risk score  One Ebola treat-
ment centre 
All ages 252/424 Quantitative PCR on 
admission; biochem-
istry laboratory tests 
with the Piccolo 
Xpress (Abaxis, Un-
ion City, CA, USA) 
and i-STAT (Abbott 
Point of Care, Prince-
ton, NJ, USA) device 
Only one treatment centre; 
investigated 14 commonly 
recorded symptoms; small 
amount and poor quality 
of patient data; excluded 
exposure as a potential 
predictor because of large 
amount of missing data or 
poor data quality; patients 
might not be representa-
tive of the overall popula-
tion of suspect Ebola 
cases; no reported external 






  Country Virus Period of data col-
lection  
Design Objective Outcomes Setting of data 
collection  






standard) and timing 
of Ebola virus con-
firmatory testing  
Limitations  
 Hsu et al (2018)24 Guinea Ebola March– October, 
2014 
Observational retro-
spective study of sur-
veillance data 
Assess the diagnostic per-
formance of the WHO sus-
pected case definition by us-
ing epidemiological surveil-
lance and diagnostic test 
Sensitivity and specificity of 
WHO case definition, WHO 
case subdefinition, symp-
toms at admission, and epi-
demiological link 
National surveil-
lance line list 
All ages 1304/2847 Quantitative PCR (on 
admission and for de-
ceased patients at the 
community level) 
Unknown how representative 
the database was for all pa-
tients with Ebola virus dis-
ease; only 1412 patients had 
complete data to assess and 
analyse the WHO case defi-
nition; possible overestima-
tion of performance of WHO 
definition because only com-
mon symptoms were rec-
orded in the early stage of 
the outbreak; poor data qual-
ity; no reported validation 
(internal or external) 
 




Ebola August, 2014– 
March, 2015 
Observational retro-
spective study of data at 
admission 
Develop a predictive score 
that could be used to tailor 
the paediatric case defini-
tion for suspected Ebola vi-
rus disease according to the 
clinical and epidemiological 
setting 
Sensitivity and specificity of 
WHO case definition and 
risk score 
11 Ebola holding 
units 
Paediatric popula-
tion (younger than 
13 years) 
309/1006 Quantitative PCR on 
admission 
Only included children 
younger than 13 years; 
poor data quality; no data 
on the true Ebola status of 
people who did not meet 
the WHO case definition 
and were not admitted; no 
reported validation, only 
internal validation 
 
 Ingelbeen et al 
(2018)28 
Guinea Ebola March, 2014– Sep-
tember, 2015 
Observational retro-
spective study of data at 
admission 
Validate risk  
score by Oza and col-
leagues13 
Risk score One Ebola treat-
ment centre 
All ages 805/2311 Quantitative PCR on 
admission; Xpert 
Ebola Assay (Ce-
pheid GeneXpert) on 
admission 
Did not propose another 
algorithm; letter; no re-
ported external validation, 
only internal validation 
 




Ebola September, 2014– 
November, 2015 
Observational retro-
spective study of data at 
admission 
Evaluate the pre-existing 
health-care infrastructure 
during the Ebola virus dis-
ease outbreak, and assess 
the provided health care and 
safeguard functionality of a 
health-care system for all 
patients not suspected to 
have or diagnosed with 
Ebola virus disease 
Sensitivity and specificity of 
WHO case subdefinitions 
Screening at one 
hospital 
All ages 22/1556 Quantitative PCR on 
admission 
Scant description of data; 
poor data quality; no re-
ported validation (external 
or internal) 
 





Figure 8. HSROC summary of sensitivity and specificity 










Table 11. Sensitivity and specificity of WHO Ebola virus disease subdefinitions against reference standard of 
laboratory-confirmed Ebola virus infection, in decreasing order of sensitivity 
   
                                          WHO subdefinition                       Sensitivity (95% CI)      Specificity (95% CI) 
 
Positive predictive   
value (95% CI) 
Negative predictive 
value (95% CI) 
Huizenga et al (2019)6 WHO definition, with the difference 
that fever with sudden onset is not a 
mandatory criterion 
100·0% 42·5%* 2·4%* 100·0% 
Fitzgerald et al (2017)26 Contact alone, fever (in children 
older than 2 years) OR fever and 
conjunctivitis (in children younger 
than 2 years) 
94·0%* 35·0%* Not provided Not provided 
Roddy et al (2010)22 Epidemiological link or a combina-
tion of myalgia or arthralgia and any 
haemorrhage 
79·0% (64·0–91·0) 73·0% (60·0–84·0) Not provided Not provided 
Loubet et al (2016)31 WHO subdefinition 2 (temperature 
≥37·5°C plus risk factor†) 
75·0% (63·5–83·9) 62·3% (49·8–73·5) Not provided Not provided 
Roddy et al (2010)22 WHO case definition (clinical criteria 
only‡) 
73·0% (57·0–86·0) 43·0% (30·0–56·0) Not provided Not provided 
Roddy et al (2010)22 Fever plus three or more symptoms§ 68·0% (52·0–82·0) 46·0% (33·0–59·0) Not provided Not provided 
Loubet et al (2016)31 Temperature ≥38·5°C plus risk 
factor† 
68·4% (56·6–78·3) 82·6% (71·2–90·3) Not provided Not provided 
Arranz et al (2016)30 Contact and three symptoms§ 67·7% (51·3–84·2) 81·8% (70·4–93·2) 72·4% (56·1–88·7) 78·3% (66·3–90·2) 
Loubet et al (2016)31 WHO subdefinition 3 (temperature 
≥37·5°C plus clinical symptoms§) 
67·1% (55·2–77·2) 76·8% (64·8–85·8) Not provided Not provided 
Loubet et al (2016)31 WHO subdefinition 1 (risk factor plus 
clinical symptoms§) 
63·2% (51·3–73·7) 66·7% (54·2–77·3) Not provided Not provided 
Lado et al (2015)5 Three or more major symptomsfj 57·8% (52·1–61·4) 70·8% (64·7–76·4) 77·9% (73·1–82·3) 47·5% (42·3–52·7) 
Arranz et al (2016)30 Fever and three symptoms§ 58·1% (40·7–75·4) 50·0% (35·2–64·8) 45·0% (29·6–60·4) 62·9% (46·8–78·9) 
Hsu et al (2018)24 Clinical criteria§   57·2%* 62·0%* 66·4%* 52·5%* 
Ingelbeen et al (2017)27 WHO case definition (clinical criteria 
only||) 
 56·9%* 46·4%* 36·3%* 66·8%* 
Roddy et al (2010)22 Epidemiological link and two 
or  more general symptoms§ 
54·0% (37·0–70·0) 91·0% (80·0–97·0) Not provided Not provided 
Roddy et al (2010)22 Epidemiological link and three or 
more general symptoms§ 
54·0% (37·0–70·0) 93·0% (83·0–98·0) Not provided Not provided 
Arranz et al (2016)30 Contact plus fever 48·4% (30·8–66·0) 77·3% (64·9–89·7) 60·0% (40·8–79·2) 68·0% (55·1–80·9) 
Roddy et al (2010)22 Fever plus haemorrhage 44·0% (28·0–60·0) 72·0% (59·0–83·0) Not provided Not provided 
Ingelbeen et al (2017)27 Three major signs** 27·7%* 79·1%* 41·5%* 67·2%* 
Fitzgerald et al (2017)26 Contact, fever, and conjunctivitis OR 
contact, fever, anorexia, and two of 
abdominal pain, diarrhoea, or male 
sex (older than 2 years) 
23·0%* 97·0%* Not provided Not provided 
Kuehne et al (2015)23 History of contact, gastrointestinal 
symptoms†† and illness duration of 
>3 days 
20·0%* 94·4%* Not provided Not provided 
Hsu et al (2018)24 Unexplained death 14·2%* 92·8%* 72·0%* 45·2%* 
*95% CI not provided in the original paper. †For example, being a health worker, have attended a funeral, and having contact with a relative suspect of having Ebola virus.	
‡Fever plus three other symptoms or fever and haemorrhage. §Symptoms or criteria not specifed in original paper. fjThree or more symptoms among the following: intense 
fatigue, confusion, conjunctivitis, hiccups, diarrhoea, or vomiting. ||Acute fever and presenting three or more of the following: headache, anorexia or lack of appetite, lethargy, 
muscle or joint pain, breathing difficulties, vomiting, diarrhoea, stomach ache, difficulty swallowing, and hiccups; or any person with unexplained bleeding.	


















































































































































































































Hartley et al 
(2017)32 89% (86–93) 
NA NA 6 3 Y NA NA NA NA NA 3 4 1 2 Y NA 






NA NA NA NA NA NA NA NA 2 2 Y Y 1 NA 
Loubet et al 
(2016)31 82% (77–87) 
NA NA 1 NA NA NA NA NA NA NA NA Y NA Y NA 3 
Fitzgerald et al (2018; 
paediatric population)25 
80%‡ NA NA 2 NA Y NA NA 1 2 Y 1 2 1 Y Y NA 
Levine et al 
(2015)29 75% (70–80) 
76%‡ NA 2 NA NA NA NA NA NA NA 1·5 NA Y Y Y NA 
Kuehne et al 
(2015)23 
53–59‡ NA NA + NA NA + + NA NA NA NA NA NA NA NA NA 
Roddy et al 
(2010)22 
‡ NA NA + NA NA NA NA NA NA NA Y Y Y + Y NA 
 

















































































































































































































































Hartley et al 






Y Y Y –1 –1 Y Y NA NA NA NA NA NA NA NA NA NA NA NA Y NA NA NA NA NA NA NA 
Loubet et al 
(2016)31 
Y 2 Y Y Y NA Y Y Y NA Y Y Y NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
Fitzgerald et al 
(2018; paediatric 
population)25 
Y 1 Y –1 1 –2 –1 –1 Y Y Y NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
Levine et al 
(2015)29 
Y 1 1 1 –1 NA Y Y Y Y NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 






NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
Roddy et al 
(2010)22 + Y + Y Y NA Y Y Y Y NA NA NA NA NA NA NA NA NA NA NA NA NA Y Y Y Y Y Y Y 
 
Predictive scores (numeric or + symbol) are shown in shaded cells (blue indicates positive scores and light pink indicates negative scores). Y indicates that the characteristic was assessed, but not used. AUC=area under the receiver operating characteristic curve. NA=not 
assessed. ORL=otorhinolaryngology. *Diarrhoea, vomiting, or anorexia or loss of appetite. †95% CI is taken from Ingelbeen et al (2018)28 because, although Oza and colleages do not report 95% CIs in their manuscript, Ingelbeen and colleagues have externally 




Table 12. Sensitivity and specificity of fever, epidemiological link, or contact history, ordered by optimal 
performance 
 
                                        Variable                                                                                                            Sensitivity (95% CI)   Specificity (95% CI) 
 
 Fever cutoff     
 Loubet et al (2016)31 ≥38·5°C 80·2% (69·2–88·2) 82·6% (71·2–90·3)  
 Loubet et al (2016)31 ≥38·0°C 88·2% (78·2–94·1) 72·5% (60·2–82·2)  
 Loubet et al (2016)31 ≥37·5°C 93·4% (84·7–97·5) 50·7% (38·5–62·9)  
 Kuehne et al (2015)23 History of fever 85·3%* 26·4%*  
 Lado et al (2015)5 ≥37·5°C or referred 85·9% (82·4–89·0) 16·4% (12·0–21·6)  
 Arranz et al (2016)30 ≥38·0°C or referred 61·3% (44·1–78·4) 29·5% (16·1–43·0)  
 Roddy et al (2010)22 >38·0°C 85·0% (71·0–94·0) 20·0% (11·0–32·0)  
 Levine et al (2015)29 >38·0°C 85·0% (79·0–91·0) 21·0% (16·0–27·0)  
 Ingelbeen et al (2017)27 >38·0°C 71·5%* 30·5%*  
 Pooled analysis† >38·0°C 80·0% (69·0–90·0) 25·0% (17·0–33·0)  
 Epidemiological link     
 Hsu et al (2018)24 Contact with infected persons or body fluid, handling of bushmeat, attending the 
funeral of a patient with Ebola virus disease 
74·7%* 67·1%*  
 Roddy et al (2010)22 Epidemiological link‡ 67·0% (50·0–81·0) 86·0% (74·0–94·0)  
 Arranz et al (2016)30 History of contact with a person with confirmed Ebola virus disease 100·0% 59·0% (43·5–74·4)  
 Levine et al (2015)29 Sick contact§ 65·0% (58·0–73·0) 61·0% (54·0–67·0)  
 Loubet et al (2016)31 Health worker or having had contact with a person with suspected Ebola virus dis-
ease or having attended funerals 
81·5% (44·0–60·7) 29·0% (19·0–41·3)  
 Kuehne et al (2015)23 Contact to case 47·3%* 71·2%*  
 Lado et al (2015)5 Travel to an Ebola virus disease hotspot area, health-care work, funeral 
attendance, or contact with an ill family member or friendfj 
21·6% (17·9–25·6) 84·6% (79·6–88·8)  
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Chapter 5: (Research paper 3) Methodological issues of retrospective surveys for 
measuring mortality of highly clustered diseases: case study of the 2014-16 Ebola 
outbreak in Bo District, Sierra Leone. 
5.1 Preamble  
	
In this chapter I present the analysis of two retrospective mortality surveys implemented to 
estimate mortality (due to EVD and non-EVD) and morbidity in areas where, due to the EVD 
outbreak, MSF suspended critical health interventions. The studies were carried out in rural 
and urban areas of Bo District, Sierra Leone during the 2014-2016 EVD outbreak. 
The studies offered empirical estimates mortality rates and design effects. Study findings 
prompted reflection on the utility of using of retrospective mortality studies for highly-
clustered diseases such as EVD. The manuscript of these studies is ready to be submitted 
5.2 Cover sheet 
 















5.3 Summary  
Background  
Cluster surveys are an accepted method for estimating mortality in humanitarian settings, but are subject 
potential limitations for highly-clustered outcomes such as Ebola Virus Disease (EVD). We used data 
from population-based surveys conducted during the 2014-2016 EVD outbreak in Sierra Leone to: i) 
estimate empirical mortality rates, ii) provide the first reported design effects (DEFF) for EVD and non-
EVD mortality; iii) discuss the methodological limitations and operational utility of mortality estimated 
from cluster-sampled studies when DEFF is high.   
Methods 
We designed two population-based surveys conducted at the end of the EVD outbreak in Bo District, 
Sierra Leone, in urban and rural areas. In each area, 35 clusters of 14 households where selected with 
probability proportional to population size. We collected information on morbidity, mortality and 
changes in household composition during the recall period (May 2014 to April 2015). Rates were 
calculated for all-cause, all-age, under-5 and EVD-specific mortality. Crude and adjusted mortality rates 
were estimated using Poisson regression, accounting for the survey sample weights and the clustered 
design. 
Results  
The surveys were conducted in 70 clusters (total 980 households; 6,522 individuals). In total, 64 deaths 
were reported, of which 20 were attributed to EVD. The crude and EVD-specific mortality rates were 
0.35/10,000 person-days (95%CI:0.23–0.52) and 0.12/10,000 person-days (95%CI:0.05–0.32), 
respectively. EVD deaths were reported in 15 households in 9 clusters, and non-EVD deaths were 
reported in 40 households in 31 clusters. Empirical DEFF for EVD mortality were higher than for non-
EVD mortality (5.53 vs 1.53).  
Conclusion 
There was a high degree of clustering in these community-based surveys of EVD. This can contribute 
to imprecise mortality estimates with large confidence intervals, which have limited utility when 
assessing the impact of disease. Alternative design options would improve the utility of future surveys, 
and the empirical DEFF estimates we provide can inform more robust study designs in future 
retrospective surveys of highly clustered diseases such as EVD. 
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5.4 Manuscript  
5.4.1 Background 
 
In humanitarian contexts, surveillance is the accepted “gold standard” to measure public health 
outcomes and to estimate the impact of a crisis (including mortality) (1). During the 2014-2016 Ebola 
Virus Diseases (EVD) outbreak in Sierra Leone, vital statistics and surveillance systems were weak (2), 
necessitating reliance on estimates of the direct and indirect impact of the outbreak based on 
mathematical modelling and retrospective analysis of burial and health facility data (3-6).   
Population-based cluster surveys can supplement surveillance data to estimate the severity of a crisis 
for advocacy or operational purposes (e.g. to prioritise areas for intervention) (7, 8). A previous study 
have explored the validity of cluster surveys versus systematic sampling methods for measuring crude 
mortality, reporting that both designs yielded similar estimations (9). Key methodological limitations 
of cluster surveys in humanitarian contexts include failure to calculate the optimal sample size, to 
sample proportionate to population size (PPS), to weight the sample during analysis, or to consider the 
design effect when calculating precision.(10) Recognised limitations of this methodology to measure 
clustered disease include the decreased precision due to high intra-cluster homogeneity, and therefore 
the recommendation to publish empirical estimates of design effects (DEFFs) to inform future studies 
(11).  
This paper assesses the utility, strengths and limitations of clustered surveys for highly-clustered data, 
using data from two cluster surveys carried out in rural and urban areas of Bo District, Sierra Leone 
during the 2014-2016 EVD outbreak. The aims of the surveys were to estimate mortality (due to EVD 
and non-EVD) and morbidity in areas where, due to the EVD outbreak, Médecins Sans Frontières 
(MSF) suspended critical health interventions and refocussed on EVD care.  
We carried out the surveys in full acknowledgement that EVD case distribution was clustered and that 
surveys estimates might be affected by that; thus, at design and implementation stages we attempt to 
mitigate for highly-cluster distribution.  
The aims of this manuscript are to: i) report estimate crude and adjusted EVD mortality rates , ii) provide 




discuss the methodological limitations and the operational utility of estimated mortality rates from 
cluster-sampled studies  when DEFF is high. 
5.4.2 Methods 
 
Study setting, design and population  
In September 2014, to reduce EVD mortality and transmission in the area MSF opened a 100-bed Ebola 
Management Center (EMC) in Bo township. Along with activities in the EMC, MSF conducted EVD 
outreach activities in Bo district, focusing on social mobilization, support of survivors, case finding, 
and case investigation efforts conducted in collaboration with the District Ebola Response Committee 
(DERC). 
Prior to the EVD outbreak, MSF was running a 200-bed secondary level referral hospital in Bo town. 
The hospital was considered a lifeline for children and pregnant women coming from Bo and other 
districts; providing more than 8,000 paediatric and 2,500 emergency obstetrical and gynaecological 
admissions per year. However, in October 2014, MSF was forced to suspend health services due to 
increasing risk of EVD nosocomial transmission and concerns about staff safety (12).  
The closure of the hospital was perceived to have contributed to an increase in mortality in the area. 
Thus, in the absence of strong routine surveillance and vital statistics, we conducted two surveys in 
MSF catchment areas in order to estimate EVD and non-EVD mortality and morbidity in Bo district 
during the Ebola outbreak. One survey was carried out in Bo rural areas which consist of 15 chiefdoms 
and 969 villages, with an estimated population of 538,751. A second survey was carried in Bo town 
(urban area of Bo District) consisting of 20 sections, with an estimated population of 178,446. 
Study design  
We used a two-stage population-based cluster survey design, an established methodology to estimate 
mortality rates in humanitarian and crisis settings (13-15). Surveys were implemented separately in two 
localities within Bo District: rural Bo chiefdom (rural area) and Bo town (urban area) to reflect 
differences in access to EVD care. 
Recall period  
In Sierra Leone the first EVD cases were reported on 24th May 2014 (16). The last confirmed case from 
Bo District was discharged on 26th January 2015(while the last confirmed case for the entire country 
was reported in March 2016). The recall period for the survey covered the period from May 2014 to 
April 2015 when the surveys were conducted (313 and 321 days for the rural and urban studies 
respectively). Group discussions with the Sierra Leone study team were used to design a local events 
calendar for the chosen recall period to improve the accuracy of the reported time of deaths using locally 




religious observance events, and community events as well as salient events linked to the EVD outbreak 
(e.g. the declaration of a state of emergency) (8, 17). 
Sample size 
There is substantial inter-cluster variability of EVD transmission, with people living in an Ebola-
affected households or village having a high household and village-level risk of EVD infection and 
mortality (e.g. due to attending the same funerals, and/or caring for a sick relative) (18). The between 
cluster-variability decreases the precision of a mortality estimates compared with a non-clustered 
sample of the same size. Prior to the EVD outbreak, the all-cause mortality rate in Sierra Leone was 
estimated between 0.5 and 0.7 deaths per 10000 people per day (19). In the absence of published DEFF 
estimation from prior EVD cluster surveys, we considered a range of sample size scenarios when 
designing our surveys, using different estimates of expected crude mortality rate (CMR), required 
precisions and assumed design effects (19, 20).  
Based on simulations, the most likely set of estimates was considered to be a CMR of 1.0 deaths/10,000 
person-days with a precision of ±0.5 deaths and a design effect of 4. Using ENA (2011) software, the 
required sample size for each area was calculated as 2390 individuals in 483 households. Since the 
value of DEFF increases with cluster size and reduced with cluster number, to further reduce the DEFF 
and increase the geographical variability we organized the survey in 35 clusters of 14 households 
(35x14) in each area instead of the classical (30x30) (21).   
Sampling 
Population estimations in Bo district (by village) and Bo town (by section) were obtained from the 
Local Ministry of Health and Sanitation (MOHS). These lists constituted the sampling frame from 
which the clusters were selected. In the first stage, villages/sections were selected with PPS. In the 
second stage, the starting household was chosen within a village (rural area) or within a section (urban 
area) using the standard World Health Organization (WHO) Expanded Programme on Immunization 
(EPI) methodology (22). A pen was spun and dropped on the ground in the central point of the village 
or section and a line drawn in its direction towards the edge of the village or section. Households along 
this line were counted, and one of these was selected using a random number table as the first to be 
interviewed in the villages/sections. To further reduce the DEFF that might occur through including 
geographically close households, subsequent households, were selected systematically as every nth 
household (where n was determined as the total estimated households in the village/section divided by 
the number of households to be included); this was different from the WHO EPI approach, that does 
not introduce a step to select subsequent households. The next (nth) household was selected by counting 
households to the left. If a household was empty, 2 further attempts were made later the same day before 





The WHO EVD case definitions were used to define suspect cases based on history of contacts and 
signs and symptoms compatible with the EVD infection (Box 1) (23).  
A household was defined as a person or a group of persons, related or unrelated, who lived together and 
who shared a common source of food. The head of household was defined as person aged 18 years and 
older who could give accurate information on demographics, illness, and mortality in his/her household 
and was present in the household during recall period.  
Quarantine was defined as a household reporting separation (i.e., the household was cordoned off) and 
restriction of movement by the local authority following a positive EVD result in the household. Contact 
tracing was defined as a process of identifying, listing, and monitoring persons who had direct or 
indirect exposure to any confirmed, EVD case within the past 21 days. 
Data management 
Interviews were conducted with the head of each selected household. A trained MSF study team elicited 
information on household members, births, arrivals, departures, illnesses, deaths, place and 
circumstance of death. Medical records at the household level were used to re-build the possible cause 
and time of illness and death, if available. If all members of a selected household were deceased, the 
household composition and outcomes were reconstructed with help from family members and/or 
neighbors. Data on whether and when the household had been placed under quarantine and if any of the 
household members was put under contact tracing were also collected. The questionnaire and consent 
forms were verbally translated into the dominant local language Mende, which does not have a written 
tradition, and back-translated into English to ensure consistency. Study team were bi-lingual (speaking 
English and Mende). Group consensus on translations was sought during the training. Questionnaires 
were piloted prior to beginning the study. The detailed study protocol is publicly available on the MSF 
research platform (https://remit.oca.msf.org/studies/159). 
Data analysis  
We present descriptive analysis as means or medians (range) of numerical variables and proportions 
with 95% confidence intervals (CI) for categorical variables. Mortality rates per 10,000 per day were 
calculated using the mid-point population estimates as the denominator. Mid-point populations 
accounted for changes in household composition (births, deaths, and in- and out-migration) during the 
recall period. Rates were calculated for all-cause, all-age, under-5 mortality and EVD-specific 
mortality. Stratified linear and logistic regression models for continuous and binary outcome variables, 
respectively, have been fitted adjusting for age and sex. We calculated the crude and adjusted mortality 
rates, and incidence rate ratios (IRR) using Poisson regression. All analyses accounted for the survey 
sample weights and the effect of clustering induced by the two-stage sampling design. Data cleaning 





The study protocol was approved by the Ethics Review Board of MSF, the Internal Review Board of 
the Sierra Leone MoHS, and the London School of Hygiene & Tropical Medicine (LSHTM). Approval 
to conduct the study was obtained from traditional authorities in all study sites prior to data collection. 
Participation was voluntary. Verbal informed consent for participation was obtained from the head of 
each household after a briefing about the aim of the study, the questions, survey and how their answers 
would be recorded, stored and used, duration of the questionnaire, and the option to end the interview 
or withdraw from the research at any time if wished. Confidentiality was protected during data 





The surveys were conducted in 70 clusters of 14 households (total 980 households; 6,522 individuals). 
Four households refused to participate (one in the rural and three in the urban area) and were replaced 
by the next consenting household. The rural area had a higher proportion of children under five (14.4%, 
95%CI:13.3-15.5%) than the urban area (9.4%, 95%CI:8.4-10.4%) (p<0.001). The proportion of 
women was lower in the rural area (51.4%, 95%CI:49.6-53.2%) than in the urban area (54.6%, 
95%CI:52.9-56.3%) (p=0.01) (Table 13).  
Morbidity 
Overall, 9.0% (n=586, 95%CI:7.2-10.1%) of the population surveyed reported that someone had been 
sick in their household at least once during the recall period. Prevalence of any morbidity was reported 
more frequently among household members aged over five compared to children under 5 (55.2% vs 
47.8%) (p<0.001). The most frequently reported illness (all ages combined) was malaria/fever (n=358, 
61.1%). Prevalence of suspected/probable EVD was 4.9% (n=29).  
 
EVD survivors  
In total, 9 people reported being EVD survivors, all of whom reported been admitted to MSF Bo EMC. 
Of these, 7 reported that their household was put under quarantine and contact tracing following their 
positive test. Only 6 of the 9 reported signs and symptoms and a contact history compatible with the 





Overall, 36 out of 70 clusters (51.4%) reported deaths (16 clusters in the rural and 20 clusters in the 
urban area). In total, 64 deaths were reported, of which 18 were among children aged under 5 years old, 
giving crude and under-five mortality rates of 0.35/10,000 person-days (95%CI:0.23–0.52) and 
0.91/10,000 person-days (95%CI:0.54-1.51) respectively (Table 14). All-cause mortality in the rural 
area was 25% higher (adjusted IRR 1.25; 95%CI: 0.67-2.33) than in the urban area (Table 14).   
The most frequently reported causes of death were EVD (31.2%, n=20) and malaria/fever (18.7%, 
n=12). EVD was the main reported cause of death for those aged over 5 years (39.1%, n=18), while 
malaria/fever was the main cause for the under-5s (50.0%, n=9) (Table 15). For two children aged 
under-5, the case of death was attributed by family members to EVD, both in the rural area and in 
households experiencing more than one EVD case.  
All households where EVD deaths were reported, experienced quarantine, and all except one, contact 
tracing. Nine EVD deaths (45.0%) met the suspect/probable EVD case definitions. Of the 20 EVD 
deaths, nine (45.0%) died at home, six (30.0%) in Bo MSF EMC, four (20.0%) in a non-Ebola health 
facility, and one (5.0%) in the ambulance.  
The overall EVD-specific mortality rate was 0.12/10,000 person-days (95% CI:0.05–0.32). EVD-
related mortality was 2.6 (adjusted IRR 2.6; 95%CI: 0.65–10) higher in rural area compared with that 
in the urban area (Table 16).  
Design effects and cluster 
The 29 EVD cases were reported in 20 households in 12 clusters, while the 358 malaria/fever cases 
were reported in 272 households in 62 clusters. Overall, 51.7% (15/29) of reported EVD cases occurred 
in six households. The DEFF for EVD infection was 28% higher compared to malaria/fever infection 
(7.01 vs 5.47) (Table 17).  
The 20 EVD deaths were reported in 15 households in 9 clusters, with the 44 non-EVD deaths reported 
in 40 households in 31 clusters. The DEFF for EVD-specific mortality rate was 3.6 times higher 
compared to non EVD mortality rate (5.53 vs 1.53) (Table 16). 
Five out of six clusters reporting more than one EVD cases where in the rural area versus one cluster in 
the urban area (83.3% vs 16.7%, p=0.063). Death at home was more frequent among clusters reporting 
more than one EVD case compared to clusters reporting one EVD case, however the difference was not 
statistically significant (26.7% vs 7.1%, p=0.385). 
DEFF for EVD-specific mortality (overall 5.53) was 11 times higher in the rural area compared with 
the urban area (6.18 vs 0.58) (Table 16).  
Overall, most of the DEFF was linked to one individual cluster reporting 6 out of 29 EVD cases 






To our knowledge this is the first and largest population study conducted during the EVD outbreak in 
Sierra Leone, and the first study to estimate mortality rates and DEFF separately for urban and rural 
areas and for EVD and non-EVD. Mortality rate estimates were lower than expected based on the 
closure of the MSF hospital and the public health impact of the EVD outbreak. Only a small proportion 
of households and clusters reported EVD deaths and cases. This may in part be due to the high degree 
of clustering as indicated by the high DEFF, which contributes to imprecise mortality estimates with 
large confidence intervals, which therefore have limited utility when assessing the impact of disease.  
Surveys in Freetown, Sierra Leone, and Monrovia, Liberia, estimated CMR and EVD-specific mortality 
rates covering a recall period which overlapped with our study, both studies were conducted with the 
assumption of an increase of mortality due to the outbreak. The Freetown study used our methodology 
(e.g. a two-stage population-based cluster but with a lower DEFF of 1.5) (24). In Monrovia a simple 
random sample of telephone numbers with remote interview was implemented, since a two-stage 
population-based cluster was deemed risky for the study team due to EVD transmission (25).  
In Freetown, CMR was 0.52/10,000 persons/day (95%CI:0.29–0.76) and Ebola-specific mortality rate 
0.19/10,000 person-days (95% CI:0.01–0.38) (24); empirical DEFF were not reported.  
In Monrovia, CMR was estimated at 0.33/10,000 person-days (95%CI:0.25–0.43) and Ebola-specific 
mortality rate at 0.06/10,000 person-days (95%CI:0.03–0.11) (25). As in our study, EVD-specific 
mortality rate estimates had wide confidence intervals and consequently imprecise estimates. Both 
authors attributed the low mortality rates to improved access to care, enhanced hygiene practices due to 
the outbreak, and low reporting of deaths in particular for under-5s. These factors may also have 
contributed to the lower than expected mortality seen in our study in particular for the urban area. 
At the start of the EVD outbreak in Monrovia, another study used a capture-recapture approach to 
estimate underreporting of EVD, showing that this method captured at least three times more EVD 
cases than officially reported (26). Lack of access to EVD surveillance data hampered the ability to 
consider capture-recapture or assess the correlation of our estimation with surveillance data. We 
recommend that future studies use capture-recapture methods or surveillance line lists as a sampling 
frame instead of the list of villages for cluster selection. Others have suggested a purposeful selection 
of clusters guided by knowledge of the spatial distribution of the outcome, instead of using the village 
sampling frame (27). These methods have the potential to allow investigation of clusters with already 
reported transmission, thus potentially providing more robust estimates and better allocations of 
resources. However, this approach might have the potential limitation of give estimates only relevant 
for the purposively selected areas with limited application to the wider population or exclude area 




As suggested by other authors, to improve the precision for outcomes with high between-cluster 
variability, we increased the number of clusters and reduced their size (35x14 vs 30x30) (21). In spite 
of this, our empirical estimate had wide confidence intervals and a large DEFF. To improve precision, 
future studies should consider increasing the number and decreasing the size of sampled clusters even 
further, or using the variance partition coefficient to calculate separate sample sizes according to groups 
that show significantly different heterogeneity (28). This latter approach has been used in veterinarian 
epidemiology to analyze herd-level predictors.  
At the implementation stage, to further mitigate DEFF, we introduced a step between households. This, 
however, induced us to skip neighbours of EVD-affected households who informally reported EVD 
infection to the study team. Future studies could consider involving community chiefs and key 
stakeholders on identification of affected households (8).  
Other authors have used a snowball approach to capture maternal death (29), and proven to be cost 
effective to capture Visceral Leishmaniasis deaths (30). More recently, this approach was suggested to 
estimate the impact of SARS-CoV-2 transmissibility starting from contact networks (31).  
Households in the rural area experienced a higher proportion of EVD deaths at home, and more clusters 
with more than one EVD case, possibly due to limited access to care along with weaker surveillance 
system delaying reaching rural areas (32). During the outbreak, EVD home deaths could be used by 
public heath actors as a key indicator to prioritise those households where secondary transmission is 
more likely to occur and prioritize them for EVD vaccination and more rigorous contact tracing for 
timely access to care.  
Death at home along with different distribution patterns of households and household interaction is 
likely to have increased the area-specific degree of cluster homogeneity for EVD transmission, as 
demonstrated by the high DEFF for the rural area compared to the urban area for EVD deaths (6.18 vs 
0.58). It is likely that urban households have less distinct borders, and more homogenous mixing and 
distribution of risk factors, and thus less within-household clustering. Future studies would be advised 
to consider different sampling methodologies for urban and rural area to allow for this.  
Malaria/fever was by far the most common morbidity reported in all ages, and was the main cause of 
death for under-5-year-olds, and similar to EVD had high clustered patterns. Surveillance, at the time, 
was focused on EVD detection with limited attention to provide specific care for other endemic diseases 
like malaria (2). As previously suggested, malaria interventions should be prioritized in EVD outbreak 
responses, in particular for children aged under-5 and in rural settings (33). This will mitigate the 
additional morbidity and mortality burden, and stimulate the community to report to surveillance if 




In Table 18, we summarise challenges, proposed methods or design improvements to mitigate the 
limitations of surveys for highly-clustered data along with requisites and additional considerations. 
Study limitations 
As with many EVD studies, under-reporting of deaths due to the fear of penalty, stigma from other 
households, and dissatisfaction of how deaths have been handled by safe burial team cannot be excluded 
(34). However, a mitigating factor is that MSF was not associated with the punitive measures introduced 
and they had an established presence in Bo preceding the Ebola outbreak as a provider of free 
healthcare. Further, we had a high response rate to the survey, and found that households were willing 
to share information on EVD even if not randomly selected. 
Misclassification of the cause of deaths (e.g. with malaria may not be distinguishable from EVD due to 
low performance of WHO EVD case definition) (35), and timing of death may have occurred, but, when 
available, we used medical records, clinical/contact history, info on quarantine and contact tracing and 
calendar of salient events to mitigate misclassification. 
Under estimation of prevalence of any morbidity for children under 5 years old compared to household 
members aged five and over might have occurred, since interviews were carried out with head of 
households who are not necessarily caregivers for children under 5.  
Finally, in our study most of the DEFF was attributed to one cluster. DEFF estimation could be 
underestimate if clusters or households inside affected clusters are not selected through the sampling 
approach used, hampering the true estimation of DEFF. A previous study found a similar spatially 
clustered EVD pattern (18). This is a key limitation of the methodology used that could be mitigated by 




For humanitarian organizations it is imperative to document the methodological limitations of studies 
and discuss the utility of estimates generated by common epidemiological tools used to quantify burdens 
and needs, in order to ensure accountability to affected populations, and best use of resources.  
Our findings demonstrate a high degree of clustering in current methodologies for community-based 
surveys of EVD. The empirical DEFF estimates we provide can inform more robust study designs in 
future retrospective surveys of highly clustered diseases such as EVD, and the alternative design 
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Box 1 World Health Organization (WHO) EVD case definitions were used to define suspect, probable, and confirmed cases 
Suspect  Probable  Laboratory confirmed  
a. Any person, alive or dead, suffer-
ing or having suffered from a sudden onset of 
high fever and having had contact with: - a 
suspected, probable or confirmed Ebola or 
Marburg case; - a dead or sick animal;  
OR  
b. Any person with sudden onset of high 
fever and at least three of the following 
symptoms: - headaches - lethargy - anorexia / 
loss of appetite - aching muscles or joints - 
stomach pain - difficulty swallowing - 
vomiting - difficulty breathing - diarrhea - 
hiccups;  
OR  
c. Any person with inexplicable bleeding;  
OR  
d. Any sudden, inexplicable death 
a. Any suspected case evaluated 
by a clinician;  
OR 
 b. Any deceased suspected case 
(where it has not been possible to 
collect specimens for laboratory 
confirmation) having an 
epidemiological link with a 
confirmed case 
a. Any suspected or probable cases with a 
positive laboratory result. Laboratory confirmed 
cases must test positive for the virus antigen, 
either by detection of virus RNA by reverse 
transcriptase-polymerase chain reaction (RT- 
PCR), or by detection of IgM antibodies directed 





















Table 13. Households characteristics and movements according to area, mortality studies Bo District  
Variable  Urban Rural p-value for difference 
No. clusters 35 35  
No. households sampled 490 490  
No. individuals at baseline 
(start recall period) 
3,266 3,048  
No. departure (deaths/out-
migration) 
122 140  
No. arrivals (births/in-
migration) 
108 100  
Total number of individuals 
in study 
3,374 3,148  














































Table 14. Reported deaths and crude and under 5 years mortality rates, crude and adjusted incidence rate ratio, 
mortality studies Bo District 
 N of deaths Mortality rate (all ages) mortality rate 
per 10,000-person-days  
Under-five mortality rate mortality 
rate per 10,000-person-days 
Area Total < 5 
years 
Rate [95% CI] Design Effect Rate [95% CI] Design 
Effect 
Overall 64 18 0.35 [0.23 – 0.52] 2.86 0.91 [0.54 – 1.51] 1.43 
Urban 28 4 0.27 [0.19 – 0.38] 0.45 0.41 [0.13 – 1.30] 0.60 
Rural 36 14 0.38 [0.23 – 0.62] 3.44 1.03 [0.59 – 1.77] 1.52 
Crude incidence rate ratio 
(IRR) 
1.41 [0.77 – 2.60]  2.51 [0.69 – 9.14]  
Adjusted IRR 1  1.25 [0.67 – 2.33]  2.56 [0.71 – 9.28]  




















Table 15. Reported causes of death by age group, mortality studies Bo District 
Cause of death	     Five years old and over (N=46)	    Under five years old (N=18)	
#	 %	 #	 %	
EVD  18 39.1 2 11.1 
Chronic diseases  8 17.4 - - 
Other* 6 13.0 1 5.5 
Old Age 5 10.7 - - 
Malaria/Fever 3 6.5 9 50.0 
Unknown 3 6.5 - - 
Trauma/Accident 2 4.3 1 5.5 




1 2.2 - - 
Neonatal death  - - 3 16.7 
















Table 16. Reported deaths, EVD specific and non-EVD specific mortality rates, crude and adjusted incidence rate ratio, 
mortality studies Bo District 
 N of deaths EVD specific mortality rate per 10,000-
person-days 
Non-EVD-specific mortality rate per 
10,000-person-days  
Area EVD Non-EVD Rate [95% CI] Design Effect Rate [95% CI] Design 
Effect 
Overall 20 44 0.12 [0.05 – 0.32] 5.53 0.22 [0.16 – 0.32] 1.53 
Urban 6 22 0.06 [0.02 – 0.14] 0.58 0.21 [0.14 – 0.31] 0.44 
Rural 14 22 0.15 [0.05 – 0.43] 6.18 0.23 [0.15 – 0.37] 1.87 
Crude IRR  2.56 [0.64 – 10.26]  1.10 [0.59 – 2.04]  
Adjusted IRR1  2.61 [0.65 – 10.35]  0.91 [0.50 – 1.65]  






















Table 17. Reported malaria and EVD infections, morbidity rates and Design effect, mortality studies Bo District 
Area N of cases Malaria/fever morbidity rate (*) EVD morbidity rate (*) 
Malaria/ 
fever 
Ebola Rate [95% CI] Design Effect Rate [95% CI] Design Effect 
Overall 358 29 1.74 [1.36 – 2.22] 5.47 0.17 [0.07 – 0.42] 7.01 
Rural 163 18 1.72 [1.25 – 2.35] 6.72 0.19 [0.06 – 0.55] 8.21 
Urban 195 11 1.86 [1.39 – 2.48] 2.07 0.11 [0.05 – 0.21] 0.62 






























Table 18. Challenges, proposed, methods and design improvements and considerations 
Challenges observed 
Proposed alternative methods and/or improvements of two-
stage cluster survey  
Requisites & considerations 
Selection of a large number of 
unaffected clusters and households 
resulting in underestimation of the 
outbreak burden/impact 
Use surveillance list or a purposeful selection of clusters as a 
sampling frame instead of the list of villages.  
Access to surveillance data.  
Previous knowledge of geographical 
distribution of health characteristics 
under investigation. 
Potential limited representativeness 
of the results (i.e, estimates only 
relevant for the purposively selected 
areas, potentially over-estimate the 
burden if estimated are inferred a to 
the whole area). 
Designing a capture-recapture study using different sources (e.g. 
surveillance line list, burial data, EVD vaccination list, local key 
stakeholders). 
Access and/or creation of at least 
three independent lists. 
Sampling urban/rural  
Differences in the distribution of population characteristics across 
urban and rural areas. 
Different sampling methodology 
according to settings.  
Precision of estimates, sample size, 
and  geographical variability 
  
Consider additional variables for stratification influencing DEFF: 
age (e.g. under 5 years old vs 5 and over) and other 
social/epidemiological parameters influencing transmission.   
Consider sampling methods used in veterinary epidemiology that 
use the variance partition coefficient (VPC), which measures the 
clustering of infection/disease for individuals with a common risk 
profile (e.g. animals in the same herd). Sample size estimates are 
obtained separately for those groups that exhibit significantly 
different heterogeneity. 
Knowledge of social and 
epidemiological factors (e.g. review 
of chain of transmission, social 
factors/traditions that could 
influence patterns of transmission) 
Increase the number of clusters to increase geographical variability Large logistical and human 
resources  
Identification of EVD-affected 
households 
Involve community chiefs, community health workers, and/or key 
local stakeholders to support identification of affected EVD 
households; 
Consider non-probabilistic methods (e.g. snowball approach) to 
identify additional affected households. If the intension is to is to 
find all affected households in a location and use whole population 
as denominator. 
Breach in confidentiality and 
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Chapter 6: Discussion and conclusion  
 
This chapter summarises the research presented in this thesis, and gaps identified, including: i) putting 
the thesis findings in context of research published since the publication of thesis papers 1 and 2, and 
writing paper 3; and ii) includes discussion of how field experiences of the EVD response in Sierra 
Leone have contributed to the evolution of the MSF-OCA approach to community consultations. This 
has led to the development of an ‘epi-anthro’ approach during outbreak investigations and the design 
of new guidance and a protocol to explore open in-depth conversations with different community groups 
from the outset of an outbreak. The MSF-OCA Community Guidance on COVID-19 and the design 
and implementation of a qualitative study carried out in Sierra Leone in May 2020 are summarized in 
this chapter as a tangible example of this change.  
 
6.1 Discussion  
 
The work presented in this thesis consolidates perspectives and evidence from EVD outbreaks and 
emphasises the essential role of communities as frontline, and the importance of contextually adapted 
and compassionate control measures (1). A common theme throughout the thesis was that the 
epidemiological chains of transmission reveal health and social inequalities. The findings underline that 
outbreaks do not occur in a vacuum and that the understanding of social dynamics and dialogues with 
heterogeneous community stakeholders are crucial steps to designing more equitable and inclusive 
models of public health interventions (2). 
 
Overall, the thesis addressed 3 main knowledge gaps; these are summarised in Table 19 together with 
















Table 19. Overview of evidence gaps, key findings and priorities for future research 
 
Evidence gap 
PhD Objective Methods  Key findings Clinical or policy 
implication 




Lack of knowledge of 





control measures over 
time. 
Investigate drivers of 
EVD transmission and 
community perspective 
toward EVD control in 
Kailahun District, 
Sierra Leone.  
Mixed-methods study 
in a rural village that 
experienced prolonged 
EVD transmission.  
Exhaustive cross-




interviews to explore 
community views. 
Outbreak was controlled after 
prolonged transmission and a 
high death toll.  
Transmission was maintained 
by a small number of large 
households. All cases and 
deaths detected were spatially 
clustered. 
 
Reasons for non-compliance 
with public health guidelines 
included burials in plastic bags, 
without female attendants or 
prayer, perceived as 
dishonourable, and perceptions 
of a moral duty to provide care 
to relatives. 
 
Low EMC survival rates, poor 
communication with EMC, and 
loss of livelihoods due to 
quarantine further contributed to 
low uptake with control 
measures. 
 
Early understanding of social 
norms and experiences and the 
ability to link this to localised 
strategies and adapted health 
interventions is essential. 
To inform responses to 
future EVD outbreaks. 
 










with control measures 











PhD Objective Methods  Key findings Clinical or policy 
implication 





concerns about the 
performance of WHO 
EVD case definitions 
and lack of evaluation 
of its performance.  
Assess performance of 
the WHO EVD case 
definitions and other 
screening scores, to 
support surveillance 
and admission testing 
decisions at EMCs. 
Systematic review and 
meta-analysis of 
studies published 
between June 13, 
1978, and Jan 14, 
2020.  
WHO EVD case definitions 
perform sub-optimally to 
identify cases at both 
community level and during 
triage at health facilities. 
 
The performance of fever as a 
symptom varied depending on 
the cut-off used to define fever. 
The most sensitive symptom 
was intense fatigue.  
 
History of contact was a key 
predictor for the WHO case 
definitions and for risk scores. 
 
Gaps related to the EVD case 
definition for the paediatric and 
pregnant population. 
 
Gaps on validating externally 
risk score for Ebola virus 
infection. 
To guide communities and 
public health practitioners 
to improve the 
effectiveness and 
efficiency of identification 
and management of 
suspected cases during 
EVD response. 
Evidence is needed on 
EVD screening tools 
for the paediatric and 
pregnant population  
 
Need to use consistent 
thresholds (e.g., for 
fever) 
 
To externally validate 













The first study of this thesis (Objective 1, Chapter 3) used a mixed-method approach which allowed 
in-depth exploration of the factors that influenced protracted EVD transmission combined with epide-
miological data. The study was conducted in a village where MSF had been unsuccessfully engaging 
since the outset of outbreak. In the village transmission lasted for several weeks and was maintained 
by a small number of large households with all cases and deaths spatially clustered.  
The exhaustive design of this study allowed us to capture all the cases and deaths that would otherwise 
not have been identified using standard sampling methods. The study provided evidence that the risks 
that contributed to EVD transmission are often hidden in the details of community life, part of coping 
mechanisms and family dynamics. Further, the study highlighted that the patterns of transmission and 
the high community death toll were the outcomes of poor communication and the failure of response 
organizations to adapt to community i.e., that households and community withdrawal was a 
consequence of the failure of the response to orientate itself according to the needs and values of the 
community. Ebola is a disease that poses the greatest risk to family members whose generosity drives 
them to look after each other while honouring ancestral practices. Household members became infected 
themselves in a brave effort to look after their loved ones, and to bury their dead honourably. Strict 
infection control procedures in Ebola isolation centres and during safe burial hampered family 
proximity and grieving, and, as observed somewhere else, were ultimately perceived as a violation of 
customary and religious rituals (3).  
Since the publication of this thesis chapter, other authors have i) documented how Ebola isolation 
centres were perceived over time in Sierra Leone, and highlighted the need for better communication 
links between communities and Ebola facilities (4), and ii) tried to rebuild local transmission chains and 
explore why in some communities in Sierra Leone the transmission was sustained, with consequent 
devastating death tool compared to others where transmission was timely controlled (5). As with our 
study, the authors documented that chains of transmission were maintained by intrafamilial behavioural, 
social events and external public health factors (i.e. delay in detection of cases, misdiagnosis, 
nosocomial transmission, lack of guidance on proper PPE procedures, poor communication with 
communities). The authors highlighted how the initial EVD WHO case definition emphasising 
haemorrhagic signs was misleading for most of the communities not experiencing these signs. In their 
study, families referred to Ebola as ‘bondawote–“family turn around” with control  achieved in the most 
affected communities when all the family had been ‘turned around’. Control in other non-affected 
community was achieved by timely implementation of local strategies (i.e. cooperation with affected 
families, strict controlling of entrance to and exit from the community), with some of those coping 
mechanisms similar to those once set up at the time of the war (5).  
Following our study, others have also used similar mixed-method approaches to understanding 




Sierra Leone (6). The authors documented the complex relationships between colonial heritage, social 
and spiritual dimensions of EVD, and the role played by local communities in acting collectively to 
control the outbreak themselves in an attempt to save their loved ones and honour their souls. In this 
study, empirical observations on how EVD was transmitted helped the community to define localised 
control strategies (e.g. separate the ill from the healthy and setup village burial teams) (6). This was in 
part similar to localised strategies implemented by the community in the village included in our study 
(e.g., stopping babies being delivered in the community, preventing children from playing contact 
games together, and not visiting other households). In their study, the military and a punitive fine system 
that were used by authorities to control the outbreak acted as a further deterrent to the community 
engaging with response agencies (6).  
We found that community attitudes toward control measures changed once the health messages given 
to the community were consistent with what households observed in their lives (i.e., "When we saw 
that people touched sick people and got sick, we could see the communication of it and realised that it 
is real."). Similarly, perceptions toward the EMC and safe burial improved when survivors returned to 
the village and when burial prayer was permitted. These helped changing perceptions of contact tracing 
as invading privacy or “selling” people to enable community safety. Quarantine was understood and 
compliance improved when food support was given to affected households (i.e. “We had no food at the 
start. They should have given us food like they did in other households at the end.”). This shows that 
vertical outbreak control can act as an additional barrier to access to care and the humanization of public 
health response can enhance compliance, demonstrating that the use of force was an unnecessary and 
had a detrimental impact by further alienating community.  
There has also been limited acknowledgement of the profound contribution of local communities to the 
generation of evidence on pharmaceutical interventions for EVD. For instance, evidence on the impact 
of investigational drugs on reducing mortality would not be available if households were not, bravely, 
delegating care of loved ones to Ebola treatment centres, despite these being places where traditional 
practices have been compromised by the strict biomedical approach. Likewise, evidence of safety and 
efficacy of experimental vaccines are a tangible result of the trust that local populations and health staff 
have placed in the research community (7). This contribution has provided clinicians and public health 
workers with new tools, altering patient outcomes and preventing transmission at community level. (see 
section 1.7 Treatments and vaccines).  
During the validation process of our study, we shared study findings in a narrative form with the village. 
This was perceived by participants as a step towards a collective healing processes and reconciliation 
between MSF and the affected community. Recently other authors have documented how, for EVD 




mechanism to heal post-traumatic distress and accelerate their acceptance and reconciliation with the 
local community (8).  
Our study also identified key gaps in how to safely incorporate accepted local social norms from the 
outset of intervention, making them more acceptable for communities and therefore effective; also the 
clustered distribution of cases and deaths indicated the need for a new methodology to benchmark the 
burden for diseases with a clustered transmission pattern like EVD. 
The second paper in the thesis, (Objective 2, Chapter 4) used a review and meta-analysis approach to 
explore the performance of EVD WHO case definitions, a critical public health tool to identify EVD 
cases in communities and Ebola centres.  
The study showed that WHO EVD case definitions perform sub-optimally to identify cases at both the 
community level and during triage at health facilities. We estimated that the EVD case definition has a 
specificity of 36% (thus 64% of people identified as EVD suspected have potentially other diseases) 
and a sensitivity of 81% % (thus 19% of patients with EVD do not meet the case definition and would 
be otherwise missed). Discordance on the use of WHO EVD case definitions can contribute to 
unnecessary admissions to Ebola treatment centres with consequent community disengagement, 
delayed access to care, and delay in outbreak control. Since the publication of this thesis chapter, others 
have reported that the WHO case definition specificity varies according to stage of the outbreak, with 
57% of suspect cases correctly identified in the early stages and 35% correctly identified in the late 
stage (9). This corroborates our results and underlies how the performance of WHO case definitions 
depends on a number of context-specific and epidemiological factors. 
In our analysis, the performance of fever as a symptom varied depending on the cut-off used to define 
fever, with intense fatigue identified as the most sensitive symptom, and conjunctivitis, unexplained 
bleeding, difficulty swallowing as the most specific. Since the publication of our study, another 
systematic review and metanalysis has explored what symptoms and signs best predict EVD (10). This 
study confirmed that the symptoms that best predict EVD are those presenting late in the diseases (i.e., 
conjunctivitis) when it is likely that transmission would have already occurred in the community and 
the prognosis for individual patients would be more severe. In our study the reported history of contact 
was a strong predictor for both the paediatric and adult populations, often performing better than many 
of the clinical symptoms and signs. However, reporting of contact history requires communities to feel 
safe enough to identify themselves as being at risk, and share information on risks and behaviour with 
responding organization. Therefore, the performance of WHO case definitions depends on key aspect 
of relationship with community identified in Objective 1. Our study identified key gaps in exploring 
the performance of EVD case definitions for paediatric and pregnant populations along with external 




The third paper in the thesis, (Objective 3, Chapter 5) used two retrospective population surveys 
conducted in urban and rural areas to benchmark mortality rates (EVD and non EVD-specific) at the 
end of the EVD outbreak in Bo district. The study offered a complementary approach to show how the 
EVD localised risk of transmission can contribute to a high degree of clustering (high design effect), 
leading to imprecise mortality estimates. A high clustering distribution of EVD was also identified in 
Objective 1. By using different methodologies and approaches, the work presented here highlights how 
the within-household and village interaction influenced the distribution patterns of EVD, with 
implication on robustness of mortality estimates to benchmark the disease burden and guide response. 
The study provides empirical estimation of the design effect that has not been reported before by similar 
studies conducted in West Africa during the EVD outbreak. Furthermore, the study prompts reflection 
on the utility of using retrospective mortality studies for highly clustered diseases and proposes several 
methodological recommendations to improve similar studies in the future.  
To date, no other study using this methodology has been published on EVD since the West Africa 
outbreak. Other authors have recently used a seroprevalence study to benchmark the outbreak burden 
in one village in Guinea, confirming localised transmission patterns and mortality higher than 
previously documented (11). Other authors have recently used ethnographic methodologies in Sierra 
Leone to explore which coping, cultural imperatives and social elements influenced the heterogeneity 
in exposure to infection, with some households and communities heavily affected with an aggregated 
pattern of infection distribution and others that instead better controlled transmission. This study further 
underlines the importance of a conjugate epidemiological with anthropological investigation when 
measuring transmission (5).  
Overall, using different methodologies and approaches, the work in the thesis highlights that outbreak 
patterns are inevitably linked to community and that community is linked to social and cultural 
environments, influencing key public health practices (i.e. surveillance, timely patient isolation, contact 
tracing, reporting of deaths, and definition of rings for EVD immunization). 
 
6.2 Implication of findings for outbreak control  
	
The research and field work presented in this thesis have strongly influenced the foundation of the MSF-
OCA “epi-anthro” approach on EVD response. This approach recognises that the risks that contribute 
to EVD transmission and prevention are intrinsically linked to family/community dynamics, and 
external public health factors. In this approach, epidemiologists, anthropologists and social scientists 
work in tandem to investigate chains of transmission, social dynamics and family relationships that 
might influence transmission, including coping mechanisms that could explain health-seeking 




The “epi-anthro” approach has been further framed in the recent MSF-OCA Community Guidance on 
the COVID-19 response10. This Guidance outlines the core principles on how to empathetically support 
communities during outbreaks and co-design local adapted responses. The practical application of these 
principles has resulted in the design of a qualitative study protocol focused on a community 
consultation, aiming to ensure that community voices and experiences are included in the early design 
of MSF/MOHS COVID-19 control measures. In May 2020, the qualitative community consultation 
study was implemented in Sierra Leone11, in one of the areas where MSF-OCA provide maternal and 
child health care. The study found that previous experiences (e.g. war, EVD) have fostered fears of 
separation and of infection from contact with strangers and health workers/facilities. The EVD 
experience had facilitated the understanding of COVID-19 isolation centres as an important control 
measure, but for the community proximity to the homestead and communication with families remain 
crucial. Vertical COVID-19 control measures such as lockdown were perceived to have a negative 
impact on essential daily activities (especially food availability) and increasing the risks of domestic 
and sexual violence and adolescent/child abuse. This finding is corroborated by another study that found 
reduction of household income as a consequence of COVID-19 lockdown in Sierra Leone (12). 
Communities suggested that MSF should prioritise access to family planning and sexual and gender-
based violence (SGBV) programming, along with the identification of an organization that could 
support safe farming activities (i.e., farming assistance and rice subsidies). In this community there was 
a clear desire for self-management of contact tracing and transmission prevention activities by 
communities, through peer supervisors/CHW/local leaders and developing a buddy system for the 
design and implementation of activities (MSF provides technical support, but community members 
must have ownership and lead the surveillance, sensitisation and implementation). The study has further 
highlighted that this is a community that is not naive to epidemics, and there is a need of recognising 
community experience and prioritising ongoing programming according to community priorities. This 
is consistent with another national survey on knowledge, perceptions and practices around COVID-19 
in Sierra Leone, which highlighted how previous experience of EVD might have highlighted preventive 
practices also for COVID-19 and which observed a strong association between infection knowledge 
and practices (13). Our findings are consistent with another study recently conducted in Sierra Leone 
in two communities that had different experiences with EVD burden (14). The study explored 
community preference for a disease with low infectivity but high mortality (i.e., EVD) versus an 
infection with high infectivity but low mortality (i.e., Covid-19). Both communities showed strong 
ability to conceptualise decisions regarding disease risks and both showed awareness of utility of  
personal action and local regulations to influence outbreak controls (14).  
																																								 																				
10 Community Approach Guidance: Maintaining health and resilience during novel coronavirus (COVID-19) transmission, MSF-OCA 
interim guideline April 2020  
 
11 Exploring the perceptions of key community leaders toward the implementation and impact on their and community lives of COVID-




6.3 Future research priorities  
 
The work presented in this thesis identified several gaps and priorities for future research. The first 
study of this thesis (Objective 1, Chapter 3) and the evidence published since its publication indicated 
how the control of transmission during outbreaks requires shifts in behaviour and a more robust 
community action plan model that includes partnership with the community since the outset of a crisis. 
Existing community knowledge, value systems, moral decision-making, structural barriers, local 
leadership, coping mechanisms influence how communities anticipate, adapt to diseases and contribute 
to mitigate the impact of the outbreak. Future research is needed to evaluate how populations’ 
interactions with control measures can lead to an interdependent solution. Incorporating local 
knowledge and health priorities will allow designing interventions that are authentic and culturally 
relevant, ultimately informing a more equitable and inclusive model of public health interventions. The 
study also identified a need to develop novel sampling methods that are appropriate for estimating 
mortality for highly clustered diseases. 
 
The second study of this thesis (Objective 2, Chapter 4) identifies important gaps related to the EVD 
case definition for the paediatric and pregnant population. Along with research to externally validate 
reviewed risk scores for Ebola virus infection; and to explore relationship between viraemia and 
symptoms at admission. Furthermore, the study highlights the need to use consistent thresholds for 
fever. 
 
The third study of this thesis (Objective 3, Chapter 5) prompt reflection on the utility of using 
retrospective mortality studies to generate robust estimates for highly clustered diseases such as EVD. 
Possible limitations on sampling model for clustered diseases were suggested from data gathered in 
Objective 1, but further elaborated using empirical data collected in Objective 3. Future studies should 
assess the validity of alternative survey methods when measuring clustered diseases to inform response. 
 
6.4 Conclusion   
	
This thesis highlights that community plays a critical role on EVD control by influencing transmission 
dynamics, uptake of control measures, performance of case definition, and death reporting. Mitigation 
of risks will require a respectful and compassionate approach to affected households and an 
understanding of social norms and experiences and will link these to localised strategies to adapted 
community-lead health interventions. EVD control is the outcome of a chain of trust from local 
communities towards public health, which requires a synergistic model of public health in close 




and identified additional areas of operational research to improve practises during outbreak response 
and benchmark the disease burden.  
 
Finally, the research presented in this thesis and field work informed the development of the MSF-OCA 
Community Guidance on COVID-19 response and the Covid-19 qualitative study conducted in Sierra 
Leone, which are a first step toward a more synergistic model of close partnering with community that 
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Abstract
Background: Little is understood of Ebola virus disease (EVD) transmission dynamics and community compliance
with control measures over time. Understanding these interactions is essential if interventions are to be effective in
future outbreaks. We conducted a mixed-methods study to explore these factors in a rural village that experienced
sustained EVD transmission in Kailahun District, Sierra Leone.
Methods: We reconstructed transmission dynamics using a cross-sectional survey conducted in April 2015, and
cross-referenced our results with surveillance, burial, and Ebola Management Centre (EMC) data. Factors associated with
EVD transmission were assessed with Cox proportional hazards regression. Following the survey, qualitative semi-
structured interviews explored views of community informants and households.
Results: All households (n = 240; 1161 individuals) participated in the survey. 29 of 31 EVD probable/confirmed cases
died (93·5% case fatality rate); six deaths (20·6%) had been missed by other surveillance systems. Transmission over five
generations lasted 16 weeks. Although most households had ≤5 members there was a significant increase in risk of
Ebola in households with > 5 members. Risk of EVD was also associated with older age. Cases were spatially clustered;
all occurred in 15 households.
EVD transmission was better understood when the community experience started to concord with public health
messages being given. Perceptions of contact tracing changed from invading privacy and selling people to ensuring
community safety. Burials in plastic bags, without female attendants or prayer, were perceived as dishonourable.
Further reasons for low compliance were low EMC survival rates, family perceptions of a moral duty to provide care to
relatives, poor communication with the EMC, and loss of livelihoods due to quarantine. Compliance with
response measures increased only after the second generation, coinciding with the implementation of restrictive by-
laws, return of the first survivor, reduced contact with dead bodies, and admission of patients to the EMC.
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Conclusions: Transmission occurred primarily in a few large households, with prolonged transmission and a high death
toll. Return of a survivor to the village and more effective implementation of control strategies coincided with increased
compliance to control measures, with few subsequent cases. We propose key recommendations for management of EVD
outbreaks based on this experience.
Keywords: Ebola virus disease, Transmission dynamics, Community perception
Background
The first case of Ebola virus disease (EVD) in Sierra
Leone is believed to have occurred in mid-May 2014, in
a remote village of Kailahun District (estimated popula-
tion 465,048) [1, 2]. On 12th June 2014, the President of
Sierra Leone declared a state of emergency in the district
[3]. The last case was recorded in Kailahun in mid-
December 2014 and the Ministry of Health and Sanitation
(MoHS) declared Kailahun District free from human-to-
human transmission on 22nd January 2015, following 42
continuous days without a confirmed case [1]. Médecins
sans Frontières (MSF) opened an Ebola Management
Centre (EMC) in Kailahun on 26th June 2014 to support
the district MoHS [4]. The MSF EMC was the only func-
tioning Ebola management centre in the district, respon-
sible for isolating 63·0% of confirmed cases. In total, the
district MoHS reported 565 confirmed EVD cases in the
population of Kailahun (attack rate 0·12%), including 287
deaths (case fatality rate [CFR] 51·0%) [5].
Evidence-based interventions for EVD control include
early detection of cases through effective surveillance
and contact tracing, admission of symptomatic cases to
EMCs where staff adhere to high standards of infection
control procedures, and safe burials by trained teams
[6, 7]. Quarantine measures were also widely imple-
mented [8], and by-laws imposed that included travel re-
strictions and penalties for hiding suspected cases [9].
The transmission dynamics of the West Africa EVD epi-
demic have, so far, been reconstructed from EMC and sur-
veillance data, and mathematical modelling [4, 10–12].
However, poor surveillance systems and limited EMC cap-
acities are likely to have resulted in underestimation of the
true extent of the outbreak, limiting the ability to under-
stand the dynamics and experience of the epidemic at
community level, in particular in Sierra Leone, the country
most affected by the West Africa EVD outbreak [13, 14].
Little is known of the factors that influence EVD trans-
mission dynamics and community compliance with con-
trol measures over time. Such understanding is essential if
interventions are to be effective, particularly in areas like
Sierra Leone with no previous local EVD experience. In
order to address this knowledge gap and inform future re-
sponses, we conducted an in-depth mixed-methods study
in a rural village in Kailahun District that experienced pro-
longed EVD transmission during the outbreak.
Methods
To enable assessment of behaviour adaptation over time,
we used data from MSF EMC patient registers to select a
village in the district that had experienced a very pro-
tracted EVD outbreak. We then conducted a mixed-
methods study combining data gathered via a cross-
sectional survey and semi-structured interviews in this
selected village. The cross-sectional survey data were
used to reconstruct the dynamics of transmission. Semi-
structured interviews were used to document commu-
nity perception, resistance, and adaptation to response
strategies. Survey and interview data were triangulated
with data from the safe burial and MoHS surveillance
databases to verify the reconstruction of the EVD trans-
mission, and explain changes in transmission and behav-
iour over time.
Cross-sectional survey
All consenting households in the village were included
in the cross-sectional household survey. A trained MSF
team, using a validated instrument for household
mortality studies and EVD case investigation forms, col-
lected demographic data from household heads on
household members, births, arrivals, departures, deaths,
illnesses (including signs and symptoms compatible with
the EVD case definition), and history of contact with in-
dividuals symptomatic for EVD [15, 16]. Verbal consent
for participation was obtained from the head of each
household after a briefing about the aim of the survey,
the questions and duration of the questionnaire, and the
option to end the interview at any time if wished.
The household survey was conducted in April 2015,
with a recall period for responses between May 2014
(date of the first reported EVD case in the district) and
the date of the survey. A local events calendar was de-
veloped to aid recall. MSF-EMC patient registers were
used to verify the date of admission, symptoms, labora-
tory confirmation of EVD, and outcomes of patients ad-
mitted to the EMC. Each household in the village was
enumerated and listed; from this list we randomly se-
lected the households for the semi-structured interview.
Geographic positioning system (GPS) data were used
to map the village layout and location of all households.
Data were de-identified and entered into a password-
protected electronic database.
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Semi-structured interviews
At the end of the cross-sectional survey, semi-structured
interviews were conducted with key community infor-
mants and selected households. Households were di-
vided into two groups based on whether they had
experienced at least one EVD case or no EVD cases.
Ten households were randomly selected for interview
from each group (total of 20 interviews).
A purposive approach was used to select key commu-
nity informants: traditional healers; biomedical health-
care providers; and community leaders including tribal
authorities, heads of community groups, and religious
leaders. The heads of the selected households and key
community informants were interviewed after verbal
consent to participate was obtained. Participants were
briefed about study objectives, questions and duration of
interview, and the option to leave the study at any time.
All interviews were semi-structured, took place in a pri-
vate space, and were conducted by a trained MSF team.
Interviews were conducted in the local language using
an interpreter to translate and back translate to English.
The local events calendar developed for the household
survey was also used in the semi-structured interviews.
Topic guides directed interviewers to explore changes
over time in perceptions of EVD and perspectives re-
lated to EVD response activities including contact tra-
cing activities, the MSF EMC, the safe burial team, and
quarantine. Interviews explored how these EVD control
strategies were implemented and how these accorded
with cultural beliefs. The topic guide was the same for
household and key informant groups except for an add-
itional section in the key informant guide, regarding
how the outbreak started in the village. After initial data
analysis had been completed, a summary narrative was
compiled and shared with the village in the format of a
story. Participant validation was achieved in this way in
order to refine findings [17].
Case definitions
World Health Organization (WHO) EVD case defini-
tions were used to define suspect, probable, and con-
firmed cases [16]. A suspect case was defined as: any
person, alive or dead, suffering or having suffered from
sudden onset of high fever and having had contact with
a suspect, probable, or confirmed EVD case or with a
dead or sick animal; any person with sudden onset of
high fever and at least three relevant symptoms (head-
aches, vomiting, anorexia/loss of appetite, diarrhoea,
lethargy, stomach pain, aching muscles or joints, difficulty
swallowing, breathing difficulties, hiccup); any person with
inexplicable bleeding; or any sudden, inexplicable death. A
confirmed case was defined as anyone with a positive
quantitative reverse transcription polymerase chain reac-
tion (PCR) result. PCR cycle threshold (Ct) results were
used as indicators of viral load. The lower the Ct value the
higher the viral load [18]. A probable EVD case was de-
fined as anyone who met the clinical case definition and
had a history of contact with a person with confirmed
EVD, but who did not have a confirmed laboratory
test result [16].
Data analysis
Cox proportional hazards regression models were fitted
to estimate hazard ratios (HRs) and 95% confidence in-
tervals (95% CI) for the association between EVD (prob-
able and confirmed cases) and covariates previously
documented to be associated with EVD, including
household size, sex, and age [19, 20]. Events were dated
by epidemiological week and used as the time parameter
in the Cox model. Cox shared frailty models were used
to allow for within-household correlation.
The crude mortality rate (CMR) and EVD-specific
mortality rate were estimated as deaths during
study period/(mid-period population at risk x dur-
ation of period), where mid-period population at
risk accounted for births, deaths, arrivals, and de-
partures during the recall period [21]. Mortality
rates were expressed as deaths per 10,000 per day.
The attributable risk percent (AR%) and population
attributable risk percent (PAR%) were used to esti-
mate excess mortality risk due to EVD in the ex-
posed households and village level, respectively.
The proportion of EVD cases isolated by admission to
the EMC and the proportion of people who died from
EVD and received safe burial were assessed by compar-
ing cases reported in MoHS surveillance, EMC, and bur-
ial team data with cases (confirmed and probable)
identified through the household survey.
Transmission dynamics were constructed using con-
tact history, and described using transmission chains.
Relationships between individuals were categorised as
nuclear (immediate family), extra nuclear (extended fam-
ily), and social (neighbours and friends).
Statistical analyses were carried out using Stata 14.0
(Stata Corporation, Texas-USA); maps were generated
using QGIS™ software (version 2.14, https://qgis.org/en/
site/). Participant responses from all semi-structured in-
terviews were translated and transcribed at the time of
the interview. Key community informants and household
interview data were analysed separately using an induct-
ive framework approach via an iterative process of cod-
ing and categorization (using ©NVivo 10) leading to the
identification of emerging themes. The former contrib-
uted to the description of initial phase of the outbreak
along with documenting the village experience over
time, and the latter to exploring affected and unaffected
household experience.
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Results
Study population
The village consisted of 240 households (1161 individ-
uals); all heads of households gave consent to partici-
pate. The median age of villagers was 18 years
(interquartile range [IQR] 7–34 years), with 44·4% (n =
515) younger than 15 years old. Approximately half the
villagers were female (52·7%). Household size ranged
from 1 to 17 people, with a median size of 5 (IQR 3–6).
Transmission dynamics
Overall, 31 EVD cases (15 confirmed, 16 probable) were
identified, giving an overall attack rate in the village of
2·7%. The index case was an adult male who was resi-
dent in a city that was a known EVD hotspot in June–
July 2014. In late July 2014, while symptomatic, he
travelled back to his village of origin and died 1 week
after his return. Table 1 details the possible routes of
EVD transmission that were reported by his household
and key informants. There was no record of the index
case being tested for EVD, although he was reportedly
taken to a holding centre for testing.
Following death, the index case was buried in an un-
safe manner by community members, many of whom
had unprotected contact with the body. It is believed
that this may have started the chain of person-to-person
transmission in the village. Transmission lasted for
16 weeks, with 30 cases arising over five transmission
generations: 11 cases in the 1st generation, seven in the
2nd, five in the 3rd, four in the 4th, and two in the 5th.
For the one remaining case, a traditional birth attendant,
a clear source of infection and transmission generation
was not established (Fig. 1). The time from exposure to
symptom onset was ≤2 weeks for all cases with
known exposure. The first survivor came back to the
village in week 35 (late August), after 7 weeks of
transmission, when most of the cases in the village
had already occurred.
Amongst the secondary cases with known exposure:
38·0% (11/29) had, as sole exposure, contact with a
symptomatic person who was a probable/confirmed
case; 10·3% (3/29) had a history of attending a funeral;
and almost half (14/29; 48·2%) had history of both con-
tact with a symptomatic person and a funeral exposure.
The proportion of cases exposed via a funeral decreased
over time from 90·9% (10/11) in the 1st generation to
71·4% (5/7) in the 2nd, 40·0% (2/5) in the 3rd, 25·0% (1/
4) in the 4th, and none in the last. Contact with a symp-
tomatic person increased from 72·7% (8/11) in the first
to 100·0% in the following generations. Among the 30 sec-
ondary cases, 28 died (93·3%) and two survived (6·7%).
There was strong evidence of clustering of EVD (p <
0·0001), with all cases occurring in 15 of the 240 house-
holds (Fig. 2). Thirty-two percent of cases occurred in
two households, in which cases occurred over three- and
four-generation chains.
Most secondary cases were exposed via the nuclear
(57·6%; 17/30) or extended family (30·0%; 9/30). Affected
households had a median of seven members (IQR 6–8),
and non-affected households a median of three (IQR
2–4) (p < 0·0001).
Factors associated with EVD
EVD was associated with older age and household size
in unadjusted analysis; these associations became stron-
ger after adjustment for both variables and sex (Table 2).
The rate of EVD was similar by sex (aHR 1·03; 95% CI
0·49–2·17 for females vs males), but was greater among
those aged 15–54 years (aHR 23·04; 95% CI 3·06–
173·12) and ≥55 years (aHR 57·28; 95% CI 7·03–466·33)
compared with those aged 5–14 years, and among those
living in larger (> 5 members) (aHR 56·53; 95% CI 19·64–
162·73) compared with smaller households (Table 2).
Mortality
Of the 31 cases (index case plus 30 secondary cases), 29
died (CFR 93·5%; 95% CI 78·6–99·2%). Thirteen of 15
confirmed cases and all 16 probable cases died. About
half (55·2%) of EVD deaths were among females; three
were pregnant and miscarried at home.
The community reported five non-EVD deaths during
the recall period. The CMR for all causes of death (EVD
and other) was 0·97 per 10,000 per day. EVD-specific
CMR was 0·83 per 10,000 per day and the non-EVD
CMR was 0·14 per 10,000 per day.
The AR% for death associated with EVD was 99·5%
(95% CI 98·6–99·8) among the exposed households,
while the PAR% for death associated with EVD in the
whole village was 84·5%.
Admission to the MSF EMC
In mid-August 2014, cases started to be admitted to the
EMC. Of the 31 cases, 15 were admitted to the EMC
and had Ebola infection confirmed by PCR testing.
Twelve cases had an exact date of symptom onset re-
corded, with a median time from first onset of symp-
toms to admission of 4·0 days (IQR 3–5). The median
time to admission was 5·0 days in the first generation
Table 1 Possible sources of infection for the index case
Contact with EVD patient(s) in the course of his work as a pharmacist
Contact with EVD patient(s) when he had a tooth extracted at a local
Government Hospital, which was, at that time, a major hotspot of EVD
Contact with a traditional healer, who reportedly came from Guinea to
treat the index case, who may have been infected
Contact with EVD patient(s) at a holding centre he was taken to for
testing because he was symptomatic following the tooth extraction
Unknown source of infection (e.g. community)
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(IQR 4–7), falling to 1·0 day in the last generation (IQR
0–1). The mean Ct value at admission was 21·8 (SD 4·5).
Among the confirmed cases at EMC, 12 (80·0%) pre-
sented at admission with at least one wet symptom
(diarrhoea, vomiting, or bleeding).
Burial, quarantine, and contact tracing
Of the 29 EVD deaths, 13 (44·8%) occurred within the
EMC; five deaths in the community then had a safe bur-
ial by the burial team. Six deaths (20·6%) were captured
during the survey but were not listed in the EMC,
MoHS surveillance system and/or safe burial database.
A further five people who died were reported by families
to have been transported to an MSF or local Govern-
ment hospital, however, there was no record of those
patients in the EMC database. Contact tracing was re-
ported to have occurred starting in late July; one in
five village households reported they had been under
contact tracing and quarantine measures. However, in
August 2014, when 18 secondary cases had already
occurred, the entire village was put under restriction
of movements.
Community perception, resistance, and adaptation to
response activities
Semi-structured interviews were conducted with 38 par-
ticipants: 10 households reporting EVD cases (affected
households (AH)), 10 households with no cases (UH),
and 18 key community informants (CI).
Introduction of EVD in the village
When discussing how EVD had been introduced to the
village, all participants referred to a single member or
index case in the family or community, ranging from a
family visitor to a health worker.
“The man [index case] brought Ebola here. He
used to treat people in [city] that was a hotspot
at the time. When he got sick, he came here to
see traditional healers and a herbalist came from
Guinea to treat him using traditional herbs.” –
(CI09_m)
“An ambulance came to collect him and take him to
[XX] holding centre. It was anecdotally reported that
he tested negative, so some relatives went to pick him
Fig. 1 EVD transmission generation, according to week of onset
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Fig. 2 Geographical distribution of cases over time, weeks 29 –week 45
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up. People were very happy, so they came to greet
him/celebrate.” - (CI04_m)
Misgivings toward Ebola
Initially, it was difficult for villagers to believe that infec-
tion could spread through everyday person-to-person
contact. This perception was compounded by a climate
of mistrust of authorities, fear of death, and lack of un-
derstanding of complex health messages such as the im-
portance of isolation of those infected.
“We had never seen a sickness like this before, where
you touch someone and you die.” - (CI12_m)
“It seemed like someone had poisoned our village;
many, many, many people died. It was similar to other
diseases [e.g. malaria].” – (CI16_m)
“We thought it was a curse; some people thought that
it was some kind of traditional medicine that was being
thrown on them.” - (CI13_f)
“People thought it was a conspiracy between the
President and the westerners, who needed blood.
They thought that if you go to the EMC, you will
die.” - (CI03_m)
“People didn’t believe it: like war, we didn’t believe it
could come here. There was lots of arguing - some
people thought Ebola wasn’t real. They thought it was
something sent by God.” - (CI04_m)
“People were hiding symptoms and deaths because
they were scared of the camp [EMC]; by the time they
were found and the ambulance called, they were
already dead.” - (CI11_m)
“Early on, people were hiding if they were sick. By the
time we knew they were sick, they weren’t alive long
enough to send them to the EMC (1-2 days).” - (UH05_m)
“We beat the contact tracers - we thought they were
responsible for our relatives’ deaths because they went
for training at the same time [end of July] XX [index
case] got sick.” - (CI16_m)
“At the start, people hated the contact tracers - they
beat them. One man in particular was beaten almost
to death.” - (CI17_f )
“The man [index case] came with a letter that said he
should be isolated for 21 days. But we didn't understand
what ‘isolation’meant.” - (CI16_m)
Change in perception
The perception of EVD held by the villagers changed
when information received from contact tracers and the
MSF health promotion team was consistent with what
villagers observed in their lives at the community level.
Implementation of the by-laws on travel and penalties
for not reporting cases supported the understanding of
the severity of the outbreak by villagers, and helped
them accept that control measures were intended to
protect and help the community.
“When we saw that people touched sick people and
got sick, we could see the communication of it and
realised that it is real.” - (CI13_f )







95% CI p Adjusted
hazard ratio





Male 549 13 (2·4%) ref ref ref
Female 612 18 (2·9%) 1·24 0·61–2·54 0·55 1·03 0·49–2·17 0·92 1·19 0·52–2·73 0·68
Age group (years)
< 5 174 4 (2·3%) 7·87 0·88–70·48 0·0001 6·02 0·66–54·39 < 0·0001 6·10 0·63–58·63 0·12
5–14 341 1 (0·3%) ref ref ref
15–54 552 18 (3·3%) 11·27 1·50–84·45 23·04 3·06–173·12 20·26 2·48–165·09 0·005




973 4 (0·4%) ref ref ref
> 5
members
188 27 (14·4%) 37·15 12·99–106·19 < 0·0001 56·53 19·64–162·73 < 0·0001 56·08 16·38–191·92 < 0·0001
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“Sensitisation from different sources [MSF/MoHS/
radio] started to make sense; symptoms in our loved
ones were exactly the same as they were telling us.” -
(CI11_m)
“We realised that no contact was good, after a while,
we saw the benefit.” - (CI15_m)
“But we had to follow the law we had to pay 500,000
Leones if there was a sick person found in the house.”
- (CI12_m)
“It was for our own safety - to avoid touching bodies.
To help them to stop the spread of Ebola. The word
‘safe’ equals ‘help’.” - (CI16_m)
Behaviour adaptation
Understanding of the route of transmission, and observ-
ing survival of cases admitted to the EMC supported
changes in behaviour and adaptation by the community.
This mainly occurred in late August coinciding with the
return of a survivor, reduced contact with dead bodies,
restriction of movements and isolation of patients.
“When we heard about people surviving people's
attitude changed.” - (CI03_m)
“We would go far away from the person and inform
contact tracers who will call an ambulance to remove
them to the camp [EMC].” - (UH04_f )
“Initially, it [burial team] was not good but when we
saw that the deaths increased, we knew it was for our
own safety.” - (AH02_m)
The village implemented a number of local measures
to prevent spread between households.
“During the outbreak, some people even devised their
own preventive measures, like stopping children from
playing football so they don’t have contact with each
other, and stop visit other households.” - (CI09_m)
“Traditional birth attendants stop doing deliveries.” -
(CI17_f )
Understanding control strategies and constraints
All strategies such us MSF/EMC, MSF health promo-
tion, contact tracing, burial practices, quarantine/re-
striction of movements were understood by the
community as helping to control EVD. However, re-
sistance to specific practices that were perceived as
offensive to socio-cultural norms was reported; this
resistance continued until the value of such practices
was understood.
MSF/EMC
The EMC was understood to help people survive:
“Without the camp [EMC] - we would have no survivors.”
- (CI04_m)
However, communication regarding the status of ad-
mitted patients was perceived as poor:
“We received no information while they were still
alive. When they died, a nurse who worked at the
camp [EMC] told us.” - (CI14_f )
“When the ambulance went with XX to the camp
[EMC], some family members went to visit and they
learned that he had died.” - (CI07_m)
The MSF health promotion team were perceived as
empowering the community:
“It gave the Community Health Workers a zeal to call
ambulances; they empowered us. They sensitised us
about preventive methods and no touch.” - (CI06_m)
“Helped to decrease cases.” - (CI12_m)
“We learned not to touch other people, and use water
and soap.” - (CI15_m)
Contact tracing
Contact tracing was perceived as a mechanism to re-
move people from the community who were thought to
be a risk, which initially created mistrust. This gave con-
tact tracers a reputation for invading privacy and dis-
rupting family and community life and sending people
to their deaths.
“There was no sensitisation about why contact tracers
were here. They would just call the ambulance and
collect people to the EMC.” - (CI01_m)
“We didn’t like the contact tracers; called them
murderers.” - (CI02_f )
“Invasion of privacy - it was not their business to
investigate our household.” - (CI04_m)
“We didn’t like the fact that they were involving
themselves in our affairs, we thought contact tracers
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were selling us to other people and that they were too
inquisitive.” - (CI17_f)
However, contact tracers were valued once people
understood that they were trying to protect people and
prevent the spread of Ebola:
“It is our culture to touch people when they are sick,
so if you don’t take people out of the village, people
will touch them.” - (CI11_m)
“Without contact tracers we would have continued
touching people. Instead, sick people were collected
to the camp [EMC].” - (CI16_m)
“Otherwise we would have far more deaths.” -
(CI14_f )
“Contact tracers should be empowered with training
to stop the spread.” - (CI13_f )
Burial practices
The value of safe burials was understood:
“Without the burial team, the disease would have
spread because touching dead bodies is bad.” -
(CI02_f )
However, burials were initially seen as lacking honour
in terms of how they were performed, specifically the
use of plastic bags, and the lack of burial clothes and
prayers. Respondents also commented on the lack of
women in the burial team and on the arrival of the
teams in the village already dressed in personal protect-
ive equipment (PPE).
“Plastic bags are not traditional - there is no honour
when you bury people this way.” - (CI03_m)
“Praying was not allowed.” - (CI09_m)
“Sometimes, in dreams, my husband appears and says
‘I have no clothes’.” - (AH06_f)
“Men burying women is not good; women should be
part of the burial team.” - (CI17_f )
“We weren't happy about it. Before the outbreak,
if a chief dies or a special person dies, they are
buried by other special people. Now, we can't do
that. There is no clothes, no dressing - and men
are burying women, which is a problem for us.” -
(CI11_m)
“People were afraid of the burial team when they
came dressed in full protective clothes. They thought
they were ghosts.” - (CI03_m)
In October, the burial procedures were improved to
incorporate greater respect for local tradition:
“We couldn’t pray before, either, but now we can.” -
(CI03_m)
“Now they [burial team] dress in protective clothes in
the village.” - (CI11_m)
Quarantine/restriction of movements
The community understood the value of quarantine:
“Because of quarantine, we couldn't spread Ebola to
other households.” - (AH07_m)
However, people were also angry about quarantine:
“It destroyed many things, especially farming, our
crops were destroyed and there is no food available
now.” – (CI15_m)
In September, quarantine measures were improved by
incorporation of food supply to quarantined households:
“We had no food at the start. They should have given
us food like they did in other households at the end.”
- (AH06_f)
Affected versus unaffected households
Both affected and unaffected households were sensitive
to law enforcement and were in favour of stricter
methods to control Ebola in the future. The conse-
quences of quarantine, in terms of financial and emo-
tional impact and stigma, were harsher in affected
households compared with non-affected households,
since non-affected households were only directly im-
pacted when the entire village was quarantined.
“Seven members of my family were taken to EMC.
They all died there. Everyone would yell at us, ‘you
brought Ebola here!’ I didn't - my brother did. But I
still felt guilty.” - (AH03_m)
Affected households provide some insight into factors
that led to continued transmission in some homes but
not in others, and why within-household transmission
continued even when between-household transmission
was reducing:
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“We could not abandon sick people – we must care
for [them].” - (AH05_f)
“People didn’t come around - it was like the devil was
here.” - (AH04_m)
Discussion
Our study provides a comprehensive description of EVD
in one village in Kailahun District, Sierra Leone that ex-
perienced sustained EVD transmission during 2014. We
attempt to capture the complexities of the social context
influencing outbreak control in this specific epidemic.
We documented that immediate family members of
large households were at greater risk of being infected,
and because of the larger number of inhabitants, these
households were more likely to maintain transmission.
This finding corroborates insights from other studies.
This may imply that future responses to an EVD out-
break could justify prioritization of affected large house-
holds and their immediate family members, in particular
when human resources are insufficient to address the
scale of the outbreak [19, 22].
Within affected households, transmission was main-
tained by the need to provide care for sick relatives, with
cases continuing to occur over several generations.
Compliance with response measures increased only after
the second generation, coinciding with the return of a
survivor, and strict implementation of other components
of the EVD response, such as restriction of movements,
reduced contact with dead bodies, and isolation of cases.
However, this changing context only occurred after
7 weeks of transmission, when most of the cases in this
outbreak had already died.
In particular, return of survivors to the village after
treatment prompted a shift toward belief in Ebola and
increasing acceptance of control measures. Late return
of survivors prevented teams from building trust within
the community. At the time that survivors returned, the
village was experiencing a peak in case numbers, the
MSF EMC was reaching the limit of its capacity (100
beds), and communication with households was primar-
ily to inform of deceased loved ones, thus contributing
to community fear and despair. People reported avoiding
the MSF EMC because of poor survival rates, which re-
inforced the community perception of the EMC as a
place where people die. One approach to improving
community understanding and uptake of EMC services
in future could include developing the role of an EMC-
village liaison, whose role would be to support timely
communication with communities about the status of
relatives throughout admission. Use of EMC-village liai-
sons could acknowledge the gap in understanding of
health system workers as to why patients may
undermine control measures when faced with the need
to look after their loved ones. Contact tracers could po-
tentially play this liaison role, and therefore have the po-
tential to be seen as providing something positive to the
community rather than just reporting and tracing cases.
Reduced misgivings and doubt about Ebola were cru-
cial to influencing attitudes toward control measures.
This change likely occurred once the health messages
given to the community mirrored their reality. Once
Ebola transmission was understood, the perceptions of
contract tracing changed from invading privacy, selling
people, to working collectively toward community safety.
The community then participated in control measures
by setting up a number of local strategies such as stop-
ping babies being delivered in the community, prevent-
ing children from playing contact games together, and
not visiting other households. These strategies contrib-
uted to outbreak control, as observed by other authors
[23]. Our findings emphasised the importance of the
community having a role in tailoring outbreak responses.
Following a localised governance approach may permit
incorporation of accepted local social norms from the
outset of intervention efforts, making them more accept-
able and therefore effective.
Clear communication of complex health messages was
challenging, but played a role in the acceptance of EVD
control measures. It was essential that the community
understood there was a 21-day incubation period, the
importance of EMC isolation (both self-imposed and in-
stitutional), and that a single negative test result could
not rule out disease during the incubation period. Other
authors described similar issues for messaging in Sierra
Leone and in previous outbreaks [24, 25].
Similar to the rest of the country, the age structure of
the village was young, with those under age 15 account-
ing 44% of the population. The limited life experience of
youth, and particularly collective experience with death
from exposure to body fluids (e.g. “touch someone and
you die”) or with infection prevention and control con-
cepts (e.g. “we didn't understand what 'isolation' meant”)
may have contributed to delays in understanding and
adoption of the necessary responses, rather than villagers
being deliberately uncooperative. However, we docu-
mented that regardless of age, the population in general
suffered an overwhelming level of inexperience toward
this disease and its impact. Response agencies must
acknowledge community demographic structure and
perspectives on the presence of EVD in parallel with
launching control measures cognisant of their baseline
understanding.
Our study findings show nuanced perceptions toward
quarantine as both a way to control the spread of Ebola
and a cause of social and livelihood disruption, which chal-
lenged compliance, as reported by other researchers [26].
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This argues for such social disruption to be taken
into account when planning how best to protect af-
fected people and control transmission.
Safe burial using plastic bags, lack of burial clothes,
and the absence of women in the burial team were de-
scribed as showing a lack of honour for the deceased.
Burials were described as being more compliant to con-
trol measures when practices such as community prayer
were permitted. In addition, the burial team started to
dress in PPE after arrival in the village as now recom-
mended by WHO Guidelines [27]. Additional measures
that can be implemented without compromising safe
burial, such as including female members in the burial
team, and safe alternatives to plastic burial bags, would
further enhance community acceptance compliance, and
should be included in EVD control guidelines.
The comprehensive design of this study enabled every
household in the village to be surveyed, and therefore a
number of deaths were captured by our survey that were
not identified by MOHS surveillance, EMC, or burial
data. All cases and deaths detected were spatially clus-
tered; this is a key finding since traditional methods to
estimate mortality rely on cluster sampling approaches,
which in this case could have generated either an under-
or over-estimation of EVD, depending on whether the
limited number of affected households was randomly se-
lected. This is an important element to take into account
while trying to benchmark the burden of highly clus-
tered diseases like EVD. Even in a highly affected com-
munity, clustering of disease means that household
sampling is likely to miss many households unless an ap-
propriate estimate of intra-cluster correlation is avail-
able. It is noted that it would not have been feasible to
carry out exhaustive studies on the wider population in
the middle of the EVD outbreak. In future, we recom-
mend developing alternative methods of sampling to es-
timate disease and mortality that account for the highly
clustered nature of diseases such as EVD.
Strengths and limitations
A major strength of this study is its mixed methods de-
sign, which provides a deeper understanding and explan-
ation of the social reactions to dealing with EVD at
community level. Half of the EVD cases in this study
were not confirmed by PCR. However, they met the sus-
pected case definition, died, had clear epidemiological
links with a confirmed case, and some generated second-
ary cases, some of which were confirmed EVD. The
number of deaths may have been under-reported, as vil-
lagers may have feared a penalty for not adhering to the
mandatory notification by-law. However, it should also
be noted that the study was well perceived by villagers,
as demonstrated by the participation of the entire village,
their help in documenting the transmission chains, and
their willingness to tell the story of the village outbreak.
We cannot exclude underestimation of the burden of
EVD infection in the village by missing mild or asymp-
tomatic cases. We also collected data on morbidity at
the time of the outbreak, and three living people re-
ported history of symptoms compatible with EVD, and a
history of exposure, but they were never tested or iso-
lated and thus not included in the analysis. If they were
true cases, our EVD mortality may be overestimated,
however, when we did include these cases in the analysis
it did not change our findings significantly. The true
EVD infection rate could be known only via a sero-
logical study [28].
Incorrect recall of the timing of deaths may have oc-
curred, but the impact of Ebola makes this less likely,
and the use of a local community calendar of events
aided recollection of timing. In addition, we validated
dates and symptoms for cases admitted to the Kailahun
EMC, MOHS surveillance, and buried by the burial
team. We were able to rebuild accurate dates for the
events of each case we identified, validated across mul-
tiple data sources.
For the qualitative part of the study, we acknowledge
it was more difficult to definitively link community
behaviour change with specific measures or events.
Furthermore, we recognise that those are reported per-
ceptions recollected at the time of the outbreak, how-
ever, these were consistent among the different people
interviewed and suggested a shift in the way the com-
munity expressed their ideas of EVD. We acknowledge
that perception of changes in the village may have been
influenced by the differing roles played by community
informants, and in relation to the differing experiences
of affected vs. unaffected households.
It is also important to note that our observations were
based on a single, high-burden village. Our findings are
therefore likely to be generalizable to similar rural set-
tings with high levels of transmission. However, it is pos-
sible that the outbreak and response would be different
in villages with lower levels of transmission, as experi-
ence of the disease was an important driver of behav-
ioural change.
Finally, the main limitation of our qualitative work was
that questions regarding burial practices seemed to pro-
voke a limited depth of response in particular among
affected households. This may have been because re-
spondents were still affected by their loss.
Conclusion
In this high-burden village, transmission was maintained
by a small number of large households; the outbreak was
controlled in this community only after prolonged trans-
mission and a high death toll. A key recommendation
emerging from these findings is to ensure that large
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households and immediate family members are priori-
tized in control and prevention activities. There is also a
need to develop novel sampling methods appropriate
for estimating mortality for highly clustered diseases
like EVD.
Our findings provide practical information on how
future interventions could be implemented more hu-
manely and effectively. We emphasise the following fac-
tors: recognising the role of communities for their
contribution in controlling outbreaks; identifying com-
munity liaison roles which can keep families informed of
their relatives’ progress in the EMC; ensuring survivors
are engaged to increase community trust to delegate
care to EMCs; conveying complex health messages
around incubation periods and infectivity clearly to the
community; using appropriate alternatives to burial in
plastic bags; including women in burial teams; and com-
pensating quarantined households and communities to
ensure they can maintain and re-establish livelihoods.
Factors underlying delays in implementing control
measures included community belief or otherwise in the
presence of EVD, lack of trust, and the toll imposed by
interventions such as safe burial procedures and the so-
cial disruption of quarantine. Early understanding of so-
cial norms and experiences and the ability to link this to
localised strategies and adapted health interventions
would be essential.
Including these findings in future recommendations
for outbreak control policy could help to improve the
accuracy of mortality estimates and avoid unnecessary
deaths and protracted suffering in future outbreaks.
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Summary
Background Ebola virus disease case definition is a crucial surveillance tool to detect suspected cases for referral and 
as a screening tool for clinicians to support admission and laboratory testing decisions at Ebola health facilities. We 
aimed to assess the performance of the WHO Ebola virus disease case definitions and other screening scores.
Methods In this systematic review and meta-analysis, we searched PubMed, Scopus, Embase, and Web of Science for 
studies published in English between June 13, 1978, and Jan 14, 2020. We included studies that estimated the 
sensitivity and specificity of WHO Ebola virus disease case definitions, clinical and epidemiological characteristics 
(symptoms at admission and contact history), and predictive risk scores against the reference standard (laboratory-
confirmed Ebola virus disease). Summary estimates of sensitivity and specificity were calculated using bivariate and 
hierarchical summary receiver operating characteristic (when four or more studies provided data) or random-effects 
meta-analysis (fewer than four studies provided data).
Findings We identified 2493 publications, of which 14 studies from four countries (Sierra Leone, Guinea, Liberia, and 
Angola) were included in the analysis. 12 021 people with suspected disease were included, of whom 4874 were 
confirmed as positive for Ebola virus infection. Six studies explored the performance of WHO case definitions in non-
paediatric populations, and in all of these studies, suspected and probable cases were combined and could not be 
disaggregated for analysis. The pooled sensitivity of the WHO Ebola virus disease case definitions from these studies 
was 81·5% (95% CI 74·1–87·2) and pooled specificity was 35·7% (28·5–43·6). History of contact or epidemiological 
link was a key predictor for the WHO case definitions (seven studies) and for risk scores (six studies). The most 
sensitive symptom was intense fatigue (79·0% [95% CI 74·4–83·0]), assessed in seven studies, and the least sensitive 
symptom was pain behind the eyes (1·0% [0·0–7·0]), assessed in three studies. The performance of fever as a 
symptom varied depending on the cutoff used to define fever.
Interpretation WHO Ebola virus disease case definitions perform suboptimally to identify cases at both community 
level and during triage at Ebola health facilities. Inclusion of intense fatigue as a key symptom and contact history 
could improve the performance of case definitions, but implementation of these changes will require effective 
collaboration with, and trust of, affected communities.
Funding Médecins sans Frontières.
Copyright © 2020 Elsevier Ltd. All rights reserved.
Introduction
Ebola virus disease case definition is a crucial surveillance 
tool to detect suspected cases for referral and as a 
screening tool for clinicians to support admission and 
laboratory testing decisions at Ebola health facilities. 
However, there have been long-standing concerns about 
the poor performance of the WHO Ebola virus disease 
case definitions, including the inability to distinguish 
Ebola virus disease from common diseases such as 
malaria and typhoid fever.1–3
The scale of the 2014–16 west African Ebola epidemic 
further challenged the operational use and validity of the 
WHO case definitions in detecting suspected cases at the 
community level and allocating patients appropriately to 
high-risk or low-risk wards for testing at specialised isolation 
centres.4 Consequently, during and since this epidemic, 
organisations involved in the Ebola virus disease response 
have estimated the sensitivity and specificity of the WHO 
case definitions and its constituent symptoms and signs, 
and developed alternative definitions and risk scores to identify 
clinical and epidemiological factors that could predict 
infection under outbreak conditions.5,6 Discordance on the 
use of WHO Ebola virus disease case definitions with 
consequent delay on outbreak control and community 
disengagement have been reported in west Africa and, in 
the current outbreak, in the Democratic Republic of the 
Congo along with its bordering countries.7–9
However, the operational use and performance of those 
definitions and risk scores has not been rigorously 
evaluated. Such an evaluation is needed to guide 
communities and public health practitioners to improve 
the effectiveness and efficiency of identification and 
management of suspected cases during Ebola virus 
disease responses.
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We aimed to assess the performance of the WHO Ebola 
virus disease case definitions and other clinical and 
epidemiological characteristics, such as symptoms and 
signs at admission and contact history, as the index test 
or test under assessment, against the reference standard 
of laboratory-confirmed Ebola virus infection.
Methods
Search strategy and selection criteria
For this systematic review and meta-analysis, we 
searched PubMed, Scopus, Embase, and Web of Science, 
without regional restrictions, for studies in English 
published between June 13, 1978 (when the first 
Ebola virus disease outbreaks were reported on), and 
Jan 14, 2020.10,11 We also endeavoured to capture data on 
the current outbreak of Ebola virus disease in the 
Democratic Republic of the Congo by contacting relevant 
people involved in the response.
 The search terms included “Ebola”, “EVD infection”, 
“case definition”, “admission symptoms”, “sensitivity”, 
“specificity”, “likelihood”, “score”, “classification”, “validity”, 
and “performance” (appendix pp 5–6).
We included observational retrospective studies that 
estimated the sensitivity and specificity of WHO Ebola 
virus disease case definitions and other clinical and 
epidemiological characteristics (symptoms and signs at 
admission and contact history) against the reference 
standard (laboratory confirmation of Ebola virus infection), 
and studies that developed, or externally validated, pre-
dictive risk scores (based on a combination of symptoms 
and signs, and epidemiological information) to predict the 
risk of being positive for Ebola virus. We also included 
studies looking at sensitivity and specificity of WHO case 
definitions for Ebola or Marburg virus infections because 
they belong to the same family of viruses (Filoviridae) and 
share the same case definitions, and the reference standard 
is laboratory confirmation of infection.12 We excluded 
studies on the sensitivity and specificity of diagnostic tests, 
animal and vaccine studies, studies of survivors of Ebola 
virus disease, and studies on predictors of outcomes or 
severity of Ebola virus disease, community surveillance, 
and outbreak and clinical management. Studies specifically 
on frequency of symptoms at admission were also excluded 
as a previous review exists.13
Two reviewers (GC and FT) independently screened all 
titles and abstracts to identify those meeting the selection 
criteria, and a third author (LI) arbitrated for studies 
without consensus. A full-text review was then done for 
these articles, and their bibliographies were assessed for 
other eligible studies. We extracted data on author, year of 
publication, country, virus, period of data collection, study 
design, study objective, outcomes measured, setting in 
which data were collected (eg, Ebola treatment centres), 
age of population included in the study, study size 
including number of patients who were negative and 
positive for Ebola virus, diagnostic method, limitation of 
Research in context
Evidence before this study
There have been long-standing concerns about the poor 
performance of WHO case definitions for Ebola virus disease, 
including their inability to distinguish Ebola virus infection 
from common tropical diseases. We did a systematic search of 
the scientific literature using PubMed, Scopus, Embase, and 
Web of Science, without regional restrictions, for research 
articles published in English between June 13, 1978, and 
Jan 14, 2020. We used the search terms “Ebola”, “EVD infection”, 
“case definition”, “admission symptoms”, “sensitivity”, 
“specificity”, “likelihood”, “score”, “classification”, “validity” and 
“performance”. We also contacted relevant experts. We found 
that different organisations have attempted to assess the 
performance of WHO Ebola case definitions and developed 
alternative definitions and risk scores. However, there has been 
no systematic and rigorous evaluation of those studies. Such an 
evaluation is needed to guide communities and public health 
practitioners to improve the effectiveness and efficiency of 
identification and management of suspected cases during an 
Ebola virus disease outbreak.
Added value of this study
To our knowledge, this study is the first systematic review and 
meta-analysis that assesses the performance of the WHO 
Ebola virus disease case definitions, and other clinical and 
epidemiological characteristics such as symptoms and signs at 
admission and contact history, against the reference standard 
(laboratory confirmation of Ebola virus infection). Our analysis 
provides the most comprehensive evidence on the limitations of 
WHO case definitions and its constituent symptoms and signs, 
and predictive risk scores. We show that the WHO case definitions 
perform suboptimally to identify cases at both the community 
level and during triage at general and specialist health facilities. 
The performance of fever as a symptom varied depending on the 
cutoff used to define fever. The most sensitive symptom was 
intense fatigue. History of contact was a key predictor for the 
WHO case definitions and for risk scores. This study identifies 
important gaps related to the paediatric and pregnant population 
and highlights the need to use consistent thresholds (eg, for 
fever) to explore viraemia and symptoms at admission, and to 
externally validate risk scores for Ebola virus infection.
Implications of all the available evidence
Inclusion of intense fatigue as a key symptom could improve 
the sensitivity, the primary requirement for community-based 
screening, of WHO and alternative case definitions. Inclusion of 
contact history will improve specificity, resulting in a lower 
number of false positives and thus a lower number of 
unnecessary admissions to Ebola health facilities. These 
improvements will contribute to reduced isolation from family, 
fear of being stigmatised, delay to appropriate care, and 
community mistrust in response activities.
See Online for appendix
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individual studies, and performance of the WHO Ebola 
virus disease case definitions, and individual symptoms 
and signs, and epidemiological links or contact history 
with known patients with Ebola virus disease.
Performance data extracted included sensitivity, speci-
ficity, predictive values and risk score, and area under the 
receiver operating characteristic (ROC) curve (AUC). We 
developed a spreadsheet to compile extracted data based 
on the Cochrane data tool.14 The primary data extracted 
from each article were checked by a second researcher 
(FT). No protocol was developed for this study.
WHO Ebola virus disease case definitions were used to 
define suspected, probable, and confirmed cases, which 
varied by context and period of outbreak. In 2014 in 
Sierra Leone, WHO included miscarriage as an additional 
symptom (eg, abdominal pain) or sign (eg, vaginal 
bleeding) to the existing definitions.12,15 For paediatric 
populations, the modified WHO case definition used in 
Sierra Leone was evaluated (figure 1).15
Data analysis
We derived the numbers of true positive, false negative, 
true negative, and false positive cases in each study using 
data provided in each article for each symptom and sign, 
and WHO Ebola virus disease case definition. Sensitivity 
and specificity are correlated, and univariate measures 
of heterogeneity, such as I², are not suitable to report 
heterogeneity in diagnostic test accuracy reviews.16 We 
used bivariate and hierarchical summary ROC (HSROC) 
models for meta-analysis.17,18
The bivariate model provides estimation of a summary 
of sensitivity and specificity, whereas the HSROC model 
provides the estimation of a summary curve from studies 
that have used different thresholds, the 95% confidence 
region for the summary point, and the 95% prediction 
region. The prediction region graphically illustrates 
between-study heterogeneity as well as the bivariate 
relationship between sensitivity and specificity.19 Only 
studies that used comparable thresholds, symptoms 
and signs, or definitions were combined using these 
methods.
Given that HSROC models cannot be fitted when there 
are data from fewer than four studies, for some 
symptoms and signs we did a random-effects meta-
analysis to calculate pooled estimates for sensitivity and 
speci ficity.20 Compared with bivariate and hierarchical 
models, pooled estimation from random-effects meta-
analysis could slightly overestimate point estimation, so 
Figure 1: WHO Ebola virus disease case definitions for all ages and the paediatric population
Suspected Any person, alive or dead, suffering or having suffered
from sudden onset of high fever and having had contact:
• a suspect, probable, or confirmed Ebola virus disease case
• with a dead or sick animal (for Ebola)
• a mine (for Marburg); 
OR 
any person with sudden onset of high fever and at least 
three of the following symptoms:
• headaches
• lethargy
• anorexia or loss of appetite








any person with inexplicable bleeding;
OR 
any sudden, inexplicable death
Any person having had contact with a clinical case 
and presenting with acute fever (>38°C); 
OR
having had contact with a clinical case 
(suspected, probable, or confirmed) and presenting 
with three or more of the symptoms below;
OR 
presenting with acute fever and presenting with 
three or more of the symptoms below:
• headache 
• nausea or vomiting 
• loss of appetite
• diarrhoea
• intense fatigue 
• abdominal pain
• generalised or articular pain 
• difficulty in swallowing








Any child with fever and either 
one symptom (in children younger 
than 5 years), two symptoms (in 
children aged 5–12 years), or more 
than three symptoms (in children 
older than 12 years); for children 
younger than 1 years old, maternal
history is very important 
WHO case definitions (August, 2014) all ages12 Late 2014 WHO case definition for 
paediatric population in Sierra Leone15
WHO case definition (December, 2014) all ages 
in Sierra Leone15
Confirmed Any suspected or probable cases with a positive laboratory 
result; laboratory-confirmed cases must test positive for 
the virus antigen, either by detection of virus RNA by 
RT-PCR, or by detection of IgM antibodies directed against 
Marburg or Ebola
Any person with a positive PCR test for Ebola or 
Marburg virus
Any person with a positive PCR test for 
Ebola or Marburg virus
Probable Any suspected case evaluated by a clinician; 
OR 
any deceased suspected case (where it has not been 
possible to collect specimens for laboratory confirmation) 
having an epidemiological link with a confirmed case
A suspect case that is known to have had contact 
with a known case (suspected, probable, or 
confirmed);
OR 
any person who is, on clinical or epidemiological 
grounds, very likely to have Ebola or Marburg
Not further specified
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estimates from the random-effects model are provided 
for completeness.
We summarised, without any further re-analysis, studies 
that developed or externally validated risk scores for 
predicting Ebola virus infection. Scores were used to 
identify individuals with a higher or lower risk of Ebola 
virus infection during screening at Ebola health facilities. 
To obtain the risk scores, these studies used the regression 
coefficients of independent risks obtained by multivariable 
logistic regression against Ebola virus infection and then 
converted regression coefficients into an integer-based 
point-scoring system. Reviewed studies assigned positive 
and negative risk scores with calculated AUC to epide-
miological, demographic, and clinical characteristics. 
Positive values indicated higher risk of Ebola virus 
infection and negative values indicated higher risk of 
another infection such as malaria or typhoid.
Values assigned to the risk score varied by study; 
therefore, a meta-analysis of risk scores was not done, 
but instead evidence was systematically reviewed. For 
comparability, we reclassified the risk scores reported in 
the included studies into categories, from very low risk to 
very high risk (appendix p 7). STATA 15 was used for 
statistical analysis.
PRISMA guidelines for Diagnostic Test Accuracy 
Studies (PRISMA-DTA) were followed (appendix pp 2–4).21
Role of the funding source
GC, KL, AS, and JG were employed by the funder, and 
participated in planning the study, carrying out the 
research, and writing the report. The funder of the study 
had no further role in study design, data collection, data 
analysis, data interpretation, or writing of the report. The 
corresponding author had full access to all the data in the 
study and had final responsibility for the decision to 
submit for publication.
Results
Of the 2493 studies initially screened using the article title, 
143 were deemed to be potentially eligible on the basis of 
the abstract, and their full-text articles were assessed. Of 
these studies, 18 met the inclusion criteria, but three were 
excluded because data on sensitivity and specificity could 
not be extrapolated (appendix p 8). One was excluded 
because it is yet unpublished (FG). Of the 14 included 
studies, 11 were full manuscripts,5,6,22,24,25,27,29–33 one a letter,28 
one an oral plenary abstract,26 and one a conference poster23 
(the author of this poster was also contacted and they 
provided an abstract with additional data [Kuehne A, 
Epicentre, Paris, France, personal communication]; table 1). 
13 studies were published between 2015 and 2019 and 


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 2: HSROC summary of sensitivity and specificity
HSROC=hierarchical summary receiver operating characteristic.
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(seven in Sierra Leone,5,6,25,26,30,32,33 four in Guinea,24,27,28,31 and 
two in Liberia23,29). The remaining article was published in 
May, 2010, assessing Marburg virus in Angola.22
Overall, 12 021 people with suspected disease were 
included, of whom 4874 were confirmed as positive for 
Ebola virus infection. Study populations varied from 
75 to about 2847 (table 1). All studies, apart from the 
national surveillance study, included patients who 
presented alive to health facilities for assessment. The 
national surveillance study included all cases (suspected, 
probable, and confirmed), including patients both alive 
and deceased, identified in both the community and 
health facilities. Eight studies’ data were from single 
Ebola treatment centres,23,27–33 with the remaining using a 
national surveillance list,24 three from Ebola holding 
units,5,25,26 and two from hospitals screening patients for 




Huizenga et al (2019)6 WHO definition, with the difference 
that fever with sudden onset is not a 
mandatory criterion
100·0% 42·5%* 2·4%* 100·0%
Fitzgerald et al (2017)26 Contact alone, fever (in children 
older than 2 years) OR fever and 
conjunctivitis (in children younger 
than 2 years)
94·0%* 35·0%* Not provided Not provided
Roddy et al (2010)22 Epidemiological link or a 
combination of myalgia or arthralgia 
and any haemorrhage
79·0% (64·0–91·0) 73·0% (60·0–84·0) Not provided Not provided
Loubet et al (2016)31 WHO subdefinition 2 (temperature 
≥37·5°C plus risk factor†)
75·0% (63·5–83·9) 62·3% (49·8–73·5) Not provided Not provided
Roddy et al (2010)22 WHO case definition (clinical criteria 
only‡)
73·0% (57·0–86·0) 43·0% (30·0–56·0) Not provided Not provided
Roddy et al (2010)22 Fever plus three or more symptoms§ 68·0% (52·0–82·0) 46·0% (33·0–59·0) Not provided Not provided
Loubet et al (2016)31 Temperature ≥38·5°C plus risk 
factor†
68·4% (56·6–78·3) 82·6% (71·2–90·3) Not provided Not provided
Arranz et al (2016)30 Contact and three symptoms§ 67·7% (51·3–84·2) 81·8% (70·4–93·2) 72·4% (56·1–88·7) 78·3% (66·3–90·2)
Loubet et al (2016)31 WHO subdefinition 3 (temperature 
≥37·5°C plus clinical symptoms§)
67·1% (55·2–77·2) 76·8% (64·8–85·8) Not provided Not provided
Loubet et al (2016)31 WHO subdefinition 1 (risk factor plus 
clinical symptoms§)
63·2% (51·3–73·7) 66·7% (54·2–77·3) Not provided Not provided
Lado et al (2015)5 Three or more major symptoms¶ 57·8% (52·1–61·4) 70·8% (64·7–76·4) 77·9% (73·1–82·3) 47·5% (42·3–52·7)
Arranz et al (2016)30 Fever and three symptoms§ 58·1% (40·7–75·4) 50·0% (35·2–64·8) 45·0% (29·6–60·4) 62·9% (46·8–78·9)
Hsu et al (2018)24 Clinical criteria§ 57·2%* 62·0%* 66·4%* 52·5%*
Ingelbeen et al (2017)27 WHO case definition (clinical criteria 
only||)
56·9%* 46·4%* 36·3%* 66·8%*
Roddy et al (2010)22 Epidemiological link and two or 
more general symptoms§
54·0% (37·0–70·0) 91·0% (80·0–97·0) Not provided Not provided
Roddy et al (2010)22 Epidemiological link and three or 
more general symptoms§
54·0% (37·0–70·0) 93·0% (83·0–98·0) Not provided Not provided
Arranz et al (2016)30 Contact plus fever 48·4% (30·8–66·0) 77·3% (64·9–89·7) 60·0% (40·8–79·2) 68·0% (55·1–80·9)
Roddy et al (2010)22 Fever plus haemorrhage 44·0% (28·0–60·0) 72·0% (59·0–83·0) Not provided Not provided
Ingelbeen et al (2017)27 Three major signs** 27·7%* 79·1%* 41·5%* 67·2%*
Fitzgerald et al (2017)26 Contact, fever, and conjunctivitis OR 
contact, fever, anorexia, and two of 
abdominal pain, diarrhoea, or male 
sex (older than 2 years)
23·0%* 97·0%* Not provided Not provided
Kuehne et al (2015)23 History of contact, gastrointestinal 
symptoms†† and illness duration of 
>3 days
20·0%* 94·4%* Not provided Not provided
Hsu et al (2018)24 Unexplained death 14·2%* 92·8%* 72·0%* 45·2%*
*95% CI not provided in the original paper. †For example, being a health worker, have attended a funeral, and having contact with a relative suspect of having Ebola virus. 
‡Fever plus three other symptoms or fever and haemorrhage. §Symptoms or criteria not specifed in original paper. ¶Three or more symptoms among the following: intense 
fatigue, confusion, conjunctivitis, hiccups, diarrhoea, or vomiting. ||Acute fever and presenting three or more of the following: headache, anorexia or lack of appetite, 
lethargy, muscle or joint pain, breathing difficulties, vomiting, diarrhoea, stomach ache, difficulty swallowing, and hiccups; or any person with unexplained bleeding. 
**As proposed by Lado and colleagues.5 ††Diarrhoea, vomiting, and anorexia or loss of appetite.
Table 2: Sensitivity and specificity of WHO Ebola virus disease subdefinitions against reference standard of laboratory-confirmed Ebola virus infection, 
in decreasing order of sensitivity
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Ebola virus disease while still functioning as general 
health facilities.6,22 All studies covered distinct patient 
groups from different periods and geographical areas, 
except for two studies from Guinea.24,27 Although these 
two studies covered overlapping patient groups, they 
reported on different clinical and epidemiological 
characteristics (WHO case definition performance vs 
symptom performance).24,27
All selected manuscripts analysed all ages combined, 
except one author who assessed, in two different studies, 
the sensitivity and specificity of 2014 WHO Ebola case 
definitions and also developed a risk score specifically for 
the paediatric population (younger than 13 years).25,26
Six studies explored the performance of a WHO case 
definition in non-paediatric populations.5,22,24,29–31 In all of 
these studies, suspected and probable cases were combined 
and could not be disaggregated for analysis. The following 
results therefore apply to this combined group of suspected 
and probable cases. The pooled sensitivity was 81·5% 
(95% CI 74·1–87·2) and pooled specificity was 35·7% 
(28·5–43·6; figure 2). One study assessed WHO 2014 case 
definitions for a paediatric population (younger than 
13 years old); the sensitivity was 98·0% (95% CI 95·0–99·0) 
and specificity was 5·0% (3·0–7·0).25
When WHO subdefinitions were assessed, history of 
contact and symptoms had high specificity compared 
with clinical symptoms alone, ranging from 62·3% 
(95% CI 49·8–73·5) to 94·4% (95% CI not provided in 
original paper; table 2). The highest sensitivity (100·0%) 
was documented for the WHO subdefinitions in which 
fever was not mandatory. Among studies using clinical 
symptoms and signs alone, the definition including 
three or more symptoms (intense fatigue, confusion, 
con juncti vitis, hiccups, diarrhoea, and vomiting) had the 
highest specificity (79·1% [95% CI not provided in 
original paper]). Unexplained death had high specificity 
(92·8% [95% CI not provided in original paper]) but the 
lowest sensitivity (14·2% [95% CI not provided in original 
paper]; table 2).
For children, the highest specificity (97·0% [95% CI 
not provided in original paper]) was with a case definition 
of contact, fever, and conjunctivitis, or contact, fever, 
anorexia, and two of abdominal pain, diarrhoea, or male 
sex (older than 2 years; table 2).26
Seven articles developed a risk score,22,23,25,29,31–33 and 
among those five25,29,31–33 did an internal validation (using 
bootstrap or test and training methods) and one assessed 
a risk score according to outbreak prevalence in a 
paediatric population.25 An eighth study28 externally 
validated the score developed by Oza and colleagues33 
without developing an alternative score. Of the 44 po-
tential predictors of Ebola virus infection included across 
(Figure 3 continues on next page)
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the seven studies that develped risk scores, 20 were 
found to be positive or negative predictors (figure 3). The 
score system ranged from very low to very high risk, with 
intermediate categories varying across studies 
(appendix p 7).
One study created a malaria sensitive score aiming to 
discriminate between Ebola virus infection and malaria 
infection, which indicated a predictor power of 89·6% 
(95% CI 86–93) to discriminate Ebola virus positive 
versus negative, reaching a discrimination power of 
98·5% (95% CI not provided in original paper) during the 
malaria season.32 The same study obtained similar results 
(AUC 76·8% [95% CI not provided in original paper] vs 
75·0% [70·0–80·0]), when externally validating the scores 
developed by Levine and colleagues.29,32
The study validating Oza and colleagues’ algorithm 
found poorer performance in their cohort (AUC 58% 
[95% CI 56–61] vs 83·0% [79–86]).28,33
The highest performing score was developed by Hartley 
and colleagues,32 a key difference being referral time 
(figure 3). For the adult population (six studies22,23,29,31–33), a 
positive risk score for infection was associated in 
more than one study with each of the following five 
characteristics: epidemiological link (eg, history of 
contact), diarrhoea, conjunctivitis, unexplained bleeding, 
difficulty swallowing (also called dysphagia; figure 3). 
Fever was assessed at different thresholds (>38·0°C or 
≥38·5°C), and inclusion of fever in the final predictive 
score was only reported by two studies31,32 (figure 3). 
Discordant values were assigned across studies (either 
positive or negative) for anorexia or loss of appetite, 
muscle pain (also called myalgia), and abdominal pain.
For the paediatric population (one study25), positive 
predictors were age (2 years or older), sex (male), epid-
emiological link, diarrhoea, conjunctivitis, fever (>38·0°C), 
anorexia or loss of appetite, and abdominal pain. Negative 
predictors were difficulty swallowing, rash, headache, and 
difficulty breathing (also called dyspnoea; figure 3). The 
same study compared two different time periods over the 
Ebola virus disease 2014–16 outbreak in Sierra Leone (high 
prevalence in October, 2014 [77% of suspected cases 
testing positive], and low prevalence in March, 2015 [4% of 
suspect cases testing positive]): a low cutoff for the risk 
score (with high sensitivity) performed better at periods of 
high prevalence transmission, and a high cutoff with high 
specificity performed better during low prevalence.25 
Similarly, the positive predictive value decreased from 
93% to 31%, and the negative predictive value increased 
from 23% to 90% when comparing high (early) to low 
(late) transmission periods in the Ebola virus disease 
outbreak in another study in Liberia in an all ages 
population.23
Figure 3: Overview of risk score by symptoms and epidemiological characteristics
Predictive scores (numeric or + symbol) are shown in shaded cells (blue indicates positive scores and light pink indicates negative scores). Y indicates that the characteristic was assessed, 
but not used. AUC=area under the receiver operating characteristic curve. NA=not assessed. ORL=otorhinolaryngology. *Diarrhoea, vomiting, or anorexia or loss of appetite. †95% CI is taken from 
Ingelbeen et al (2018)28 because, although Oza and colleages do not report 95% CIs in their manuscript, Ingelbeen and colleagues have externally validated Oza and colleagues’ score and they do report 
the 95% CI. ‡95% CI, AUC, or both AUC and 95% CI not given in original paper.
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Eight studies measured sensitivity and specificity of 
individual symptoms at admission, assessing a total 
of 35 symptoms.5,22–24,27,29–31 The pooled sensitivity per 
symptom ranged from 79·0% (95% CI 74·4–83·0) for 
intense fatigue (seven studies) to 1·0% (0·0–7·0) for pain 
behind the eyes (three studies). By contrast, the pooled 
specificity ranged from 98·0% (95% CI 91·0–100·0) for 
pain behind the eyes to 32·3% (25·8–39·4) for intense 
fatigue (appendix p 9).
Haemorrhagic symptoms and signs were the most 
specific indi cator of infection. Other symptoms and signs 
with high specificity included confusion, coma, hiccups, 
rash, and sore throat with specificity ranging from 92·0% 
(95% CI 91·0–94·0) for hiccups to 97·8% (95·2–99·0) for 
rash (appendix p 9). Performance of fever was assessed by 
seven studies, but each one used a different definition of 
fever.5,22,23,27,29–31 The optimal performance (definition that 
achieved best balance between maximising sensitivity 
vs maximising specificity) for fever was a threshold 
at ≥38·5°C (sensitivity 80·2% [95% CI 69·2–88·2]; 
specificity 82·6% [71·2–90·3]; table 3).31 In the random-
effects analysis, a threshold at greater than 38·0°C 
(three studies22,27,29) gave a pooled sensitivity of 80·0% 
(95% CI 69·0–90·0) and specificity of 25·0% (17·0–33·0; 
table 3).
Seven studies assessed sensitivity and specificity of an 
epidemiological link.5,22–24,29–31 Across these studies, the 
sensitivity of an epidemiological link ranged from 21·6% 
(95% 17·9–25·6) to 100·0% and specificity ranged from 
29·0% (95% CI 19·0–41·3) to 86·0% (74·0–94·0). The 
most sensitive definition was history of contact with a 
person with confirmed Ebola virus infection (100·0%; 
table 3). The most specific definition was direct contact 
with an individual potentially infected with Marburg virus 
or his or her body fluids, or direct contact during funeral 
practices.22
Discussion
Our results indicate that, for all ages combined, the 
WHO case definitions have a sensitivity of 81·5% and a 
specificity of 35·7%. The sensitivity is not high enough to 
achieve acceptable false negative rates, particularly in 
low-prevalence settings, the primary requirement for 
community-based screening. The low specificity results 
in high numbers of false positives and thus potentially 
unnecessary admissions to Ebola treatment centres, with 
associated risk of nosocomial transmission and costs of 
managing suspected cases.1 As a consequence, a large 
number of people who do not have Ebola virus disease 
will experience unnecessary invasive procedures, risk of 
Variable Sensitivity (95% CI) Specificity (95% CI)
Fever cutoff
Loubet et al (2016)31 ≥38·5°C 80·2% (69·2–88·2) 82·6% (71·2–90·3)
Loubet et al (2016)31 ≥38·0°C 88·2% (78·2–94·1) 72·5% (60·2–82·2)
Loubet et al (2016)31 ≥37·5°C 93·4% (84·7–97·5) 50·7% (38·5–62·9)
Kuehne et al (2015)23 History of fever 85·3%* 26·4%*
Lado et al (2015)5 ≥37·5°C or referred 85·9% (82·4–89·0) 16·4% (12·0–21·6)
Arranz et al (2016)30 ≥38·0°C or referred 61·3% (44·1–78·4) 29·5% (16·1–43·0)
Roddy et al (2010)22 >38·0°C 85·0% (71·0–94·0) 20·0% (11·0–32·0)
Levine et al (2015)29 >38·0°C 85·0% (79·0–91·0) 21·0% (16·0–27·0)
Ingelbeen et al (2017)27 >38·0°C 71·5%* 30·5%*
Pooled analysis† >38·0°C 80·0% (69·0–90·0) 25·0% (17·0–33·0)
Epidemiological link
Hsu et al (2018)24 Contact with infected persons or body fluid, handling of bushmeat, attending 
the funeral of a patient with Ebola virus disease
74·7%* 67·1%*
Roddy et al (2010)22 Epidemiological link‡ 67·0% (50·0–81·0) 86·0% (74·0–94·0)
Arranz et al (2016)30 History of contact with a person with confirmed Ebola virus disease 100·0% 59·0% (43·5–74·4)
Levine et al (2015)29 Sick contact§ 65·0% (58·0–73·0) 61·0% (54·0–67·0)
Loubet et al (2016)31 Health worker or having had contact with a person with suspected Ebola virus 
disease or having attended funerals
81·5% (44·0–60·7) 29·0% (19·0–41·3)
Kuehne et al (2015)23 Contact to case 47·3%* 71·2%*
Lado et al (2015)5 Travel to an Ebola virus disease hotspot area, health-care work, funeral 
attendance, or contact with an ill family member or friend¶
21·6% (17·9–25·6) 84·6% (79·6–88·8)
Optimal performance is the definition that achieved best balance between maximising sensitivity versus maximising specificity. *95% CI not provided in original paper. 
†The pooled analysis was used for the studies that had the same cut-off for fever (>38°C).22,27,29 ‡Epidemiological link was defined as direct contact with an individual 
potentially infected with Marburg haemorrhagic fever or his or her body fluids or direct contact during funeral practices. §Direct or indirect contact with a patient with 
suspected or confirmed Ebola virus disease in the previous 21 days, including living in the same household or providing direct care for the patient. ¶A contact is any person 
who comes into contact with a case or suspected case by sleeping in the same household within the past month; direct physical contact with the case (dead or alive); 
touching his or her linens or body fluid; or attendance at a funeral of a person with confirmed or suspected Ebola virus disease.
Table 3: Sensitivity and specificity of fever, epidemiological link, or contact history, ordered by optimal performance
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being infected with Ebola virus, isolation from family, 
fear of being stigmatised, and delay to appropriate care, 
and community mistrust in response activities will 
increase.
In our meta-analysis, fever had low specificity (25·0%), 
except for when defined as a threshold at 38·5°C or more 
(82·6%), and the WHO case subdefinition had 100% 
sensitivity only when fever was not a mandatory criterion. 
In the risk score systematic review, the association of 
fever with Ebola virus infection was not consistent across 
studies, with only two studies including it in the final 
predictive score. Presence of fever is likely to be related to 
the stage of infection at admission, with previous studies 
reporting absence of fever in a large proportion of 
suspected cases at admission.34 This finding is consistent 
with a recent Ebola seminar reporting that fever was 
absent in at least 10% of the cases in the west Africa 
outbreak.35
Therefore, exclusion of fever from the case definition at 
the community level is likely to increase the sensitivity of 
the case definition. Intense fatigue was the most sensitive 
symptom (79·0%) that could be used at the community 
level to facilitate early referral of suspected cases and 
prevent community transmission.
The meta-analysis did not identify any individual symp-
tom or sign having an optimal trade-off between sensitivity 
and specificity. Conjunctivitis, unexplained bleeding, diffi-
culty swallowing, and diarrhoea were individual symptoms 
and signs with the best discriminatory accuracy in the 
studies that explored risk score for the all-age population 
and with the exception of diarrhoea all had high specificity 
(>80%) in the studies that explored their performance. 
However, these symptoms and signs could also be a proxy 
for late-stage disease when the virus infects endothelial 
cells, compromising vascular integrity, with massive tissue 
injury resulting in dis seminated intravascular coagulopathy 
with risk of thrombosis, bleeding, and damage to the 
adrenal glands and gastrointestinal system.36–38 These 
symptoms and signs could enable health practitioners to 
prioritise patients for admission to an Ebola treatment 
centre when resources are scarce but are less useful at the 
community level because they appear at a late stage of the 
disease when transmission risk is the highest.
None of the studies assessed miscarriage, despite it 
being included in the December, 2014, WHO case 
definition.15 History of miscarriage and other associated 
pregnancy complications (eg, stillbirth) could help to 
identify cases that can be a major source of nosocomial 
transmission in general health facilities.39
Although only one study focused on a paediatric 
population, this study used data from 11 Ebola holding 
units and included a large population of children (1006), 
providing useful guidance for this age group.26 The WHO 
paediatric definition had very high sensitivity (98·0%) but 
very poor specificity (5·0%). When the same authors 
assessed a WHO subdefinition (including contact, fever, 
and conjunctivitis, or contact, fever, anorexia, and two of 
abdominal pain, diarrhoea, or male sex [older than 
2 years]), the sensitivity dropped markedly to 23·0% but 
the specificity improved to 97·0%. The optimal fever 
temperature cutoff for the paediatric population was 
not explored. However, in another study of a paediatric 
population of patients with confirmed Ebola virus disease 
admitted to one Ebola treatment centre in Sierra Leone, 
25% of children aged 5 years and younger were afebrile.40 
This difference might be due to several factors: how fever 
was assessed (either reported in their history or measured 
at admission), age groups included (younger than 
13 years vs younger than 5 years), period of data 
collection (August–March, 2015, vs June–Dec, 2014) when 
seasonality of other febrile illnesses could have influenced 
fever prevalence, background Ebola virus transmission 
rates, and viraemia at admission and time since onset of 
symptoms.
The paediatric analysis did not explore sensitivity and 
specificity of individual symptoms and signs at admission 
for children. Alongside the fact that they might have 
different clinical presentations compared with adults, 
children are more likely to experience adverse outcomes 
from Ebola virus disease and are less able to report 
symptoms and history of contact.
Similarly, pregnant women with non-Ebola virus 
disease-related complications usually present with 
symptoms (such as bleeding and abdominal pain) that 
mimic Ebola virus infection.39 As suggested elsewhere, 
the paediatric and pregnant women populations might 
require adaptation of case definitions that take into 
account their specific characteristics.41–43 None of the 
selected manuscripts explored the performance of WHO 
Ebola case definitions among pregnant women. Therefore, 
further evidence specifically applicable to children and 
pregnant women is required to develop appropriate tools 
for screening for Ebola virus disease in these populations.
Reported history of contact was a strong predictor for 
paediatric and adult populations, often performing better 
than many of the clinical symptoms included in accepted 
case definitions, as also reported by other studies.44 
However, it is likely that this is an underestimate of the 
potential performance of actual contact history in 
screening for Ebola virus disease.
Levels of disclosure of self-reported clinical information 
and contact history depend on community engagement 
with intervention strategies, including trust in the health-
care provider. Therefore, to improve WHO case definition 
performance, effective and trusted collaboration with 
communities is essential to ensure reliable understanding 
and reporting of such crucial epidemiological infor mation. 
Equally, it is the responsibility of response agencies to 
understand the underlying pattern of Ebola virus 
transmission, local traditions, coping mechanisms, and 
family dynamics in order to identify people at risk of 
infection. Genetic sequencing has also been put forward as 
a tool for identifying chains of transmission when contact 
history is unknown.45 One of the limitations in interpreting 
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the results of this meta-analysis is that all the evidence 
reviewed, apart from the national surveillance study, came 
from patients triaged at health facilities or Ebola isolation 
centres. Thus, this meta-analysis might represent only 
cases with severe symptoms, limiting generalisability to 
the performance of these screening criteria at the 
community level and in early stages of disease. Second, 
there was significant heterogeneity between selected 
studies, and considerable variation in the quality of data on 
clinical symptoms and recollection of patients’ history, 
with different variables and thresholds used in each study, 
and limited data on co-infection. For example, fever is a 
key symptom in the WHO case definitions, but different 
temperatures were used to define fever, which could 
explain the between-study heterogeneity. Inconsistency on 
thresholds for fever and the decision to include fever or not 
have been reported in the Democratic Republic of the 
Congo and in four neighbouring countries.9
For the two studies with overlapping patient popu-
lations, performance of WHO case definitions was 
assessed only using national surveillance data, with Ebola 
treatment centre data for these patients being assessed for 
only individual symptoms or WHO subdefinitions. These 
two studies were therefore not included together in pooled 
estimations, so the cohort overlap would not have affected 
results. Individual studies mentioned small sample size 
and poor quality of data as part of their limitations.
A range of contextual factors related to study setting 
will affect the performance of Ebola virus disease case 
definitions, including seasonally occurring diseases such 
as malaria and Lassa fever, which have a similar clinical 
presentation to Ebola virus disease. Such factors will 
affect the generalisability of our findings to other settings. 
In addition, only two of the recommended risk scores 
were externally validated,28,32 limiting the generalisability 
of those scores because performance appears to vary 
across outbreak periods and populations.
Finally, there is potential for publication language bias 
because we considered only studies in English. However, 
for Guinea, a French-speaking country, we included data 
from national surveillance and two major Ebola treatment 
centres; therefore, we consider that bias due to language 
restrictions was minimised in our results. We included 
peer-reviewed abstract and poster data to capture data on 
paediatric populations and additional evidence for all age 
cohorts, and we sought unpublished evidence from French-
speaking countries.
This systematic review is relevant to inform public 
health practitioners in the current Ebola virus disease 
outbreak in the Democratic Republic of the Congo, in 
which only 8% of suspected cases isolated are confirmed, 
possibly because of inconsistent use of WHO case 
definition at community and health facility levels. 46
In conclusion, this first systematic review and 
meta-analysis of the strengths and limitations of the 
WHO Ebola virus disease case definitions highlights the 
need for further studies to assess consistent thresholds 
for fever, to explore viraemia and symptoms and signs at 
admission, and to externally validate risk scores for Ebola 
virus infection. The sensitivity and specificity of WHO 
Ebola case definitions could be improved by excluding 
fever and instead including both intense fatigue and 
history of contact. However, reliable disclosure of 
reported symptoms and history of contact requires 
effective collaboration with, and the trust of, affected 
communities. To achieve this trust and collaboration, 
responding organisations must recognise the paramount 
role of communities in controlling transmission and 
ending outbreaks. We also identified important gaps 
related to the paediatric and pregnant population, which 
must be addressed through future research.
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